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Abstract
The dysregulation of RNAs has global effects on all cellular pathways. The regulation
of RNA metabolism is thus tightly controlled. Terminal RNA nucleotidyltransferases
(TENTs) regulate RNA stability and activity through the addition of non-templated
nucleotides to the 3′-end. TENT-catalyzed adenylation and uridylation have opposing
effects; adenylation stabilizes while uridylation silences or degrades RNA. All TENT
homologs were initially characterized as adenylyltransferases; the identification of
caffeine-induced death suppressor protein 1 (Cid1) in Schizosaccharomyces pombe as an
uridylyltransferase led to the reclassification of many TENTs as uridylyltransferases.
Cid1 uridylates mRNAs that are subsequently degraded by the exonuclease Dis-like 3′-5′
exonuclease 2 (Dis3L2), while the human homolog germline-development 2 (Gld2) has
been associated with adenylation of mRNAs and miRNAs and uridylation of Group II
pre-miRNAs. Mechanisms regulating these enzymes and the extent of TENT activity on
cellular RNA homeostasis remain largely unknown. In this thesis, the regulation of
human Gld2 and the role of the yeast Cid1/Dis3L2-mediated RNA decay pathway were
investigated. An enzyme kinetic study revealed that Gld2 is a true adenylyltransferase
with only weak activity for UTP. A detailed phylogenetic analysis revealed that
uridylyltransferases arose multiple times during evolution through a single histidine
insertion in the active site of adenylyltransferases. Insertion of the critical histidine into
Gld2 changed its nucleotide preference from ATP to UTP. Next, the regulation of Gld2
through site-specific phosphorylation in the predicted disordered N-terminal domain was
investigated using phosphomimetic substitutions at specific serine (S) residues. Two sites
(S62, S110) increased Gld2 activity while one site (S116) drastically reduced 3′adenylation activity. Mass spectrometry and in vitro activity assays identified protein
kinases A (PKA) and B (Akt1) as kinases that specifically phosphorylate Gld2 at S116 to
obliterate nucleotide addition activity similarly to the S116E phosphomimetic mutant.
Finally, RNA deep sequencing of cid1 and dis3L2 S. pombe deletion strains revealed that
the role of Cid1 is redundant in uridylation-dependent mRNA decay while Dis3L2 is the
bottleneck to RNA decay. Deletion of either gene increases the accumulation of
misfolded proteins but only the dis3L2 deletion up-regulates stress response proteins.
ii

Overall, this thesis demonstrates how terminal nucleotidyltransferases regulate RNA
stability.
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Summary for Lay Audience
Ribonucleic acids (RNAs) play important roles in protein production and regulating
cellular processes such as cell proliferation. Dysregulation of RNA expression,
maturation, and/or degradation is associated with multiple human diseases such as cancer
and cardiovascular disease. RNAs can be regulated through the addition of adenine or
uridine nucleotides to its 3’-end. The proteins that perform these additions are known as
terminal RNA nucleotidyltransferases (TENTs). All TENTs were initially thought to add
adenine residues (adenylyltranferases), but more extensive studies revealed that some
TENTs preferred to add uridine residues (uridylyltransferases). The addition of adenine is
associated with stability while uridine addition is associated with silencing/degradation.
Thus, the simple addition of different nucleotides can change the fate of an RNA
molecule. The yeast TENT uridylates RNAs which are recognized and degraded by the
exonuclease Dis-like 3′-5′ exonuclease 2 (Dis3L2). On the other hand, its human
counterpart, germline-development 2 (Gld2), has been associated with RNA adenylation
and uridylation. Mechanisms regulating these proteins and the extent of TENT activity on
cellular RNA homeostasis remain largely unknown. In this thesis, the regulation of
human Gld2 and the role of the yeast Cid1/Dis3L2-mediated RNA decay pathway were
investigated. First, Gld2 was shown to be a true adenylyltransferase. The simple insertion
or deletion of the amino acid histidine in the active site was shown to change the
nucleotide preference of TENTs. Secondly, Gld2 was shown to be regulated through
phosphorylation of specific serine residues (S). Two sites (S62, S110) increased Gld2
activity while one site (S116) drastically reduced activity. Two cancer-related kinases,
protein kinases A (PKA) and B (Akt1), were identified to phosphorylate Gld2 at S116 to
obliterate nucleotide addition activity. This discovery provided the first link between
cancer-related kinases and RNA regulation. Finally, deletion of either the Cid1 or Dis3L2
genes in yeast revealed that Cid1 is redundant in uridylation-dependent mRNA decay
while Dis3L2 is the bottleneck to RNA decay. Deletion of the Dis3L2 gene elicited a
larger change in the RNA population. Overall, this thesis demonstrates how terminal
nucleotidyltransferases regulate RNA stability.
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Introduction

1.1

Central Dogma of Molecular Biology

In 1958 Francis Crick defined the Central Dogma of molecular biology as the flow of
information from DNA to RNA to proteins1 (Figure 1.1). Deoxyribonucleic acid (DNA)
contains the genetic information in the form of a double-stranded helix2, which serves as
a blueprint for life. The genome contains all the genetic information for an organism,
encoded in a four-letter DNA code represented by the nucleotide bases adenine, thymine,
cytosine, and guanine. Genes are sequences of DNA that are transcribed to ribonucleic
acid (RNA) polymers, including messenger RNAs (mRNAs) and non-coding RNAs
(ncRNAs). RNA polymerase recognizes and binds to specific DNA sequences and uses
the DNA as a template to synthesize complementary RNA strands 3. Of the different RNA
polymerases, RNA polymerase II (Pol II) transcribes mRNAs. The transcriptome
includes the collection of all mRNAs in the cell. These RNA messages are read or
translated by the ribosome to synthesize proteins of specific sequences as defined in the
mRNA3,4.
The mRNA carries the protein-encoding information in a four-letter code, similar to
DNA. The thymine bases found in DNA are replaced by uracil in RNA transcripts, and
the RNA bases are linked by a sugar phosphate backbone that contains ribose sugars
instead of deoxyribose sugars found in DNA. The mRNA is recognized as a substrate by
the ribosome in synthesizing all cellular proteins 5. In protein synthesis, often referred to
as mRNA translation, the mRNA is read in nucleotide (nt) triplets known as codons.
RNAs encode up to 64 different codons, which either correspond to an amino acid or
serve as a stop signal (stop codon) that terminate translation.
The genetic code is redundant and there can be more than one codon per amino acid;
a total of 20 canonical amino acids are encoded by 61 codons. Three codons (UAG,
UAA, UGA) serve as stop codons 6. In some organisms, including Escherichia coli and
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humans, UGA is recoded to the 21 st amino acid selenocysteine in a small set of genes 7–9.
In a certain species of archaea and bacteria, UAG is reassigned to pyrrolysine, the 22 nd
genetically encoded amino acid7,10.
Small RNA molecules, transfer RNA (tRNA), serve as adaptors or decoders of the
three-letter nucleic acid code into amino acids. tRNAs contains an anti-codon that is
complementary to a codon or set of codons. Each tRNA species is charged with the
cognate amino acid by the aminoacyl-tRNA synthetases11. tRNAs encode identity
elements that allow aminoacyl-tRNA synthetases to specifically recognize tRNAs and
ligate them with the correct amino acid6. Following elongation factor binding, the
aminoacyl tRNA anti-codon base-pairs with the corresponding mRNA codon in the
ribosome. The decoding process allows the correct amino acid, as specified in the
mRNA, to be added to the growing protein chain. The ribosome, comprised of ribosomal
RNAs (rRNAs) and protein subunits, catalyzes the peptidyl transfer reaction that adds the
next amino acids to a growing peptide. The protein product is completed once a stop
codon is reached and, following recognition by release factors, the ribosome dissociates
and is prepared for the next round of translation12.
The primary structure of a protein is determined by its amino acid sequence. As the
peptide grows, it forms a secondary structure. The secondary structure is influenced by
the amino acid sequence and intramolecular interactions are formed between the amino
acid residues and backbone atoms. At the secondary structure level, protein
conformations include α-helices, β-sheets, and random coils. Most proteins then fold into
a ground state or low energy tertiary structure referred to as the native state. Quaternary
structures may form when different proteins or subunit monomers that have already
formed tertiary structures interact with each other to form higher order complexes 13.
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Figure 1.1: Central Dogma of Molecular Biology.
The schematic diagram depicts transcription and translation. For protein coding genes,
their DNA sequences are transcribed to mRNAs. The translation machinery then decodes
the mRNA into a specific protein sequence (N, N-terminal; C, C-terminal). The
nucleotide bases are colour-coded: green, adenine; red, thymine; dark blue, guanine;
orange, cytosine; pink, uracil.

1.2
1.2.1

Regulation of mRNA
mRNA transcription in eukaryotes

Transcription of mRNA starts with Pol II and transcription factors binding to a DNA
promoter and opening the double-stranded helix to form a transcription bubble3,4 (Figure
1.2). During transcription elongation, Pol II moves along the DNA template and adds
complementary RNA nucleotides to synthesize the growing mRNA transcript.
Transcription ends when the complex reaches the transcription terminator and the
resulting RNA is known as a precursor mRNA (pre-mRNA)14.
The pre-mRNA undergoes a series of modifications before becoming a mature
mRNA. The processing starts as the pre-mRNA is formed with the addition of a 7methylguanosine cap on the 5′-end15,16. RNA triphosphatase first hydrolyzes the 5′triphosphate to a diphosphate; RNA guanylyltransferase then adds a guanosine
monophosphate (GMP). Finally, RNA guanine-7 methyltransferase will the methylate the
guanosine base at position N716.
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The mRNA 5′-cap is important for many events including mRNA stability,
processing, nuclear export, and translation16. The pre-mRNA also require splicing to
remove the non-protein coding introns15,17. The spliceosome is a complex of five small
nuclear ribonucleoproteins (snRNPs) that catalyzes the splicing event and requires
specific sequences within the intron for efficient splicing17,18. Once the polyadenylation
signal sequence and the downstream GU-rich motif are transcribed, the mRNA is cleaved
between those two regions at the cleavage site and transcription is terminated 19–21. The 3′end of the transcript is polyadenylated by poly(A) polymerase (PAP) and the resulting
poly(A) tail is bound by poly(A) binding proteins (PABPs)19–21.
For the mRNA to leave the nucleus, various mRNA-binding proteins come together
to form a messenger ribonucleoprotein (mRNP) export complex. The complex is
exported out of the nucleus by nuclear pore complexes and will undergo changes in the
cytoplasm to release the mRNA and prevent the mRNA from returning to the nucleus 22.
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Figure 1.2: Transcription of mRNA.
The double-stranded DNA (blue and dark red strands) is bound by RNA polymerase II
(orange oval, Pol II) and transcription factors such as transcription factor IIB (green oval)
and transcription factor IID (purple oval) to form a transcription bubble. The pre-mRNA
(purple and black line) is transcribed as Pol II moves along the DNA strand. The introns
(black lines) are spliced out and a 7-methylguanosine cap (red circle) is added to the 5′end as transcription occurs. Once transcription is terminated, a poly(A) tail is added by a
poly(A) polymerase (dark red oval) to the 3′-end of the mRNA and bound by poly(A)
binding proteins (light blue ovals). Various mRNA binding proteins such as the
transcription-export complex (pink oval) and nuclear RNA export factor 1 and p15
heterodimer (Tap-p15, yellow oval) will bind the mRNA to form a messenger
ribonucleoprotein (mRNP) export complex to export the mRNA out of the nucleus. Once
in the cytoplasm, the mRNA binding proteins will undergo conformational changes to
release the mRNA and this prevents the mRNA from returning to the nucleus.

1.2.2

Role of the poly(A) tail

The poly(A) tail plays an important role in the life cycle of mRNA. The poly(A) is
added to the 3′-end of the mRNA during RNA processing after cleavage by nuclear PAPs
and is important for events such as mRNA nuclear export, stability, and translation19–21.
Transcripts lacking a poly(A) tail are confined in the nucleus 23. More recent studies show
that the poly(A) tail induces mRNA export by contributing to the length of the mRNA
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transcript and the export can actually be inhibited if the poly(A) tail is too long24. The
poly(A) tail is required to bind PABP and it is the PABPs that confer stability to the
mRNA25,26. Indeed, a mRNA transcript without a poly(A) tail can be stabilized if PABP
is tethered to the transcript25. The poly(A) tail is also involved in translation through
PABP26–29. PABP binds eukaryotic translation initiation factor 4G (eIF4G), a component
of the eukaryotic translation initiation factor 4 (eIF4) translation initiation complex, that
then binds to the 5′-end cap-binding eukaryotic translation initiation factor 4E (eIF4E)27–
30

. This allows the mRNA to take on a circular form to promote translation and, possibly,

the stability of the mRNA by preventing decapping at the 5’-end and deadenylation at the
3′-end26,28,29.
While initial polyadenylation occurs in the nucleus by canonical PAPs, the poly(A)
tails of mRNAs can be further extended by non-canonical PAPs in the cytoplasm to
facilitate translation31–34. Polyadenylation of mRNAs by mammalian homologs of the
non-canonical PAP germline-development 2 (Gld2) has been shown to enhance mRNA
translation in Xenopus oocytes31. Another study showed that dormant mRNAs in the
cytoplasm have shortened poly(A) tails and require polyadenylation to be active for
translation32,34. The extended poly(A) tail recruits additional PABP and the associated
proteins required for translation26–29,34. The activation of dormant mRNAs is commonly
observed during development with mRNAs involved in meiosis and mitosis 34. In
Caenorhabditis elegans, the absence of Gld2 led to abnormal germline cell growth35,36.
The poly(A) tails of maternal mRNAs during oocyte maturation are extended to promote
translation33, and the absence of the extended tails can be observed in mature oocytes and
early-stage embryos when the non-canonical PAP is deleted37.

1.2.3

5′-3′ and 3′-5′ degradation of mRNAs

Degradation of mRNA can occur in both the 3′-5′ and 5′-3′ directions (Figure 1.3A).
In eukaryotes, deadenylation-dependent degradation of the poly(A) tail is initially carried
out by the poly(A) specific ribonuclease subunits Pan2 and Pan3 (Pan2-Pan3) of the
poly(A) nuclease (PAN) deadenylase complex in the nucleus. The complex has been
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observed to slightly trim the poly(A) tail to approximately 70-80 nts in Saccharomyces
cerevisiae and 110 nts in mammalian cells before the mRNA transcript is exported out of
the nucleus26,38–42. Most of the deadenylation is carried out in the cytoplasm by the
glucose-repressible alcohol dehydrogenase transcriptional effector and CCR4-associated
factor 1 (Ccr4-Caf1) complex43,44. This triggers the dissociation of PABP, leaving the 3′end exposed for degradation by the exosome. Deadenylation, however, initially triggers
the 5′-3′ decay pathway. The loss of PABP will de-circularize the mRNA, exposing the
5′-end cap. This leads to decapping by the mRNA-decapping enzyme subunits 1 and 2
(Dcp1/2) and like Smith 1-7 (Lsm1–7) decapping complexes. Following decapping, the
RNA is degraded by the 5′-3′ exoribonuclease 1 (Xrn1)45.
An alternate deadenylation-independent RNA degradation pathway characterized by
the addition of uridine residues to polyadenylated mRNAs was identified in
Schizosaccharomyces pombe46. A similar, uridylation-dependent RNA degradation
process has also been found in human cells 46–50 (Figure 1.3B). mRNAs with poly(A) tails
less than 25 nts lose the protection of PABPs and are polyuridylated by human terminal
uridylyltransferase 4 (TUT4, Zcchc11) and terminal uridylyltransferase 7 (TUT7,
Zcchc6), leading to degradation by Dis3-like 3′-5′ exonuclease 2 (Dis3L2)47. Dis3L2 is a
3′-5′ cytoplasmic exonuclease, that specifically degrades 3′-uridylated RNA species, but
is not part of the exosome51. Dis3L2 recognizes polyuridylated mRNAs51 and miRNAs52
and catalyzes their 3′-5′ degradation. Mutations in Dis3L2 have been linked to Perlman
syndrome and formation of Wilms’ tumor in children53. Due to its ability to recognize
and degrade any RNAs that are polyuridylated, Dis3L2 is believed to play a key role in
maintaining cellular RNA homeostatsis53. The poly(U) tails of mRNAs are also
recognized by the Dcp1/2 and Lsm1–7 decapping complexes54, leading to 5′-3′
degradation by Xrn145. Interestingly, depletion of Lsm1 from the Lsm1-7 complex leads
to an increase in mRNAs with oligo(U) tails, suggesting that mRNAs with 3′-uridine
residues are first recognized by the decapping complexes and subjected to 5′-3′ decay
before 3′-5′ degradation47.
This uridylation-dependent decay pathway is the major decay pathway for histone
mRNAs (Figure 1.3C). These mRNAs encode a unique 3′-stem-loop structure, which is
7

uridylated at the end of S-phase to initiate degradation49. The terminal uridylyltransferase
TUT4 is the key player in histone mRNA uridylation; knockdown of TUT4 reduces
histone mRNA uridylation and increases overall histone mRNA abundance50. In addition,
TUT7 was shown to uridylate mature histone mRNA. TUT7 interacts with the
exonuclease 3′-hExo to maintain a length of 3 nts after the stem-loop structure and both
enzymes take part in the initial degradation of the histone mRNA55. When the histone
mRNA 3′-end stem-loop structure is polyuridylated, the RNA is subsequently degraded
by both the 5′-3′56 and Dis3L2 3′-5′ degradation pathways49.
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Figure 1.3: mRNA degradation pathways.
Three major RNA degradation pathways in eukaryotes. A) Deadenylation-dependent
degradation of mRNAs begins with the Pan2-Pan3 deadenylase complex slightly
trimming the poly(A) tail and continues in the cytoplasm with extensive deadenylation by
Ccr4-Caf1. This causes PABPs (light blue ovals) to dissociate from the tail and will
trigger 3′-5′ degradation by the exosome as well as 5′-end decapping (5′-cap, red circle)
by Dcp1/2 and Lasm1-7 and 5′-3′ degradation by Xrn1. B) Uridylation-dependent
degradation of mRNAs is initiated when poly(A) tails less than 25 nts lose the protection
of PABPs and are polyuridylated by TUT4 or TUT7. The poly(U) tail is recognized by
the U-specific exonuclease Dis3L2 for 3′-5′ degradation. The poly(U) tail also triggers
decapping by Dcp1/2 and Lsm1-7 and 5′-3′ degradation by Xrn1. C) Replicationdependent histone mRNAs encode a 3′-end stem-loop structure instead of a poly(A) tail.
The stem-loop acts as a cis element for mRNA degradation and is bound by stem-loop
binding protein (SLBP) and other proteins (not shown in figure) 49. The mRNAs are
degraded through the uridylation-dependent degradation pathway.
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1.3

miRNAs: Functions in Gene Expression

MicroRNAs (miRNAs) are small, single-stranded, regulatory RNAs that were
discovered in the 1990s57,58. They are approximately 19-24 nts in length and take part in
degrading mRNAs to suppress protein synthesis. miRNAs regulate gene expression by
binding to complementary sequences in the target mRNA58. In animals, miRNAs regulate
mRNAs through the RNA-induced silencing complex (RISC). As miRNAs in animals are
typically not perfect complements to their mRNA targets, the mRNA is not degraded by
endonucleolytic cleavage. The mRNA will be degraded and/or translationally suppressed
through other methods (section 1.3.1)59,60. miRNAs play important roles in critical
cellular pathways such as proliferation and apoptosis, ultimately affecting the well-being
of the entire organism58,61. Correspondingly, de-regulation of miRNAs in humans has
been shown to result in cardiovascular diseases 62,63 and other diseases such as
cancer58,61,64,65 and diabetes66.

1.3.1

Role of miRNAs in regulating gene expression

Many models have been put forth to explain translation repression5,67,68. Some models
suggest that miRNA bound RISC (miRISC) inhibits translation initiation by competing
with the 5′-cap binding protein eIF4E to bind the mRNA 5′-cap, preventing assembly of
the 40S and 60S ribosomal subunits on the mRNA, or inhibiting formation of the
translation initiation complex5,67,69–71. miRNAs also inhibit translation during elongation
where miRISC causes early release of the ribosomes from the mRNA72. The miRISC has
been suggested to prevent circularization of the mRNA, preventing translation from
starting67,68. The miRISC can also sequester the mRNAs in processing bodies (P bodies),
preventing translation of the mRNA67,73. The partial complementarity of the miRNA to
its target mRNA directs the mRNA towards decay pathways instead of mRNA cleavage
by RISC by recruiting the Ccr4-Caf1 complex for deadenylation60,67,74. Deadenylation
will lead to deadenylation-dependent 3′-5′ decay and 5′-3′ decay through mRNA
decapping as described in section 1.2.3.
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1.3.2

miRNA maturation pathway

In animals, miRNA maturation takes place in the nucleus and the cytoplasm67,75
(Figure 1.4). Most miRNAs are transcribed by Pol II as they are encoded within the
sequences of coding and noncoding RNA transcripts67,75,76. miRNAs are mostly encoded
within the introns but can be found in the exons67,75.
In addition, some miRNAs such as miR-23a/27a/24-2 have their own promoters that
are recognized by Pol II76. A small subset of miRNAs with their own promoters, such as
C19MC miRNAs and miR-886, are transcribed by RNA polymerase III (Pol III)77,78. The
resulting RNA is known as a primary miRNA (pri-miRNA) and takes the form of a long
RNA strand with a hairpin-loop structure. Each hairpin-loop structure corresponds to one
miRNA and clusters of miRNA sequences will have multiple hairpin-loop structures on
the RNA strand. Drosha, a class II RNase III enzyme, with the help of a cofactor
(DiGeorge syndrome critical region in gene 8 (DGCR8) in humans) processes the primiRNA to the hairpin loop structure of about 60-70 nts79,80. Drosha recognizes a large
loop (≥10 nts) at the end of the hairpin structure as well as structural features of the
hairpin stem81.
This processed form is known as the precursor miRNA (pre-miRNA). The premiRNA is transported out of the nucleus by exportin-5 (Exp-5), a nuclear transport
receptor82,83. Once in the cytoplasm, the pre-miRNA is cleaved by the RNase III enzyme
Dicer to form a double-stranded mature miRNA that is approximately 22 nts
long67,75,84,85.
The double-stranded miRNA is then loaded onto the Argonaute (Ago) proteins to
form the RISC. The miRNA will undergo strand selection where the passenger strand is
degraded and the guide miRNA strand is left in the RISC86,87. Thermodynamic stability is
an important factor in strand selection. The double-stranded miRNA is unwound and the
miRNA strand with the weakest 5′-end binding is chosen as the guide strand. Thus, there
is a bias to have an uracil residue on the 5′-end of the guide strand as this contributes to
weaker binding. However, many other factors are involved in selecting the guide strand.
Some examples are the orientation of the double-stranded duplex when it is loaded onto
11

RISC, the cell type, and proteins such as Ago, whose functions in the process remain
unknown86. The RISC scans the mRNA pool to find the target mRNA through basepairing interactions between the guide miRNA and mRNA 3′-untranslated region (UTR)
to suppress translation of the mRNA target60,67.

Figure 1.4: Maturation pathway of miRNAs.
Schematic diagram depicting the miRNA maturation process. The primary miRNA (primiRNA) is transcribed from the DNA and processed by Drosha and DGCR8 to a single
hairpin loop structure with a 2 nucleotide (nt) 3′-overhang, known as the precursor
miRNA (pre-miRNA). The pre-miRNA is exported out of the nucleus by the nuclear
transport receptor protein exportin-5 (blue) and undergoes processing by Dicer to form a
double-stranded mature miRNA. The miRNA then undergoes strand selection by
Argonaute (maroon) and incorporation into the RNA-induced silencing complex (RISC)
where it will then bind its target mRNA to form the mRNA RISC (mRISC).

1.3.3

Regulation of miRNA through untemplated nucleotide addition

Recent high-throughput sequencing studies revealed the presence of untemplated
nucleotide additions to the 3′-termini of nearly 40% of miRNAs88,89. As part of miRNA
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maturation and degradation, untemplated uridine90,91 and adenine92 residues are added to
pre-miRNAs and mature miRNAs. These additional nucleotides present an efficient
means to control the level of active miRNA in a cell. Nucleotide additions to the 3′-end
of miRNAs are widespread in eukaryotes and catalyzed by several terminal RNA
nucleotidyltransferases (TENTs)48,90,93–102.
While single nucleotide additions play a crucial role in miRNA maturation, recent
reports suggest that monoadenylation of miRNAs also leads to increased miRNA
stability92,103. Monoadenylation of miRNAs are carried out by the same enzymes that
polyadenylate mRNAs. The minimal TENT Gld2 is able to polyadenylate mRNAs in the
cytoplasm as well as monoadenylate miRNAs 54,92. Gld2, thus, promotes miRNA
stabilization: Gld2-mediated monoadenylation stabilizes miRNA miR-122 transcripts in
the liver104 and human fibroblasts92 and plays a role in the translational regulation of
p53105,106(Figure 1.5B). In addition, Gld2 knockout mice show decreased miRNA
monoadenylation107.
Uridylation of miRNAs can occur on pre-miRNAs and mature miRNAs. In the
miRNA maturation pathway, a small group of pre-miRNAs known as Group II premiRNAs are processed to a single nucleotide overhang on the 3′-end and require the
addition of a second nucleotide to generate the required 2 nt 3′-overhang108. In vitro
uridylation assays and in vivo knockdowns showed that the humans TENTs TUT4,
TUT7, and Gld2 act redundantly in monouridylating the Group II pre-let-7 pre-miRNA90
(Figure 1.5A). This single nucleotide addition leads to the generation of a 2 nt 3′overhang that would allow recognition and processing by Dicer, followed by the
formation of the multiprotein RISC (Figure 1.5A), which leads to RNA silencing and
cleavage by argonaut75,90,110,111.
Polyuridylation, as opposed to monouridylation, of Group II pre-miRNAs leads to
degradation by Dis3L2 (Figure 1.5C). In general, polyuridylation requires the presence of
an accessory protein to enhance RNA binding. Lin-28 homolog A (Lin28A) is a RNA
binding protein that recruits TUT4, and to a lesser extent TUT7, via its zinc knuckle
domain to polyuridylate pre-let-791,112,113. The full-length Lin28A protein recognizes the
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let-7 stem-loop and a conserved GGAG motif near the 3′-end114. Lin28A suppresses the
biogenesis of the tumor suppressor let-7 to prevent stem cell differentiation and protein
levels slowly decrease during development to promote differentiation 115. Lin28A is an
oncogene as high levels correlate with a poor prognosis due to the suppression of mature
let-7, leading differentiated cells to become pluripotent stem cells 115,116. Lin28A
expression is, however, tissue-specific after development and can be detected in tissues
such as the placenta116.
A recent structure of Ago-cleaved pre-miRNAs (ac-pre-miRNAs) contains a 5′overhang due to trimming of the 3′-end by Ago2 or an unknown nuclease117 (Figure
1.5D). The overhang structures are thought to stem from imperfect pre-miRNA
processing. The presence of the overhangs allows TUT4 and TUT7 binding in a Lin28Aindependent manner, leading to polyuridylation and rapid RNA degradation117. In
addition to pre-miRNA polyuridylation, which prevents miRNA maturation, the TENT
terminal uridylyltransferase 1 (TUT1, Star-PAP) was shown to polyuridylate mature
miRNAs, marking them for degradation118.
TENTs play an essential role in pre-miRNA maturation and are further involved in
miRNA degradation. These mechanisms control the amount of miRNA transcripts in the
cell, but do not directly influence their specific activity. However, a recent report
suggests that TUT4 directly controls miR-26a activity93,94. The addition of a single 3′uridine to mature miR-26a, a miRNA involved in cytokine expression, silences miR-26a
activity without altering miRNA abundance94 (Figure 1.5B). Deep sequencing of TUT4depleted mouse livers revealed a decrease in the number of uridylated miRNAs but not a
decrease in miRNA abundance93. TUT4 and TUT7 were shown to be redundant in
monouridylating the 3’-end of mature miRNAs95. Depletion of one or both enzymes did
not affect mature miRNA levels, suggesting that monouridylation leads to silencing and
not degradation95. These uridylation events were observed for several distinct miRNA
species such as let-7a, let-7g, and miR-10a, likely representing a general and direct
mechanism to regulate miRNA activity93,95.
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Figure 1.5: miRNA modifications.
The miRNA is regulated at various points during its maturation through untemplated
nucleotide additions. A) Group II pre-miRNAs have a 1 nt 3′-overhang and can be
monouridylated or monoadenylated to produce the 2 nt 3′-overhang recognized by Dicer.
B) Mature miRNAs are regulated by Gld2 mediated 3′ monoadenylation, enhancing their
stability, or by TUT4 catalyzed 3′ monouridylation, leading to silencing. C) Group II premiRNAs are polyuridylated by TUT4 or TUT7 in collaboration with Lin28A, leading to
3′-5′ degradation by Dis3L2. D) Ago-cleaved pre-miRNAs (ac-pre-miRNAs) with a 5′overhang are polyuridylated by TUT4, TUT7, or Gld2, possibly leading to rapid
degradation.

Terminal RNA Nucleotidyltransferases

1.4

Many terminal RNA nucleotidyltransferase (TENT) homologs have a biochemically
characterized biological function and are categorized

as PAPs

or terminal

uridylyltransferases (Tutases), yet some homologs remain uncharacterized. Tutases have
been identified as novel key players in mRNA turnover47,48,119–121, with additional roles in
pre-mRNA122, non-adenylated histone mRNA49,50,55,56, and miRNA metabolism93–
95,112,123

.

Humans

encode

three

Tutases

(TUT1124,125,

TUT447,50,90,93–95,126,

TUT747,55,90,95,117) and two non-canonical PAPs (Gld292,104–106,127, PAPD1128,129). In
fission yeast, several PAPs (Cid11130, Cid12131, Cid13132, Cid14133,134) and Tutases
(Cid1135,136, Cid16137) have been identified. A variety of TENTs have been characterized,
and we highlighted these discoveries in a recent review 138. In the following sections, I
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will focus on the TENTs relevant to this thesis: S. pombe TENT caffeine induced death
protein 1 (Cid1) and the human TENTs TUT1, TUT4, TUT7, and Gld2.

Figure 1.6: Domain organization of selected TENTs.
TENTs share the major catalytic domains but differ in their RNA binding domains. Ntr,
Nucleotidyltransferase domain; PAP, Poly(A) polymerase associated domain; Zn, Zinc
finger; PnG, PneumoG domain; Atr, Atrophin-like domain; RRM, RNA recognition
motif; PRR, proline-rich region.

1.4.1

Adenylation vs. uridylation

Enzymes with uridylyl- and adenylyltransferase activity are closely related in amino
acid sequence and similar in their protein domain architecture and structure. Significant
sequence similarity between PAPs and Tutases has obscured identification of sequence or
structural features

that

differentiate a true

adenylyltransferase

from a true

uridylyltransferase.
The biochemical characterization of the non-canonical PAP Cid1 from S. pombe
revealed an unexpected in vitro and in vivo Tutase activity, introducing Cid1 as the first
identified

uridylyltransferase121.

nucleotidyltransferase

domain

The
and

catalytic

core

PAP-associated

of

Cid1

domain,

consists
much

of

like

a
its

adenylyltransferase counterpart Gld2109,136. This homologous catalytic core is also found
in TUT4 and TUT7. All of these enzymes are members of the DNA polymerase β-like
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superfamily (Figure 1.6). While Cid1, TUT4, and TUT7 have been shown to act as
uridylyltransferases in vivo46,50,93–95,112,123,136,139, Gld2 has been shown to act as both an
adenylyltransferase and uridylyltransferase31,92,104,105,109,140.
The crystal structure of U-specific Cid1 revealed the molecular basis of nucleotide
discrimination: a single histidine residue in Tutases sterically hinders ATP from entering
the active site (Figure 1.6)141. Some uridylyltransferases such as Naegleria gruberi Cid1
encode a phenylalanine instead of a histidine at this site, however both aromatic amino
acids may serve to block ATP from the active site through steric hindrance 109. Mutation
of this histidine to an asparagine in Cid1 and to a leucine in Xenopus laevis TUT7 yielded
an enzyme that lost its specificity for UTP, indicating that the histidine is crucial for UTP
selectivity141,142.
It is important to note that adenylation and uridylation can have opposing effects on
mRNA and miRNA stability (Figures 1.5 and 1.7). Generally, the addition of an adenine
residue to mature miRNAs leads to stability104 while an uridine residue leads to
silencing93. Group II pre-miRNAs, however, require the addition of an uridine residue90
on the 3′-end for proper maturation, while an oligo(U) tail, with the help of Lin28A, will
lead to degradation by Dis3L291,112. The addition of an oligo(U) tail to a shortened
poly(A) tail (less than 25 nts) of mRNAs can lead to degradation by the 3′-5′ exonuclease
Dis3L250 and decapping of the 5′-end45. On the other hand, an oligo(A) tail will lengthen
the poly(A) tail and extend the half-life of the mRNA31,96,143–145. In addition, histone
mRNAs are subjected to 5′-3′ and 3′-5′ degradation when polyuridylated49. These
opposing biological roles by very similar enzymes emphasize the need to define the
biochemical activity of every TENT in order to correctly assign their biological function.
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Figure 1.7: Overview of mRNA modifications by adenylation and uridylation in
humans.
Polyadenylation of A) mRNAs by Gld2 and B) pre-mRNA by TUT1 extends their halflife. C) TUT4 or TUT7 uridylation of histone mRNAs leads to 5′-3′ and 3′-5′
degradation. D) TUT4 or TUT7 uridylation of mRNAs with short poly(A) tails leads to
5′-3′ and 3′-5′ degradation.

1.4.2

Human uridylyltransferases

Like the yeast homolog Cid1, human TUT4 and TUT7 both encode a
nucleotidyltransferase (NTR) domain and an adjacent PAP-associated domain141,146–150
(Figure 1.6). While Cid1 lacks obvious RNA binding motifs, TUT4 and TUT7 encode
several zinc finger domains thought to be responsible for substrate binding and substrate
specificity. Both enzymes share a similar domain structure with three CCHC zinc fingers,
an N-terminal C2H2 zinc finger, and a C-terminal catalytic core consisting of the NTR
domain and the PAP-associated domain (Figure 1.6). An additional copy of the catalytic
core exists in the N-terminal region and is believed to be inactive as it lacks the aspartate
triad in the NTR domain required for catalytic activity126. Due to the similarity in domain
structure between TUT4 and TUT7, studies have shown that they may play redundant
cellular roles47,90,112. TUT4 and TUT7 localize to the cytoplasm and can add single
nucleotides to miRNAs (Figure 1.5A, B) or many uridine residues to histone mRNAs,
miRNAs, and mRNAs (Figures 1.5C, D and 1.7C, D)50,93,94,112,123. The three CCHC-zinc
finger domains flanking the active site are thought to assist in RNA binding 112 and the
C2H2 domain plays a specific role in the miRNA decay pathway, mediating the
association of TUT4 to the RNA binding protein Lin28A117 (Figure 1.6). Lin28A recruits
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Tutases to certain substrate RNAs and is most likely required for processive
uridylation112. Mutational analysis of the conserved cysteine residues in the C 2H2 zinc
finger domain showed a decrease in Lin28A-enhanced uridylation activity112. Additional
domains unique in TUT4 (Atrophin-like and Pneumo-G like domain, Figure 1.6) are not
required for Tutase activity, but may be involved in substrate specificity and regulation of
TUT495. Taken together, these studies suggest polyuridylation in humans is coordinated
by multiple Tutases that control mRNA degradation pathways.
Terminal uridylyltransferase 1 (TUT1, Star-PAP) is localized to the nuclear speckle
and plays a role in cellular stress response, global regulation of miRNA abundance, and
intron splicing88,118,124,125,151–153. TUT1 encodes an NTR domain and a PAP-associated
domain but differs from the other TENTs with a proline-rich region (PRR) that is inserted
in the NTR domain. TUT1 also encodes a N-terminal C2H2 zinc finger and RNA
recognition motif (RRM)154 (Figure 1.6). TUT1 activity is associated with both
adenylation-dependent pre-mRNA stabilization (Figure 1.7B) and uridylation-dependent
RNA turnover. TUT1 restores the 3′-end uridyl residues of the U6 small nuclear RNA
(snRNA) in the nucleus124,125,152.
TUT1 utilizes an unusual mechanism of 3′-cleavage and polyadenylation when
modifying pre-mRNAs155. TUT1 is activated by phosphorylation which directs substrate
specificity and enhances activity. The activated enzyme binds to a GC-rich region in the
3′-UTR of its pre-mRNA substrates via its RRM and C2H2 zinc finger122,151,156. Upon
binding, TUT1 directly interacts with the cleavage and polyadenylation stimulating factor
(Cpsf) 160 and Cpsf 73 which subsequently recruit Cpsf 100 and Cpsf 30122. Cpsf 73 acts
as an endonuclease and cleaves the pre-mRNA strand, followed by TUT1-catalyzed
polyadenylation and subsequent stabilization of the mRNA122. Among the bestcharacterized pre-mRNA targets of TUT1 are coding sequences for heme oxygenase-1
(HO-1) and Bcl2-interacting killer (BIK). HO-1 and BIK are involved in oxidative stress
and apoptotic responses, respectively122,151,155,157. Under oxidative stress, TUT1 is
phosphorylated at serine and threonine residues in the PRR and targets HO-1120,122,155,158–
161

. Cellular stress such as viral infections and DNA damage will activate a different

signaling pathway that results in phosphorylation of the PRR in TUT1, resulting in TUT1
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targeting BIK151,162–164. TUT1 can also be phosphorylated at serine 6 in the N-terminal
zinc finger domain by casein kinase 1 isoform α (CK1α) independently of oxidative
stress162.

1.4.3

Gld2, the minimal human nucleotidyltransferase

While single nucleotide additions play a crucial role in miRNA maturation, recent
reports suggest that monoadenylation of miRNAs leads to increased miRNA
stability92,103. The TENT homolog Gld2 was first described as a non-canonical PAP
involved

in

C.

elegans

germline

development,

stabilizing

mRNAs

through

polyadenylation36 (Figure 1.7A). Gld2 may associate with RNA-binding proteins to target
specific RNAs as the enzyme lacks identifiable RNA binding domains165. In C. elegans,
efficient and processive mRNA polyadenylation requires the association of Gld2 with
Gld3, a developmental regulator36. In humans, Gld2 has been shown to associate with the
RNA binding proteins QKI-7 to polyadenylate mRNA targets166. Additionally, Gld2
promotes miRNA stabilization. Gld2-mediated monoadenylation stabilizes miRNA miR122 transcripts in the liver104 and human fibroblasts92, while it also plays a role in the
translational regulation of p53105,106 (Figure 1.5B). Gld2 knockout mice show decreased
miRNA

monoadenylation,

suggesting

a

primary

role

of

Gld2

in

miRNA

monoadenylation107. In liver cells, miR-122 abundance is likely controlled as a balance
between the stabilizing effect of Gld2-catalyzed adenylation and the antagonistic,
destabilizing effect of 3′-deadenylation by poly(A) specific ribonuclease (Parn)127.
Biochemical assays with recombinant human Gld2 discovered a previously unknown
Gld2-mediated uridylation activity. Different reports documented Gld2 catalyzed
adenylation and uridylation of miR-12292 and monouridylation of pre-let-790 in vitro. As
such, the biological role of Gld2 was unclear, as both uridylation and adenylation activity
were shown, which have opposing effects on RNA stability.
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1.4.4

The founder uridylyltransferase Cid1

S. pombe Cid1 was initially identified as a protein required for S-M phase cell cycle
checkpoint control135 and was thought to exhibit PAP activity promoting mRNA
stability165. Deletion of Cid1 prevents yeast cells from growing when exposed to the cell
cycle check point inhibitors caffeine and hydroxyurea135. Overexpression of Cid1,
however, allowed the cells to suppress the effects of hydroxyurea135.
When a deadenylation-independent pathway initiated by the addition of uridine
residues to polyadenylated mRNAs was identified in S. pombe, it raised the possibility of
Cid1

acting

as

a

Tutase46.

From

a

detailed

biochemical

and

structural

characterization121,141,146,147,165, it has now become clear that Cid1 is in fact a Tutase,
catalyzing the polyuridylation of mRNAs in vitro, with predominantly monouridylated
RNAs produced by Cid1 in vivo46,51. Upon uridylation, the Lsm1-7 decapping complex is
recruited for mRNA 5′-3′ degradation46 and 3′-5′ degradation is carried out by the
exonuclease Dis3L251,168–172. It is unknown how (U)-tail length is controlled in the cell,
and whether these RNA species are exclusively uridylated by Cid1, as several additional
TENT homologs are present in S. pombe109.
Cid1 is known as the minimal TENT, containing only the two domains necessary for
catalytic activity, the NTR domain and PAP-associated domain. These are also the only
two domains present in Cid1’s adenylyltransferase counterpart Gld2. As both enzymes
lack defined RNA binding domains, both enzymes display substrate promiscuity in
vitro109,173. Substrate selectivity in vivo is thought to be achieved by interactions with
RNA binding interacting proteins31,36,145,166,174.
The major difference between Cid1 and Gld2 lies in their nucleotide preference, Cid1
prefers UTP while Gld2 prefers ATP109,136. This is due to the presence of a critical
histidine residue in the PAP-associated domain of Cid1 that sterically hinders ATP from
entering the catalytic site141. Gld2 lacks this histidine residue and is thus able to accept
ATP109. Interestingly, Cid1 is capable of adding a biotinylated ATP derivative, in the
absence of UTP, to in vitro RNA transcripts under optimized conditions and is currently
used for 3′-biotinylation of RNAs175.
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1.5

Scope of Thesis

The regulation of RNAs through the addition of untemplated nucleotides to their 3′ends has become an increasingly recognized regulatory modification. Adenylation and
uridylation are associated with opposite biochemical outcomes with regard to RNA fate.
Generally, adenylation stabilizes RNAs while uridylation silences miRNAs or marks
RNAs for degradation. These additions play important roles in the regulation of mRNAs,
either directly through nucleotide additions to the 3′-end of mRNAs or indirectly through
miRNA regulation19,20,101,138,175. The enzymes that perform these tasks, TENTs, are thus
of great interest. Therefore, I hypothesize that TENTs are required to maintain RNA
homeostasis. In this thesis, the abilities of the TENTs Gld2 and Cid1 to catalyze
nucleotide addition and regulate RNA stability were examined using precise biochemical
assays.
Gld2 is a member of the non-canonical poly(A) polymerases, which include enzymes
with varying nucleotide specificity, ranging from strictly ATP-adding to ambiguous to
exclusively UTP-adding enzymes. Human Gld2 has been associated with transcript
stabilizing miRNA monoadenylation and cytoplasmic mRNA polyadenylation 92,104,166.
More recent data revealed an unexpected miRNA uridylation activity, which promotes
miRNA maturation90. These conflicting data raise the question of Gld2 nucleotide
specificity. Chapter 2 biochemically characterizes human Gld2 and demonstrates that it is
a bona fide adenylyltransferase in vitro with only weak activity toward other nucleotides.
Despite its sequence similarity with uridylyltransferases (TUT4, TUT7), I show that Gld2
displays an 83-fold preference for ATP over UTP. I further show that Gld2 is
promiscuous for its RNA substrate, with activity toward miRNA, pre-miRNA, and
polyadenylated RNA substrates. In vitro Gld2 activity is restricted to adding single
nucleotides109 while processivity observed in vivo likely relies on additional RNAbinding proteins166. In a phylogenetic analysis of the PAP/Tutase superfamily, I further
show that uridylyltransferase activity, which is derived from distinct adenylyltransferase
ancestors, arose multiple times during evolution via insertion of an active site histidine
residue. A corresponding histidine insertion into the Gld2 active site switches substrate
specificity from ATP to UTP109.
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Chapter 3 elucidates the first link between oncogenic kinase activity and the
regulation of miRNA stability. The de-regulation of miRNAs is associated with multiple
human diseases, yet cellular mechanisms governing miRNA abundance remain largely
unknown58. While Gld2 activity was shown to stabilize miRNAs 92,104, the regulation of
Gld2 itself remained unclear. Human miR-122 is required for Hepatitis C proliferation
and low miR-122 abundance is associated with hepatic cancer176. Gld2 catalyzes the posttranscriptional addition of a single adenine residue (A+1) to the 3′-end of miR-122,
enhancing its stability92. I found that Gld2 activity is regulated by site-specific
phosphorylation in its predicted disordered N-terminal domain. I identified two
phosphorylation sites (S62, S110) where phosphomimetic substitutions increased Gld2
activity and one site (S116) that markedly reduced activity. Using mass spectrometry, I
confirmed that HEK 293 cell extracts readily phosphorylate the N-terminus of Gld2 at
S62. I also identified protein kinase A (PKA) and protein kinase B (Akt1) as kinases that
site-specifically phosphorylate Gld2 at S116, abolishing Gld2-mediated nucleotide
addition. The data demonstrate a novel phosphorylation-dependent mechanism to
regulate Gld2 activity, revealing tumor suppressor miRNAs as a previously unknown
target of Akt1-dependent signaling.
Uridylation-dependent RNA decay is a widespread eukaryotic pathway modulating
RNA homeostasis99,168. Tutases add untemplated uridine residues to RNA 3′-ends,
marking them for degradation by the U-specific exonuclease Dis3L2168. In S. pombe,
Cid1 uridylates a variety of RNAs121,136. Chapter 4 investigates the prevalence and impact
of uridylation-dependent RNA decay in S. pombe by transcriptionally profiling cid1 and
dis3L2 deletion strains. I found that the exonuclease Dis3L2 represents a bottleneck in
uridylation-dependent mRNA decay, whereas Cid1 plays a redundant role that can be
complemented by other Tutases. Deletion of dis3L2 elicits a cellular stress response, upregulating transcription of genes involved in protein folding and protein degradation.
Misfolded proteins accumulate in both deletion strains, yet only trigger a strong stress
response in dis3L2 deficient cells. While deletion of cid1 increases sensitivity to protein
misfolding stress, a dis3L2 deletion showed no increased sensitivity or was even
protective. Furthermore, uridylyl- and adenylyltransferases were shown to cooperate to
generate a novel 5′-NxAUUAAAA-3′ RNA motif on dak2 mRNA. These studies
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elucidate the role of uridylation-dependent RNA decay as part of a global mRNA
surveillance, and perturbation of this pathway leads to the accumulation of misfolded
proteins and elicits cellular stress responses.
This thesis presents work characterizing the adenylyltransferase Gld2 and identifies
site-specific serine phosphorylation as a means of TENT regulation. In addition, the
cellular impact of the founder uridylyltransferase Cid1 on global RNA uridylation was
explored. Altogether, the work takes a closer look at the regulation and impact of the
minimal TENTs Gld2 and Cid1 that can be used as a starting point in the study of other
TENTs.
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Chapter 2

2

Nucleotide specificity of the human terminal
nucleotidyltransferase Gld2 (TUT2)

2.1

Introduction

Since microRNA (miRNA) discovery in the early 1990s 1,2, it has become evident that
post-transcriptional gene regulation by miRNAs is involved in most biological
processes3–7. The latest miRBase release contains 24,521 experimentally validated
miRNA genes from 206 species8. Dysfunctional miRNA expression, processing, and
degradation have been found in breast cancer9, acute myeloid leukemia10, ovarian
cancer11, and hepatocellular carcinoma12. Deregulated miRNA processing also
contributes to other major diseases such as Hepatitis C 13 and cardiovascular diseases14.
Because miRNAs regulate genes that change cellular fate, miRNAs and proteins involved
in miRNA regulation are promising next-generation cancer therapeutic targets. In
addition, specific components of the RNA processing machinery are currently used as
biomarkers for cancer detection15–19.
The generation of miRNAs is a multistage process and translational inhibition by
miRNAs is achieved through base pairing with the 3’-UTR of the respective target
mRNA, leading to mRNA decay or silencing20. Recent high-throughput sequencing
studies revealed the presence of untemplated nucleotide additions to the 3′ termini of
nearly 40% of miRNAs21,22. Of these, depending on the miRNA species, ~50% displayed
an extra adenine, 25% contained a single additional uridine, and the remaining 25%
contained multiple nucleotides appended to the 3′-termini22. During miRNA maturation
and degradation, untemplated uridine23,24 and adenine25 residues are added to premiRNAs and mature miRNAs. These untemplated nucleotide additions are an efficient
means to control the levels of active miRNAs in the cell. The seemingly innocuous
addition of a single nucleotide can initiate miRNA maturation, stabilization, or convert an
active miRNA to an inactive form26. While multiple adenine residues are added to mRNA
for stabilization, extending the transcript life-span27, multiple uridine residues mark both
miRNA and mRNA for degradation28–30. The presence of untemplated nucleotides on a
34

variety of miRNAs is now well known; however, the corresponding enzymes have only
recently become the focus of biochemical characterization.
Nucleotidyltransferases such as the human terminal uridylyltransferases (TUTs)
TUT4 (Zcchc11, TENT3A), TUT7 (Zcchc6, TENT3B) and the minimal homolog Gld2
(TUT2, PAPD4, TENT2) have been shown to play fundamental roles in the regulation
and maturation of miRNAs let-7 and mir-122. Tutase homologs are part of the
nucleotidyltransferase superfamily of enzymes and were initially identified as
adenylyltransferases associated with miRNA and mRNA adenylation. Gld2 was first
described

as

a

cytoplasmic

non-canonical

poly(A)

polymerase

involved

in

Caenorhabditis elegans germline development. C. elegans Gld2 displayed very little
activity on its own however, and relies on an additional protein, Gld3, to promote
adenylation31,32. In Drosophila, specific depletion of the Gld2 homolog WISPY
connected its function with mRNA polyadenylation required for oocyte to egg
activation33, as well as long term memory34 (Figure 2.1A). Recent data showed that in
addition to mRNA adenylation, WISPY adenylates miRNAs in S2 cells leading to a
reduction of miRNA levels35. This observation that adenylation reduces miRNA levels35
contradicts reports that monoadenylation stabilizes naturally unstable miRNAs 25 and
demonstrates the complexity of untemplated nucleotide additions.
In humans, Gld2 has been equally associated with miRNA and mRNA adenylation as
well as miRNA uridylation. The first reports associated human Gld2 with mRNA
polyadenylation36 by monitoring translation of a reporter mRNA tethered to human Gld2
and injected into Xenopus oocytes. In vivo, RNA polyadenylation requires either artificial
RNA tethering36 or accessory RNA binding proteins such as the cytoplasmic
polyadenylation element binding protein (CPEB) in Xenopus37,38 and Gld3 in C.
elegans31. Further studies showed that Gld2 mediated monoadenylation stabilizes miR122 transcripts in human fibroblasts25 and plays a role in translational regulation of
p5339,40. Monoadenylation is, in contrast to polyadenylation not entirely dependent on
RNA binding proteins, as purified Gld2 from human cells displayed catalytic activity in
vitro. With the discovery of the poly(U) polymerase activity of enzymes previously
thought to be poly(A) polymerases, specifically the human Gld2 homologs TUT4 and
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TUT741, most recent research has uncovered a previously unknown Gld2 mediated
uridylation activity. D’Ambrogio and colleagues demonstrated for the first time that
human Gld2 is the enzyme responsible for monoadenylation and subsequent stabilization
of miRNA-122, but they also reported a weaker uridylation activity25. Gld2 has further
been shown to catalyze the monouridylation of pre-microRNA let-7a, which is crucial for
its maturation24. Flag-tagged human Gld2 purified from HEK 293T cells adds a single
uridine to pre-let-7a but also displayed catalytic activity adding GTP and ATP, but not
CTP in vitro24. Interestingly, Gld2-mediated polyuridylation has been observed on prelet-7a overhang variants42 in the absence of accessory proteins. Further evidence linking
Gld2 to pre-microRNA uridylation stems from knockdown assays, showing that TUT4,
TUT7 and Gld2 redundantly control pre-let-7 maturation and are required for let-7
biogenesis24. Gld2 can thus function as either a Poly(A)-Polymerase (PAP) or a TUT in
vitro.
Gld2 is composed of two major domains, a PAP associated domain and a
nucleotidyltransferase (NTR) domain (Figure 2.1B). Its closest human homologs, TUT4
and TUT7 are comprised of the same domains but feature additional RNA-binding
motifs, such as Zinc-finger domains. TUT4 and TUT7 have been characterized in vivo
and in vitro as true uridylyltransferases and are involved in multiple processes including
miRNA and mRNA uridylation. For example, uridylation of the let-7a precursor by
TUT4 can drive processing by Dicer or mark the precursor miRNA for degradation, thus
directly controlling let-7a levels in the cell23,26,30,43. Gld2 has been proposed to carry out a
similar function during miRNA maturation24,42. While the role of TUT4 and TUT7 in
these processes is becoming increasingly clear, the catalytic activity and biological role
of the minimal nucleotidyltransferase Gld2 is uncertain. Evidence for both uridylation
and adenylation activity of the human enzyme has been shown in in vivo and in vitro
experiments, but a conclusive investigation of Gld2 nucleotide preference is lacking.
We here present a biochemical characterization of Gld2, identifying it as a bona fide
adenylyltransferase in vitro with only weak activity towards UTP and GTP. Conversely,
Gld2 displays a wide target RNA substrate range, adenylating multiple RNAs in vitro.
The data suggest that Gld2 RNA substrate selectivity may require association with other
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protein factors in the cell. A detailed phylogenetic analysis shows that uridylyl- and
adenylyltransferases are closely related, and that uridylyltransferase activity arose
independently multiple times during evolution.

Figure 2.1: Proposed catalytic activities and domain organization of Gld2.
A) Gld2 has been implicated in nucleotide addition to multiple RNA substrates in
different pathways. B) Domain organization of Gld2 and its homologs TUT4 and TUT7.
Dark purple: Pneumo-G domain; Red: C2H2 Zinc finger domain; Blue:
Nucleotidyltransferase domain; Orange: Poly(A) polymerase associated domain; Green:
CCHC type Zinc finger domain; Light purple: Atrophin-like domain.

2.2
2.2.1

Materials and Methods
Gld2 cloning and site-directed mutagenesis

Total RNA was extracted from HeLa cells using the GeneJET RNA purification Kit
(Thermo Scientific) and reverse transcription was performed with SuperScript II Reverse
Transcriptase (Invitrogen) using an oligo(dT)16 primer. PCR was carried out on the
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cDNA with gene specific primers (Gld2EcoR1for 5′-GAATTCGATGTTCCCAAACTC
AATTTTGGG-3′ and Gld2Xho1rev 5′-CTCGAGTCTTTTCAGGA-CAGCAGCTC-3′).
The cDNA was digested with EcoRI/XhoI and ligated into pET20b. Quickchange Site
directed mutagenesis (Agilent) was employed according to manufacturer’s instructions to
generate

a

Gld2-His

insertion

variant,

using

primers

Tut2Hisfor

5′-

GAACCTTTTGATGGAACA CATAATACAGCCAGAGCAGTGC-3′ and Tut2Hisrev
5′-GCACTGCTCTGGCTGTA TTATGTGTTCCATCAAAAGGTTC-3′. The construct
and mutation were verified by DNA sequencing (Genewiz).

2.2.2

Gld2 expression and purification

Escherichia coli BL21 (DE3) RIL cells (Agilent) were transformed with pET20bGld2 and grown in LB medium containing ampicillin (100 µg/mL) and chloramphenicol
(34 µg/mL) at 37°C until OD600 = 0.6. The temperature was lowered to 20°C and
isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to a final concentration of 250
µM to induce protein expression. Cells were harvested after 19 hours by centrifugation
and suspended in Buffer A (10 mM Tris-HCl, pH 8.0, 200 mM KCl, 5 mM MgCl2). Cells
were broken by the addition of lysozyme followed by sonication on ice. The cell lysate
was centrifuged for 45 minutes at 15,000g and 4°C. Cell free extract was loaded onto
HisPur Ni-NTA resin (Thermo Scientific) equilibrated with Buffer A. The resin was
washed with Buffer B (10 mM Tris-HCl, pH 8.0, 200 mM KCl, 5 mM MgCl2, 10 mM
imidazole) and proteins were eluted with Buffer C (10 mM Tris-HCl [pH 8.0], 200 mM
KCl, 5 mM MgCl2, 250 mM imidazole). The elution fractions containing Gld2 were
dialyzed against Buffer D (10 mM Tris-HCl, pH 8.0, 200 mM KCl, 5 mM MgCl2, 10%
glycerol) overnight at 4°C with gentle mixing and stored at -80°C. Gld2 protein
concentration was determined by a Bradford test.

2.2.3

Size exclusion chromatography

A 200 µL sample containing Gld2 in Buffer A was passed through an ENrich SEC
650 high-resolution size exclusion column (Bio-Rad) equilibrated with Buffer A. The
flow rate was 0.75 mL/min and 1 mL fractions were collected upon injection of the
sample. The fractions that corresponded to the peaks on the absorbance graph were
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subjected to ammonium sulfate protein precipitation and analyzed by sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on a 15% polyacrylamide gel.
For the purposes of calibration, vitamin B12 (Mr ≈ 1.3 kDa), bovine insulin (Mr ≈ 6
kDa), cytochrome c (Mr ≈ 13.6 kDa) bovine carbonic anhydrase (Mr ≈ 30 kDa),
ovalbumin (Mr ≈ 43 kDa), BSA (Mr ≈ 67 kDa), ferritin (Mr ≈ 440 kDa) and
thyroglobulin (Mr ≈ 669 kDa) were used as marker components and chromatographed
under identical conditions.

2.2.4
The

RNA substrate preparation
following

RNA

substrates

were

purchased

from

Sigma

Aldrich:

monophosphorylated human let-7a-5p (5′ (p)-UGAGGUAGUAGGUUGUAUAGUU3′), unphosphorylated human let-7a-0p (5′-UGAGGUAGUAGGUUGUAUAGUU-3′),
diphosphorylated human let-7a-5p-2p (5′ (pp)-UGAGGUAGUAGGUUGUAUAGUU3′), triphosphorylated human let-7a-5p-3p (5′ (ppp)-UGAGGUAGUAGGUUGUAUAGU
U-3′), the poly(A) tail mimic 15A RNA (5′ (p)-AAAAAAAAAAAAAAA-3′), human
microRNA miR-122-5p (5′ (p)-UGGAGUGUGACAAUGGUGUUUG-3′), and total E.
coli tRNA. The coding sequence for a ribozyme-pre-let-7a with a T7 Promoter sequence
was cloned into pUC19 for in vitro transcription with T7 RNA polymerase using the
following primers (pre-let7 5′-CTAGATAATACGACTCACTATAGGGAGACTACTA
CCTCACTGATGAGTCCGTGAGGACGAAACGGTACCCGGTATAGGTTGTATAG
TTTTAGGGTCACACCCAACTGGGAGATAACTATACAATCTACTGTCTTTCGAA
-3′ and pre-let-7rev 5′-ATCCTTCGAAAGACAGTAGATTGTATAGTTATCTCCCA G
TGGTGGGTGTGACCCTAAAACTATACAACCTACTACGGGTACCGTTTCGTCCT
CACGGACTCATCAGTGAGGTAGTAGTCTCCCTATAGTGAGTCGTATTA-3′).
Primers were phosphorylated, annealed and cloned into pUC19 using XbaI/BamHI. For
in vitro transcription, the DNA template was amplified using primers Theforward (5′GTTGGGAAGGGCGATCGGTG-3′) and let-7PCRrev (5′-GAAAGACAGTAGATTGT
ATAG-3′). The PCR product was purified by phenol chloroform extraction, and RNA
was transcribed with T7 RNA polymerase as described previously44. Upon transcription,
the ribozyme constructs auto-cleaves into ribozyme and pre-let-7a. The transcripts were
separated by electrophoresis on a 12% denaturing polyacrylamide gel, the band
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corresponding to self-cleaved pre-let-7a was excised from the gel and eluted as described
previously45.

2.2.5

Determination of enzymatic activity and substrate range

10 µL reactions were carried out containing 100 nM Gld2 in Buffer D and 1 µM of
the respective RNA substrates. Dithiothreitol (DTT) and MgCl2 were added for a final
concentration of 1 mM and 3.2 mM, respectively. [α-32P]-UTP or [α-32P]-ATP (Perkin
Elmer) were used as indicated at a final concentration of 0.33 µM. All reactions were
incubated at 37°C for 20 minutes and stopped by the addition of 2 x RNA loading dye
(95% v/v formamide, 0.1% w/v xylene xyanol, 0.1% w/w bromophenol blue, 10 mM
ethylenediaminetetraacetic

acid

(EDTA)).

Reactions

were

analyzed

via

gel

electrophoresis on a 12% denaturing polyacrylamide gel and visualized with a
phosphorimager (Storm 860 Molecular Imager). The radiolabelled RNA Decade marker
(Ambion) was used as reference.

2.2.6

Determination of enzyme kinetics

20 µL reactions were carried out containing 100 nM Gld2 in Buffer D and 2 µM of
let-7a. DTT and MgCl2 were added to a final concentration of 1 mM and 3.2 mM,
respectively. Separate reactions contained one of the four NTPs at various concentrations.
Three technical replicates were performed for each nucleotide concentration. Higher
nucleotide concentrations were achieved by using a mixture of [α-32P]-labelled and
unlabelled nucleotides. Nucleotide concentrations were adjusted so that in an 8-minute
time course the reaction progressed linearly and < 10% of the total substrate RNA was
converted to product. The following nucleotide concentrations were used: ATP 0 - 15
µM (0 µM, 0.01 µM, 0.1 µM, 1 µM, 10 µM, 15 µM); UTP 0 - 1000 µM (0 µM, 0.01 µM,
0.1 µM, 1 µM, 10 µM, 50 µM, 100 µM, 300 µM, 1000 µM); GTP 0 - 1300 µM (0 µM, 1
µM, 10 µM, 50 µM, 100 µM, 300 µM, 1000 µM, 1300 µM); CTP 0 - 1500 µM (0 µM, 1
µM, 10 µM, 100 µM, 600 µM, 1000 µM, 1200 µM, 1500 µM). All reactions were
incubated at 37°C for 30 seconds before Gld2 was added (at t = 0) and 5 µL samples
were then taken out at 2, 4, 6, and 8 minutes. The reactions were stopped with the
addition of 2 x RNA loading dye. Reactions were analyzed via gel electrophoresis on a
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12% denaturing polyacrylamide gel and visualized by phosphorimaging overnight. To
quantify product formation, a strip of Whatman filter paper was spotted with different
known concentrations for each [α-32P]-labelled nucleotide and imaged on the same
phosphorimaging screen. Spot intensity was quantified using ImageJ. Kinetic constants
were derived from plotting initial velocity (vo) against nucleotide concentration. Kinetics
were fitted to the standard Michaelis–Menten curve using Kaleida Graph 3.1 (Synergy
Software) and SigmaPlot (Systat Software). Error bars represent 1 Standard Deviation
from 3 replicates.

2.2.7

Phylogenetic analysis

Sequences were downloaded from the National Center for Biotechnology Information
(NCBI). Sequence alignment and alignment editing was carried out using Muscle 46 and
the Multiseq alignment editor from VMD 1.8.747. A maximum likelihood phylogeny for
Gld2 sequences was determined using PhyML48. The starting tree was generated with
BioNJ, and the tree space was searched with the SPR followed by the NNI algorithm to
find the best tree. The JTT+Γ model with 4 rate categories was applied. Likelihood
parameters were initially estimated from the alignment, Shimodaira–Hasegawa bootstrap
values were computed as implemented in PhyML.

2.3
2.3.1

Results
Gld2 displays RNA substrate promiscuity

Gld2 has been implicated in multiple pathways of mRNA and miRNA regulation. To
test whether Gld2 displays enzymatic activity in vitro, we recombinantly expressed and
purified full length human Gld2 from E. coli. Gld2 eluted from a gel filtration column as
a monomer. To evaluate Gld2 activity, we first assessed its substrate range. Previously
suggested roles for Gld2 activity are in miRNA regulation, including miR-122
adenylation25 and the uridylation of pre-let-7a and let-7a24,38. Another study linked Gld2
to mRNA adenylation49. We therefore included miR-122, pre-let-7a, let-7a, total human
mRNA and a poly(A) tail mimic comprised of 15 adenines (15A) in our initial assays and
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total E. coli tRNA as a control.
Surprisingly, Gld2 displayed adenylation activity on all substrates in vitro (Figure
2.2). For miRNAs and the 15A RNA a single band was observed, corresponding to
monoadenylation of the substrate RNAs. For the premature miRNA substrate, pre-let-7a,
a band around 70 bases was observed, indicating single nucleotide addition. While the in
vitro transcribed pre-let-7a was purified as a single transcript (Figure 2.3), additional
bands of lower molecular weight were observed. These bands are likely due to the
adenylation of partially degraded substrate RNA or degradation during the enzymatic
reaction. For both total tRNA and total mRNA multiple bands were observed, but due to
heterogeneity of the substrates we are unable to confirm that these are single nucleotide
additions. Nevertheless, no clusters of ladder-like nucleotide additions were observed in
these cases, indicating that the heterogenic substrates were likely monoadenylated.

Figure 2.2: RNA substrates of Gld2.
Gld2 was incubated with different RNA substrates and [α-P32]-ATP as indicated.
Formation of [α-32P]-labelled RNA products was monitored by electrophoretic separation
and subsequent phosphorimaging. Gld2 catalyzed [α-32P]-ATP addition to RNA
substrates pre-let-7a (72 nts), mature human miRNAs let-7a-5p (22 nts), miR122 (22 nts),
an oligo (A) tail mimic 15A (15 nts), and total E. coli tRNA and total human mRNA. A
representative gel is shown. C is no enzyme control.
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Figure 2.3: In vitro transcription of pre-let-7 RNA.
Pre-let-7a was transcribed as a ribozyme-fusion RNA, which self-cleaves after
transcription. The band corresponding to pre-let-7a (72 nts) was excised from the gel,
purified and a single band was observed in a denaturing polyacrylamide gel
electrophoresis after purification.

2.3.2

Nucleotide preference of recombinant Gld2

We determined the specificity of Gld2 for all of the four nucleotides ATP, CTP, GTP
and UTP. In enzyme assays containing a single nucleotide species, pre-let-7a, and Gld2,
the enzyme was active with all NTPs (Figure 2.4A). Gld2 can accommodate each NTP in
the active site and catalyze their 3′ addition to pre-let-7a. In a competition assay, which
included all four nucleotides in equimolar concentrations with only one [α-32P]-labelled
nucleotide, only ATP was added to pre-le-7a (Figure 2.4B). Thus, while Gld2 displays
relaxed specificity towards RNA substrates in vitro, it exhibits a clear preference for ATP
in the presence of all four NTPs. We further investigated whether the 5′-end of the RNA
substrates influenced substrate recognition. No difference in enzyme activity was seen
when differentially 5′-phosphorylated RNA substrates were assayed with [α-32P]-ATP
(Figure 2.4C).
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Figure 2.4: Nucleotide substrates of Gld2.
Gld2 was incubated with varying nucleotides and the precursor miRNA let-7a or mature
miRNA let-7a-5p. A) Addition of single [α-32P]-labelled nucleotides to pre-let-7a and
Gld2 as indicated. B) Competitive nucleotide addition: In a competition assay, Gld2 was
incubated with pre-let-7a in the presence of all four unlabelled nucleotides in equimolar
amounts with a portion of the indicated nucleotide in an [α-32P]-labelled form. C) 5' end
phosphorylation: Gld2 activity on let-7a-5p substrates with differentially phosphorylated
5' ends were assayed with [α-32P]-ATP. Representative gels are shown. 5'-no p =
unphosphorylated, 5'-p = monophosphate, 5'-pp = diphosphate, 5'-ppp = triphosphate.

2.3.3

Gld2 is an adenylyltransferase

Our initial experiments showed that Gld2 catalyzes the addition of all four
nucleotides to pre-let-7a (Figure 2.4A). In the subsequent competition assay, a clear
preference for ATP was observed (Figure 2.4B). This led us to further investigate the
nucleotide specificity of Gld2, and we performed a detailed kinetic characterization of
Gld2 with all four nucleotides with let-7a (Figure 2.5, Table 2.1). Our kinetic analysis
confirmed that Gld2 displays the most affinity for ATP (KM ~ 0.2 µM) and is most
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efficient with ATP. Significantly increased KM values for the other nucleotides, suggests
far weaker binding affinity. Gld2 showed increases in KM of > 700-fold for UTP, 240fold for CTP, and > 1000-fold for GTP. The relative catalytic efficiency for the reactions
indicates an 83-fold preference of ATP over UTP and 71-fold over GTP. Overall catalytic
efficiency is greatest for ATP (kcat/KM = 12.8 x 10-5 µM-1s-1) with 12.9% relative
efficiency for CTP (kcat/KM = 1.66 x 10-5 µM-1s-1), and 1.2% for UTP (kcat/KM = 0.15 x 105

µM-1s-1) and 1.4% for GTP (kcat/KM = 0.18 x 10-5 µM-1s-1). Taken together, these data

indicate that Gld2 NTP specificity is determined by productive binding of Gld2 to the
respective nucleotide. While ATP is preferred and outcompetes all other NTPs, no
nucleotide is specifically excluded from the active site.

Figure 2.5: Dependence of the reaction rate on nucleotide concentration.
The plot shows the initial velocity of the enzyme reaction plotted against concentration of
A) ATP, B) CTP, C) GTP and D) UTP. Three technical replicates were performed for
each nucleotide concentration. Error bars show one standard deviation.
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Table 2.1: Nucleotide addition kinetics of Gld2.
Relative catalytic efficiency is the relative percentage in kcat/KM that is calculated as the
ratio of kcat/KM for the nucleotide listed in the far-left column over the kcat/KM for ATP.
Physiological nucleotide conditions are derived from Traut et al., 1994. Standard
deviations are reported. Reaction conditions are given in Materials and Methods.
KM (µM)

kcat (s-1)

kcat/KM (µM-1s-1)

ATP (2.93 ± 0.16) x 10-6

0.229 ± 0.077

(2.93± 0.16) x 10-5

12.8 x 10-5

UTP (24.8 ± 1.17) x 10-6

169 ± 23.3

(24.8 ± 1.17) x 10-5

0.15 x 10-5

CTP (91.4 ± 5.16) x 10-6

55.0 ± 21.9

(91.4 ± 5.16) x 10-5

1.66 x 10-5

GTP (40.3 ± 5.97) x 10-6

230 ± 112

(40.3 ± 5.97) x 10-5

0.18 x 10-5

Vmax (µM/s)

Relative efficiency kcat/KM

Physiological concentrations

ATP

100%

2102 µM

UTP

1.2%

253 µM

CTP

12.9%

91 µM

GTP

1.4%

305 µM

2.3.4

Nucleotidyltransferase specificity arose multiple times during
evolution

Gld2 is a member of the non-canonical poly(A) polymerases, a diverse group of
enzymes with varying RNA and nucleotide preferences. It includes enzymes with
nucleotide specificity ranging from strictly ATP to ambiguous ATP or UTP, to exclusive
UTP-adding enzymes. While some enzymes have a distinct substrate preference, such as
the U6 snRNA uridylating enzyme TUT628,50, which is both UTP and U6 snRNA
specific, other enzymes are more promiscuous in their substrate specificity. TUT4 and
TUT7, for example, have been shown to uridylate miRNAs 24,36, as well as histone
mRNA51 and cytoplasmic mRNA30. The Schizosaccharomyces pombe homolog Cid1
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protein was initially thought to act as an mRNA adenylating enzyme but was later
characterized as a uridylyltransferase with 1% residual adenylation activity52.
Gld2 was initially annotated as an adenylyltransferase, but recent in vivo24 and in
vitro24,25,38 evidence and its sequence similarity to confirmed TUTs (30% and 32% amino
acid sequence identity with TUT4 and TUT7, respectively) suggests a possible
uridylyltransferase

activity.

The

similar

domain

structure

of

uridylyl-

and

adenylyltransferases, as well as a high sequence similarity, suggests that these enzymes
evolved from a common ancestor. To elucidate the phylogenetic background evolution of
these enzymes, we performed a detailed phylogenetic analysis of the enzyme superfamily
to trace the evolutionary origins of NTP specificity. The phylogeny of the
nucleotidyltransferase family includes over 400 sequences (Figure 2.6).
Our analysis shows that nucleotidyltransferases display a classical star phylogeny,
with several distinct subgroups. Interestingly, uridylyl- and adenylyltransferases do not
form two separate clades, but rather Tutases emerge from distinct groups dominated by
PAPs. Uridylyltransferases are derived from distinct subfamilies of adenylyltransferases,
and Tutase activity, thus, evolved multiple times independently. One group shows the U6
snRNA uridylating enzyme TUT650 evolved from a parent clade composed of known and
putative adenylyltransferases. The nucleotide specificity of TUT6 is, however, not
restricted to snRNA uridylation, as it was additionally found to adenylate selected
mRNAs53,54. TUT6 is most closely related to the non-canonical mitochondrial poly(A)
polymerase PAPD1, which mediates RNA decay by polyadenylation55. A second distinct
subgroup includes the uridylyltransferase Cid1, which initiates RNA decay by
uridylation29, and Cid14, a poly(A) polymerase that acts on rRNAs 56 and telomeres57.
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Papd1-like

Cid16

Figure 2.6: Phylogeny of the Tutase/PAP superfamily.
Gld2 is most closely related to the genuine uridylyltransferases TUT4/TUT7. Known
enzymatic activities are colour-coded: purple, UTP preference; green, ATP preference;
black, unknown. Bootstrap values over 90% are denoted with a star. Sequence data were
downloaded from the Integrated Microbial Genomes database. The tree was calculated
with PHYML using a BioNJ starting tree and SPR tree search followed by NNI branch
swapping to optimize the tree. Bootstrap values were computed according to the
Shimodaira–Hasegawa re-estimation of log-likelihood test implemented in PHYML.

2.3.5

Insertion of a histidine residue confers UTP specificity

Gld2 displays clear nucleotide specificity for ATP, as demonstrated by kinetic
analysis of Gld2 activity on all four nucleotides and in competition experiments. Our
phylogenetic

analysis

of

the

nucleotidyltransferase

family

suggests

that

uridylyltransferase activity evolved from adenylyltransferases multiple times during

48

evolution (Figure 2.6). Previous reports showed that the mutation of the S. pombe Cid1
uridylyltransferase active site histidine (H336, Figure 2.7) to asparagine broadens its
substrate specificity to include ATP58. In Gld2, the corresponding amino acid is lacking
(Figure 2.7A). Consequently, we tested whether an insertion of a histidine residue at the
position homologous to Cid1 position H336 (between Gld2 amino acids T439 and N440
(Figure 2.7B)) confers UTP specificity over ATP. Purified recombinant Gld2 and Gld2His (Figure 2.8A) were tested with RNA substrates let-7a (Figure 2.8B) and 15A (Figure
2.8C) and radiolabelled ATP or UTP. As expected, Gld2 displayed activity with ATP and
UTP for both substrates in a non-competitive assay (Figures 2.8B panel 1, and 2.8C panel
1 and Figure 2.4A). The Gld2-His insertion variant, however, displayed significantly
decreased activity with ATP. For let-7a, no activity was observed with ATP, while a band
is visible when incubated with UTP. Similarly, we observed no band for the poly(A) tail
mimic 15A when incubated with ATP, while incubation with UTP lead to a ladder-like
addition of nucleotides. In all cases, unlike UTP, ATP was excluded as a substrate. Thus,
the insertion of a histidine residue homologous to Cid1 H336 conferred UTP selectivity
in Gld2.
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Figure 2.7: Nucleotide preference is defined by a histidine residue.
A) Excerpt from a multiple sequence alignment of 440 nucleotidyltransferase sequences.
After the alignment sequences were grouped into phylogenetic subgroups and two
representative sequences are depicted. Sequence similarities within each group were
colour-coded. Confirmed nucleotidyltransferases Cid1, TUT4, TUT6 and TUT7 and their
homologs contain a histidine (#), which confers uridyl selectivity. Adenylyltransferases
either substitute histidine with a smaller amino acid (leucine in PAPD1) or entirely lack
this residue (Gld2). B) Excerpt of a structural alignment between Cid1 (pdb 4FHP) and
PAPD1 (pdb 3PQ1). The depicted ribbon diagram shows a structural superposition of
human mitochondrial PAPD1 (grey) and Cid1 (cyan). Asn367 of Cid1 aligns with the
homologous Asn273 of PAPD1. Cid1 His336 points into the active site and makes
contact with UTP.
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Figure 2.8: Insertion of an active site histidine into Gld2 alters nucleotide specificity.
A) Gld2 and Gld2-His purification. Recombinant His-tagged Gld2 and the Gld2-His
mutant were purified via Ni-NTA chromatography to apparent homogeneity as judged by
SDS-PAGE. B) and C): Nucleotide preference of Gld2 and Gld2-His. Recombinant
enzymes were incubated with and without RNA substrates and radiolabelled ATP or
UTP. Formation of [α-32P]-labelled RNA products was monitored by electrophoretic
separation and subsequent phosphorimaging. RNA substrates were B) let-7a and C) 15A.
Representative gels are shown.

2.4
2.4.1

Discussion
Gld2 is an adenylyltransferase

Previous studies presented evidence associating Gld2 with monoadenylation25 or
monouridylation24,25,38 of miRNAs in humans. While monoadenylation confers increased
miRNA stability, monouridylation is a required step in biogenesis of Group II miRNAs.
During maturation, Group II miRNAs are processed into pre-miRNAs with a single
nucleotide 3′-overhang. TUT4, TUT7, and potentially Gld2 add an essential uridyl
residue to 1 nt 3′-overhang pre-miRNA to yield a 2 nucleotide 3′-overhang, which is a
prerequisite for processing by Dicer24,42. In Xenopus laevis and Caenorhabditis elegans,
Gld2 is required for polyadenylation of specific mRNAs, aided by RNA binding proteins
such as CPEB and Gld3, respectively31,38.
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To elucidate the nucleotide preference of human Gld2, we carried out a detailed
enzyme kinetic analysis. Using purified enzyme, we demonstrated that Gld2 is an
adenylyltransferase preferentially adding single nucleotides to small RNAs. The catalytic
efficiency of Gld2 is reduced 83-fold for UTP in comparison to ATP. Conversely, the
uridylyltransferase Cid1 displays a 100-fold higher specificity for UTP over ATP58,59.
Our data shows a clear preference of ATP over all other nucleotides. The rate-limiting
step is most likely the NTP binding event. The KM for ATP is 0.23 µM, which is about
10,000-fold lower than the cellular ATP concentration of 2.1 mM 60. Thus, Gld2
encounters a vast excess of ATP in the cell and will attain maximal substrate turnover.
Cellular UTP, GTP, and CTP concentrations are overall lower than ATP concentrations60.
In addition, we measured KM values in the 100 μM range for the other NTPs.
Physiological concentrations for UTP and GTP are between 250-300 μM60, which is
between 1 and 6-fold higher than the respective KM. The overall higher KM of Gld2 for
UTP, CTP, and GTP combined with a much higher cellular ATP concentration further
shifts enzymatic activity towards adenylation. Interestingly, at a CTP concentration 1000fold in excess of the physiological concentration the catalytic turnover for CTP is 30-fold
higher than for ATP. Once NTP binding occurs, the other NTPs are ligated to the
substrate RNA more rapidly than ATP (Table 2.1). Nevertheless, the low affinities of
Gld2 for nucleotides other than ATP and the fact the other NTPs fail to outcompete ATP
(Figure 2.4B) indicate Gld2 activity is shifted to adenylation under physiological
conditions.
Our data indicate that Gld2 may not have evolved to function exclusively with
ATP, as we could show that Gld2 is active with UTP as well as GTP and CTP, albeit with
low efficiency. While we cannot exclude that post-translational modifications or
interactions with other proteins may influence nucleotide specificity, our data suggests
that the observed NTP specificity is only in part determined by binding constants. Gld2
nucleotide specificity alone provides an 83-fold preference for ATP over UTP, which is
combined with a cellular environment that has 10-fold excess of ATP compared to the
other NTPs. Gld2 substrate preference and the cellular nucleotide concentrations together
increase Gld2 selectivity towards ATP to >800-fold, enhancing the enzyme’s specificity
without evolving a precisely selective adenylyltransferase.
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2.4.2

Gld2 monoadenylates small RNA substrates

In in vitro activity assays, Gld2 monoadenylates a variety of small RNAs, and does
not specifically discriminate between different substrate RNAs. Our data shows that Gld2
displays activity on tRNAs, miRNAs, pre-miRNAs and mRNA alike, with a slight
preference for miRNAs (Figure 2.2). This agrees with earlier studies of X. laevis and C.
elegans Gld2 homologs, which showed a role for Gld2 in miRNA metabolism32. The
RNA substrate promiscuity that we observed with human Gld2 may be related to the fact
that this minimal adenylyltransferase lacks RNA binding domains, which are thought to
confer substrate specificity in Gld2’s closest human homologs, TUT4 and TUT7 (Figure
2.1). Interestingly, we found no evidence of polyadenylation activity on any of the
employed substrates. For processive polyadenylation, human Gld2 most likely requires
the assistance of RNA proteins in vivo, which may confer specificity or activate
elongation. Intriguingly, an extended incubation of Gld2 or Gld2-His with 15A RNA and
UTP lead to a ladder-like addition of nucleotides (Figure 2.8C). While UTP is not the
natural Gld2 substrate, it is possible that polyuridylation, in contrast to polyadenylation,
does not require accessory proteins.
Several studies from non-human Gld2 homologs show that in the presence of RNA
binding proteins such as CPEB38 and Gld331 in X. laevis and C. elegans, respectively,
Gld2 can processively add multiple adenine residues. To date, no such interaction has
been shown for human Gld2, but the fact that Gld2 alone hardly discriminates between
several RNA substrates suggests the regulation of substrate specificity by additional RNA
binding proteins. While humans lack a Gld3 homolog, several CPEB homologs are
encoded in the genome. In X. laevis, an additional poly(A) polymerase Gld4 enzyme
polyadenylates p53 mRNA in a CPEB dependent manner. In this case, Gld2 is not
associated with CPEB directly, but regulates its expression via miR-122 adenylation39. In
C. elegans the RNA binding protein Gld3 stimulates Gld2 catalyzed polyadenylation by
increasing its affinity to the substrate RNA32. Similarly, TUT7 can be triggered to
polyuridylate RNA substrates in association with the RNA binding protein Lin28A 23,61.
Potential Gld2 associated proteins, however, remain to be identified.
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2.4.3

Convergent evolution of Tutase activity by histidine insertion in
the PAP active site

Recent biochemical and structural data on fission yeast Cid1 58,59 and X. laevis TUT762
suggested that the nucleotide preference of nucleotidyltransferases is determined by a
single histidine near the active site (Figure 2.7A and B). In Cid1, histidine 336, which is
located on a flexible loop near the catalytic site, sterically excludes ATP from the active
site. Prior experiments have shown that mutation of this histidine to a smaller amino acid
broadens nucleotide specificity in uridylyltransferases to include ATP, concluding that an
asparagine to histidine mutation confers ATP specificity58,59,62. Our multiple sequence
alignment (Figures 2.7B) and structural superposition of Cid1 and human mitochondrial
PAPD1 (Figure 2.7B) show that the Asn337 in Cid1 is homologous to Asn273 residue of
PAPD1. This Asn is strictly conserved in all members of the nucleotidyltransferase
superfamily. The multiple sequence alignment clearly shows that Cid1 His336 is an
inserted residue relative to the PAPD1 homolog (Figure 2.7A). His336 points directly
into the active site in the structural superposition, making contact with the UTP substrate,
while the Asn337/Asn273 residue is oriented away from the active site (Figure 2.7B).
The Asn conformation is structurally conserved between Tutases and PAPs.
Consequently, UTP selectivity of Gld2, which is phylogenetically derived from TUT4/7
(Figure 2.6), is conferred by a histidine insertion, rather than an Asn to His mutation as
previously suggested58,59,62.
The here presented phylogenetic analysis shows that the presence/absence of the
TUT-specific histidine is consistent within all nucleotidyltransferase groups and
coincides with the divergence of uridylyltransferases from adenylyltransferases. While
previous studies alluded to a point mutation from histidine (denoted with # in Figure
2.7B) to asparagine58, conferring ATP over UTP selectivity, our sequence alignment
clearly shows that the respective asparagine (denoted with a * in Figure 2.7B) is part of a
highly conserved motif found in all nucleotidyltransferases. Thus, a histidine insertion
rather than a mutation confers uridine specificity. In agreement with our biochemical
data, the respective residue is absent from the Gld2 amino acid sequence, which vacates
the active site for the larger ATP. Similarly, Cid14 is also lacking the respective histidine
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residue, conferring a preference of ATP over UTP. Consequently, a histidine insertion
into Gld2 switched the nucleotide preference from ATP to UTP, excluding the larger
ATP from the active site. Gld2-His shows no activity towards ATP but is active on
multiple substrates with UTP (Figure 2.8B and C). These data clearly show that a single
amino acid insertion can change nucleotide specificity in nucleotidyltransferases.
The human uridylyltransferases TUT4 and TUT7 are closely grouped within the
phylogeny and are likely the result of recent gene duplication in the chordata linage.
Consistent with their amino acid sequence similarity, Gld2 is most closely related to the
TUT4/7 phylogenetic group, although Gld2 has the conserved Tutase histidine deleted. In
adenylyltransferases, such as human PAPD1 and its homologs, leucine replaces histidine.
How a leucine insertion impacts enzyme activity and substrate specificity remains to be
elucidated. Considering that uridylyltransferase activity has evolved multiple times, the
flexible loop which harbors histidine 336 in Cid1 can be denoted as a preferred spot for
mutations and insertions, allowing for facile alterations in substrate specificity. Once
RNA specificity has been determined, the ability to change nucleotide specificity through
this preferred spot would allow the cell to easily obtain different enzymes that
differentially modify the same RNAs.
The phylogeny, supported by our mutational analysis of Gld2, shows that
uridylyltransferase activity diverged from adenylyltransferase activity multiple times
during evolution and prior to the split of slime molds and bilateria. Interestingly, noncanonical nucleotidyltransferases are very prevalent in Fungi, which include several
nucleotidyltransferase clades (e.g., Cid16, Cid11/13) not found in other organisms. These
homologs appear to result from initial gene duplication, giving rise to Cid16 and Cid
11/13 groups, with a more recent duplication leading to the divergence of Cid11 and
Cid13. The nuclear poly(A) polymerase Cid1163 and the Cid13 homolog encode an Arg,
while Cid16 homologs a Lys in position His336 of Cid1. The biological function of these
enzymes is not entirely clear, but the small positively charged side chain suggests a role
in RNA adenylation, as ATP could still be spatially accommodated in the active site. One
nucleotidyltransferase clade of entirely unknown function contains PAPD1-like proteins
with homologs in Drosophilidae and plants. No data are available on nucleotide
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specificity or biological function of these proteins. This group is diverse in its active site
constituents. Interestingly, members of the Drosophilidae encode two PAPD1-like
homologs. One homolog encodes an arginine, and one a histidine, suggesting a recent
gene duplication to allow for both uridylyltransferase and adenylyltransferase activity.
These homologs could potentially share a specific RNA substrate range or interacting
protein partners, while differing in nucleotide preference, thus fulfilling distinct
biological functions.
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Chapter 3

3

Gld2 activity is regulated by phosphorylation in the Nterminal domain

3.1

Introduction

MicroRNAs (miRNAs) are critical regulators of gene expression that are essential to
human life, normal cellular function, and development. De-regulation of miRNAs is,
perhaps not surprisingly, associated with a number of human diseases 1. MiRNAs regulate
the expression of many genes, including oncogenes, by complementary base pairing with
the 3′-untranslated regions (UTRs) of mRNAs, which normally inhibits protein
synthesis1.
MiRNAs themselves are post-transcriptionally regulated by the addition of single or
multiple adenine (A) or uridine (U) residues to their 3′-ends. This untemplated RNA
editing is now recognized as an important mechanism regulating cellular miRNA
homeostasis2,3. The addition of a single A to the 3′-end on certain miRNAs leads to
increased stability4. Conversely, the activity of mature miRNAs is reduced by the
addition of a single 3′-U residue5,6. The addition of multiple U residues to precursor
miRNAs (pre-miRNAs) triggers subsequent degradation by the U-specific exonuclease
Dis3L2 (Dis3-like 3′-5′ exonuclease 2)3. Although uridylation is commonly associated
with silencing and degradation of RNAs, monouridylation of Group II pre-miRNAs
lacking a critical 3′-end overhang nucleotide is required for miRNA maturation and
processing by Dicer7. Cellular mechanisms that regulate miRNAs through 3′-terminal
nucleotide additions are of fundamental relevance to the molecular basis of diseases
characterized by de-regulated miRNA metabolism3,8.
A diverse family of terminal RNA nucleotidyltransferases (TENTs) catalyzes 3′-A
and U additions to RNAs in human cells. The nucleotidyltransferase Gld2 (germlinedevelopment 2, TENT2) was first identified as a regulator of meiosis in Caenorhabditis
elegans9 and was later shown to extend the poly(A) tails of mRNAs (Figure 3.1A),
leading to enhanced mRNA stability and increased abundance of the encoded protein 10.
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In humans, Gld2 stabilizes

miR-122

in the liver and fibroblasts

through

monoadenylation4,11 and mRNAs via polyadenylation12 (Figure 3.1A).
Gld2 is thought to be part of a larger protein complex involved in RNA modification
and germ cell formation13. Although some reports7 suggested that Gld2 may function as a
uridylyltransferase, we recently characterized

human Gld2

as

a

bona

fide

adenylyltransferase in vitro14. Our data confirmed a basal activity of Gld2 with UTP, but
the 80-fold higher catalytic efficiency for ATP makes the enzyme strongly selective for A
additions14. Gld2 encodes a nucleotidyltransferase domain and a poly(A) polymeraseassociated domain that are required for catalytic activity as well as a predicted disordered
N-terminal domain of unknown function10 (Figure 3.1B), yet lacks identifiable RNA
binding motifs. The crystal structure of a truncated C. elegans Gld2 in complex with the
interacting protein Gld3 shows that the two essential Gld2 catalytic domains share the
same fold as other nucleotidyltransferases15.
Cellular mechanisms that regulate miRNAs through 3′-end nucleotide additions are of
fundamental relevance to the molecular basis of diseases characterized by de-regulated
miRNA metabolism3,8. Gld2 and its substrate miR-122 play a role in Hepatitis C virus
(HCV) infection and in hepatic cancer16. MiR-122 is one of the most abundant miRNAs
in the liver, with an essential role in maintaining liver homeostasis and differentiation16.
During HCV infection, miR-122 binds to two sites in the viral 5′-UTR of the Hepatitis C
viral RNA and is required for HCV infection16,17. The miR-122 interaction with the 5′UTR enhances viral replication by increasing the formation of ribosome complexes to
increase viral protein production. The binding of miR-122 to protein argonaute-2 (Ago2)
in the RNA-induced silencing complex (RISC) also protects viral RNA from
exonucleases16. Interestingly, the HCV core protein was shown to bind to Gld2 in the
cytoplasm and inhibit its nucleotide addition activity. The subsequent reduction in miR122 abundance allows HCV to maintain low levels of viral protein production to facilitate
continuous viral replication and infection of host cells 18. Consequently, inhibition of Gld2
by the HCV core protein decreases miR-122 stability and abundance. Low miR-122
levels, in turn, are associated with hepatic cancer, linking HCV infection to the
development of hepatocellular carcinoma (HCC)18,19. Hepatitis B virus X-protein (HBx)
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was also shown to reduce Gld2 protein levels and cause an increase in cationic amino
acid transporter 1 (CAT-1), a target of miR-12220–22. CAT-1 is involved in the
tumorgenesis of the Hepatitis B virus (HBV)20. Miravirsen, an anti-miR-122
oligonucleotide, is in Phase II trials to treat Hepatitis C and has been shown to decrease
levels of miR-122 for a prolonged period of time, resulting in decreased HCV RNA
levels in patients23–25. As high levels of miR-122 have been observed in colorectal liver
metastasis, Miravirsen has been suggested as a potential anti-cancer drug as well26.
While it is clear that Gld2 plays a role in promoting miRNA stability3,14,16, cellular
mechanisms that regulate Gld2 activity were previously unknown. In HCC cells, miR122 is destabilized despite no observed changes in Gld2 protein levels 18,19. These data
suggest the existence of a clinically relevant mechanism that regulates Gld2 activity via
post-translational modification. We demonstrate that Gld2 activity is indeed regulated by
phosphorylation. We found that Gld2 is phosphorylated at specific serine residues in the
predicted disordered N-terminal domain in vivo, which dramatically impact catalytic
activity and substrate specificity. We found protein kinases A (PKA) and B (Akt1) sitespecifically phosphorylate Gld2 at S116, which abolishes 3′-nucleotide addition activity.
The data reveal tumor suppressor miRNAs as a previously unrecognized target of
oncogenic protein kinases.
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Figure 3.1: Pathways regulated by Gld2 and Gld2 domain architecture.
A) Known functions of Gld2. Gld2 stabilizes mature miRNA and mRNA through
monoadenylation or polyadenylation of the 3’-end. Mononucleotide addition of Group II
pre-miRNAs on the 3′-end by Gld2 allows recognition by Dicer to be processed to mature
miRNAs. This is followed by strand selection by Argonaute (AGO) and incorporation
into the RNA-induced silencing complex (RISC). The different pathways are represented
by solid or dashed lines. B) Schematic of Gld2 showing the nucleotidyltransferase
domain (NTR) and poly(A) polymerase-like domain (PAP).

3.2

Materials and Methods

3.2.1

Multiple sequence alignment

Alignments was performed as previously described in Chapter 214. Briefly, 250
mammalian Gld2 sequences were downloaded from NCBI. Sequence alignment and
alignment editing were performed with Muscle27, MultiSeq from VMD 1.8.728, and
Wasabi29.
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3.2.2

Plasmids

Homo sapiens Gld2 was codon-optimized (Genewiz, South Plainfield, NJ, USA) for
expression in Escherichia coli. The gene was cloned into pGEX-6P-2 with an N-terminal
TEV cleavage site using BamHI and XhoI restriction sites. Mutants were generated
through site-directed mutagenesis30. All primers are listed in Appendix A Table A1.
Successful cloning was verified by DNA sequencing at the London Regional Genomics
Centre, London, ON, Canada. Cloning of Akt1 and PDK1 and Akt1 production and
purification were previously described31.

3.2.3

Gld2 protein production and purification

Wildtype Gld2, glutamic acid mutants, and alanine mutants were transformed into E.
coli BL21 (DE3) cells (Invitrogen, Carlsbad, CA, USA) and grown to an OD 600 of 0.6 at
37°C. Protein production was induced by 500 µM isopropyl β-D-1-thiogalactopyranoside
(IPTG) and grown at 16°C for 18 hrs. Cells were harvested in GST wash buffer (50 mM
Tris-HCl [pH 8.0], 300 mM NaCl, 5 mM MgCl2) and ethylenediaminetetraacetic acid
(EDTA)-free mini protease inhibitor cocktail (Roche, Basel, Switzerland) before cell
lysis with a French pressure cell press. The cell lysate was centrifuged at 64,000 x g for 1
hr at 4°C and the supernatant was loaded onto a GSTrap Fast Flow 5mL (GE Healthcare).
Protein purification was automated on the ÄKTA Pure (GE Healthcare). Protein was
eluted with an increasing gradient of GST elution buffer (50 mM Tris-HCl [pH 8.0], 300
mM NaCl, 5 mM MgCl2, 10 mM reduced glutathione). Eluted fractions were pooled,
concentrated, and dialyzed against storage buffer (50 mM Tris-HCl [pH 8.0], 200 mM
NaCl, 5 mM MgCl2, 10% glycerol) at 4°C overnight. The proteins were aliquoted and
stored at -80°C until further use.

3.2.4

Western blotting

Purified enzyme samples were combined with 3 x sodium dodecyl sulfate (SDS)
loading dye (188 mM Tris-HCl [pH 6.8], 3% SDS (w/v), 30% glycerol, 0.01%
bromophenol blue, 300 mM Dithiothreitol (DTT)) and electrophoresed on two identical
10% polyacrylamide SDS gels. One gel was stained with Coomassie Brilliant Blue G-250
and imaged on the ChemiDoc MP Imaging System (BioRad). The other gel was
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transferred to a polyvinylidene difluoride (PVDF) membrane using the Trans-Blot Turbo
Transfer System (BioRad). The membrane was blocked in 3% bovine serum albumin
(BSA), 1 x phosphate-buffered saline 1% Tween (PBS-T) for 2 hrs at room temperature
(RT) and incubated with anti-Gld2 (PA5-25015, ThermoFisher Scientific) in 3% BSA, 1
x PBS-T (1:1000) overnight at 4°C. The membrane was washed 3 x 10 min in 1% BSA, 1
x PBS-T at RT, incubated with IRDye 800CW goat anti-rabbit IgG (926-32211, LI-COR)
in 1% BSA, 1 x PBS-T (1:5000) for 2 hrs at RT, washed 3 x 10 min in 1 x PBS-T, and 10
min in 1 x PBS. The membrane was imaged on the Odyssey Classic (LI-COR).

3.2.5

Nucleotide addition assay

Gld2-catalyzed reactions and product quantification were carried out as described
previously in Chapter 2. Briefly, reactions contained 1 µM ATP (0.835 µM unlabelled
ATP and 0.165 µM [α-32P]-ATP (Perkin Elmer)), 2 µM 5p-miR-122 (22 nt) or 15A RNA
(15 nt) (SigmaAldrich), and 100 nM Gld2. Each Gld2 enzyme was incubated with 1 µM
unlabelled and [α-32P]-labelled ATP and 2 µM RNA substrate. Reactions were incubated
at 37°C and samples were taken every 2 minutes and stopped with the addition of 2 x
RNA loading dye. Reactions were analyzed via electrophoretic separation and subsequent
phosphorimaging on a Storm 860 Molecular Imager. Product formation was quantified by
spotting a range of known concentrations of [α-32P]-ATP onto a strip of Whatman filter
paper that was imaged on the same phosphorimaging screen as the gel. Specific activity
was calculated from the linear slope of the curve using Microsoft Excel and the standard
errors and deviations were obtained from triplicate reactions. SigmaPlot (Systat
Software) was used to determine statistical significance (p values) for changes in Gld2
activity.

3.2.6

Fluorescence anisotropy

Dissociation constants (Kd) of Gld2 substrates miR-122 and 15A were determined in
100 µL reactions in black plates containing 3.2 mM MgCl2, 1 mM DTT, 20 nM 5′-end
labelled miR-122 (22 nt) or 15A RNA (15 nt), and 0-100 nM Gld2 enzyme incubated for
20 minutes at room temperature in the dark. The RNAs were labelled on the 5′-end with
6-carboxyfluorescein (6-FAM) (SigmaAldrich) and the following enzyme concentrations
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were used (nM): 0, 0.5, 1, 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20, 30, 40, 50, 60, 80, 100.
Fluorescence polarization was measured on a Victor 3V (PerkinElmer) with an excitation
of 492 nm and emission of 535/20 nm. Readings were subtracted from the no enzyme
control and three technical replicates were performed for each RNA and enzyme.
SigmaPlot (Systat Software) was used to generate the plots, determine the Kd, and
calculate the standard errors and p values.

3.2.7

Identification of potential kinases

Two online tools were used to generate a list of potential Gld2 kinases. PhosphoMotif
Finder identifies putative kinase binding sequences in a query sequence based on the
binding motifs of kinases as well as their substrate sequences identified in the literature 32.
GPS 3.0 predicts kinase phosphorylation sites in the query sequence using a
computational prediction program33.

3.2.8

Dot plot kinase activity assays

Kinase assays were performed as previously described 31. Briefly, reactions containing a
kinase, wildtype Gld2, and [γ-32P]-ATP (Perkin Elmer) were carried out at 37°C.
Samples were taken at various timepoints and stopped by spotting on P81 paper. The P81
paper was washed, air-dried, exposed to a phosphor screen, and visualized with a
phosphorimager (Storm 860 Molecular Imager).

3.2.9

Kinase activity assays using SDS gels

In the following assays, Gld2 was tested as a protein substrate for several human
kinases. Kinase assays were performed in 60 µL reactions containing 900 nM Gld2,
kinase buffer (20 mM MOPS [pH 7.0], 25 mM β-glyceraldehydephosphate, 25 mM
MgCl2, 5 mM EGTA [pH 8.0], 1 mM Na2VO4, 0.1 mM ATP, 13.2 nM [γ-32P]-ATP
(Perkin Elmer)). Reactions were initiated with the addition of the specified kinase. Since
kinases varied in activity, final concentrations were adjusted according to published
values using 25 nM CK2α, 1.43 nM CK2 holoenzyme, 33 nM fully activated
ppAkt1T308,S473, 30 nM Abl, 0.45 nM PKA, or 12 nM CDK5 in a kinase dilution buffer
(0.1 mg/mL BSA, 5 mM MOPS [pH 7.2], 25 mM β-glyceraldehydephosphate, 5 mM
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MgCl2, 1 mM EGTA [pH 8.0], 1 mM Na2VO4, 100 mM NaCl). Reactions were incubated
at 37 °C for 15 minutes on a microcentrifuge shaker. Samples (20 µL) were taken every 5
minutes and the reaction was stopped with the addition of 2 x SDS loading dye. Purified
recombinant kinases CK2α, CK2 holoenzyme, Abl, PKA, and CDK5 were a generous
gift from Dr. David W. Litchfield (The University of Western Ontario, Canada). Reaction
products at each time point were separated on a 10% polyacrylamide SDS gel. The gel
was exposed to a storage phosphor screen overnight at -80°C and visualized with a
phosphorimager (Storm 860 Molecular Imager). Kinase assays and quantification were
previously described31,34.

3.2.10

Isolation of phosphorylated Gld2 for downstream assays

For mass spectrometry and downstream Gld2 activity assays, large-scale kinase
reactions were performed as above with 0.1 mM unlabelled ATP and 80 nM PKA for 15
minutes. To isolate the resulting phosphorylated Gld2 (pGld2), the reactions were loaded
onto GST SpinTrap columns (GE Healthcare) and pGld2 was eluted with GST elution
buffer. The isolated pGld2 was used immediately for downstream assays. The large-scale
kinase reaction was repeated with a control lacking the kinase.

3.2.11

Phosphorylation of Gld2 using HEK 293 cell extract

HEK 293 cells in 100 mm plates were grown to approximately 90% confluency in
Dulbecco’s Modified Eagle’s Medium (DMEM) (319-005-3L, Wisent) with 10% fetal
bovine serum (FBS) (098150, Lot #185700, Wisent) and 1% penicillin-streptomycin
(450-201-EL, Wisent). Epidermal growth factor (EGF) was added to each plate to a final
concentration of 50 ng/mL and incubated at 37°C for 1 hr. Cells were harvested and
resuspended in 5 x kinase buffer with 5 mM phenylmethylsulfonyl fluoride (PMSF).
Cells were broken with a Q125 Sonicator (Qsonica) six times at 20% amplitude and 1 sec
on, 1 sec off. Using the cell extract as a source of active kinases, we performed a kinase
reaction. This was repeated with unstimulated HEK 293 cell extract. Gld2 was isolated
using a GST Spintrap column and possible Gld2 phosphorylation sites were analyzed by
mass spectrometry.
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3.2.12

Mass spectrometry

Mass spectrometry (MS) analysis of tryptic digested peptides was carried out on the
EasyLC1000-QExactive tandem LC-MS system (ThermoFisher Scientific). A full
scanning (full MS/dd-MS2 TopN, data dependent acquisition mode in a Q-Exactive) was
performed to obtain an overview of all possible protein modifications within Gld2.
Parallel-reaction monitoring (PRM) was then carried out to further verify the
phosphorylation at S62 or S116 in Gld2. We analyzed Gld2 and Gld2 phosphorylated by
purified recombinant kinases and by HEK 293 cell extract. Gld2 or pGld2 was
precipitated in ice-cold acetone/ethanol/acetic acid (50/50/0.1 v/v/v). The protein
precipitate was re-suspended in 8 M urea then reduced in 5 mM DTT at 37°C for 1 hr and
alkylated in 14 mM iodoacetamide in darkness at RT for 1 hr. Unreacted iodoacetamide
was neutralized by adding 5 mM DTT and final protein concentration was determined by
Bradford assay. Trypsin digestion was performed at 37°C overnight with a
protein:trypsin ratio of 20:1 w/w. The digest was desalted in a C18 column (Phenomenex,
Torrance, CA, USA) according to the manufacturer’s protocol and re-suspended in MSgrade water for MS injection. Data were analyzed using Skyline software 35.

3.3

Results

Gld2 plays an important role in miRNA stability, but the regulation of Gld2 activity
or substrate specificity is unknown. Studies in other nucleotide polymerases 36,37 found
that phosphorylation of serine and threonine residues can increase activity or
processivity. For example, serine phosphorylation in the disordered C-terminal domain of
RNA polymerase II is required for transcription initiation and elongation36.
Phosphorylation of the terminal uridylyltransferase TUT1 at S6 is required for TUT1
nuclear retention and regulation of specific mRNAs 37. Multiple independent proteomelevel mass spectrometry studies of human cells revealed phosphorylated residues in
Gld238–40, including five conserved serine residues (S62, S69, S95, S110, S116) in the
predicted disordered N-terminal domain (Figure 3.2). Despite these observations, the
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putative Gld2 kinase(s) and the impact of phosphorylation on Gld2 activity was
unknown.

Figure 3.2: Multiple sequence alignment of mammalian Gld2 sequences.
Sequences were downloaded from NCBI and the alignment and editing were performed
with Muscle27, MultiSeq from VMD 1.8.728, and Wasabi29. Numbers above the alignment
indicate the position in H. sapiens Gld2.

3.3.1

Phosphorylation of the Gld2 N-terminal domain by HEK 293 cells

Although the above studies suggest the existence of a Gld2 kinase in human cells, we
analyzed Gld2 following incubation with HEK 293 cell lysates to confirm
phosphorylation activity towards Gld2. The HEK 293 cells were stimulated with
epidermal growth factor (EGF) to activate cellular kinases. Purified Gld2 (Appendix A
Figure A1) was incubated with cell extracts from HEK 293 cells after EGF stimulation of
signaling pathways. The phosphorylation status of Gld2 was subsequently analyzed by
mass spectrometry and we unambiguously identified phosphorylation at S62 in the
sample incubated with EGF-stimulated cell lysate (Figure 3.3B). We did not identify
pS62 in unstimulated cells or in recombinantly produced Gld2. As Gld2 has been
previously shown to be involved in miRNA metabolism4,7, this indicates the existence of
physiologically relevant signaling pathways connecting EGF-stimulated protein kinases
to miRNA metabolism via phosphorylation-dependent regulation of Gld2. EGF activates
many cellular pathways involved in regulating growth, proliferation, differentiation, and
survival. EGF binds to receptor tyrosine kinases, leading to their activation. This in turn
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activates cascades of cellular kinases. Within 10 minutes of EGF stimulation, mammalian
cells display 100s of new phosphorylation events 41. Data from this study also indicate
that following EGF stimulation 30 tyrosine and more than 100 serine/threonine kinases
are activated by phosphorylation, which may be responsible for S62 phosphorylation.
Any of these serine/threonine kinases are potential candidates for catalyzing S62
phosphorylation.

Figure 3.3: Gld2 is phosphorylated at S62 when incubated with EGF-stimulated
HEK 293 cell extract.
Mass spectra of Gld2 after incubation with cell extracts from EGF stimulated HEK 293
cells showing A) unphosphorylated S62 and B) phosphorylation at S62 (bolded and
underlined). The intensity for y and b-ions resulting from fragmentation of the peptide
containing S62 is shown; these intensities are overlaid on the retention time position of
the full peptide mass. M/z values for each y and b ion are shown. Gld2 was isolated using
a GST Spintrap column before mass spectrometry. Trypsin was used to generate the Gld2
peptides and the ions from the peptides are shown in the mass spectra. A full scanning
was performed to obtain all possible modifications and was followed by parallel reaction
monitoring (PRM) to verify the modification at S62.
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3.3.2

Gld2 N-terminal domain phosphomimetic variants regulate
catalytic activity

To rapidly assess the effects of phosphorylation at positions in the Gld2 N-terminal
domain, human Gld2 variants were produced in Escherichia coli with respective serine
phosphorylation sites mutated to the phosphomimetic glutamic acid 30. Wild type and
phosphomimetic Gld2 variants were produced and purified to homogeneity (Appendix A
Figure A1). Kinetic parameters for specific activity and binding affinity were determined
for wildtype Gld2 and phosphomimetic variants with glutamate substitutions at the
phosphorylation sites S62, S69, S95, S110, and S116
Nucleotide addition activity was measured by incubating each enzyme variant with an
RNA substrate and [α-32P]-ATP (Figures 3.4, and A2A, A2B). Enzymatic and binding
assays were conducted with RNA substrates miR-122 and a mRNA poly(A) tail mimic of
15 adenine residues (15A). MiR-122 and 15A RNA were used based on previous studies
demonstrating their competence as Gld2 substrates4,14.
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Figure 3.4: Phosphomimetic Gld2 variants modulate catalytic activity and RNA
binding.
A) Activity assay gels of wildtype and mutant Gld2. Wildtype (WT) Gld2 and glutamic
acid mutants were incubated with [α-32P]-ATP and miR-122 (22 nts) or 15A RNA (15
nts) at 37°C with samples taken every 2 minutes for 8 minutes. Reactions were repeated
in triplicate (R1-3) and analyzed via gel electrophoresis and phosphorimaging. A no
enzyme control was performed for each RNA substrate in triplicate and the average of the
no enzyme triplicates for each RNA was calculated for the 0-minute timepoint. Reaction
products were quantified by exposing a Whatman filter strip dotted with different known
concentrations of [α-32P]-ATP to the same phosphorscreen as the gel. R, replicate. B) and
C) Bar graphs showing the fold change in specific activity at 1 μM ATP calculated from
the activity assays and binding affinity (Kd) between wildtype Gld2 and Gld2 glutamic
acid mutants with B) miR-122 (22 nts) or C) oligo(A) tail mimic 15A RNA (15 nts).
Specific activity is the activity of an enzyme per milligram of purified enzyme and was
calculated from the linear slope of the curve. Fluorescence anisotropy was used to
determine the Kd. Each Gld2 enzyme was incubated with a RNA substrate fluorescently
labelled on the 5’-end with 6-FAM and incubated at room temperature for 20 minutes.
Fluorescence polarization was measured at Ex. 492nm and Em. 535/20 nm and the Kd
was calculated using SigmaPlot. Error bars represent one standard error calculated from
triplicate reactions. Significant changes calculated using a two-tailed t-test are indicted by
asterisks. p ≤ 0.05 (*); p ≤ 0.01 (**); p ≤ 0.001 (***). Fold changes were calculated using
data from Table 3.1 and Appendix A Figure A2.
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Depending on the residue location, phosphomimetic substitutions had distinct effects
on enzyme activity (Table 3.1, Figure 3.4). S62E markedly increased activity with both
RNAs compared to wildtype Gld2, indicating an overall activating effect. In contrast, a
S116E mutation severely decreased Gld2 activity with miR-122 and 15A RNA.
Interestingly, S110E increased activity for miR-122 but decreased activity for 15A RNA.
Gld2 S69E showed no significant changes in activity for either RNA while S95E was
1.6-fold more active with 15A RNA.
Based on a comparison of the specific activities (Figure 3.4, Table 3.1), only S62E
and S116E displayed statistically significant changes in activity with both RNA
substrates. S62E enhanced the nucleotide addition activity by ~5-fold. S116E exhibited
the opposite effect, decreasing Gld2 activity by 111-fold with miR-122 and 16-fold with
15A RNA. As the S62E and S116E mutants displayed opposite effects on Gld2 activity, a
double mutant (S62E/S116E) was generated to investigate cumulative effects.
Interestingly, the inhibitory effect of the S116E mutation overpowered the activating
effect of the S62E mutation and decreased the activity of Gld2 74-fold with miR-122 and
5-fold with 15A RNA compared to the wildtype enzyme. The double mutant
counteracted the silencing effect of S116E alone by 3.1-fold with 15A RNA and 1.5-fold
with miR-122.
The ability of the mutants to alter the nucleotide addition activity varied between
RNA substrates. The molecular basis for the higher specific activity of Gld2 with miR122 compared to 15A RNA remains to be elucidated to discern whether Gld2 recognizes
a specific RNA sequence and/or discriminates substrates based on the RNA length.

3.3.3

Gld2 phosphomimetic substitutions impact RNA substrate affinity

As changes in catalytic activity were RNA-dependent, the RNA binding affinities of
all Gld2 phosphomimetic variants were quantified using fluorescence anisotropy (Figures
A2C, A2D). The binding affinities (Kd) for all enzyme variants were in the nanomolar
range (Figure 3.4, Table 3.1). Changes in RNA binding affinity were substrate dependent.

73

The binding affinity to miR-122 was unchanged for most mutants, except for S62E,
which showed a 5.5-fold increase in RNA binding compared to wildtype Gld2 with miR122. The same mutant showed no change in binding to a 15A substrate. For the 15A
RNA, two mutants (S69E and S95E) showed a decrease in affinity, while all other
mutants showed no change. With a 6.6-fold reduced Kd compared to wildtype, Gld2 S95E
showed the most dramatic impact on 15A RNA binding; S69E was 3.3-fold decreased in
binding affinity to 15A.
Overall, our phosphomimetic analysis suggests that each phosphorylation site has a
distinct role in regulating Gld2 activity or substrate selectivity. We found that S62E
increases activity with either no change (15A) or with increased binding affinity (miR122), which may favor miRNA stabilization over mRNA. S69E and S95E caused no
significant change in activity, but decreased affinity towards 15A RNA, indicating a
reduced preference for mRNA adenylation. S110E appears to have an insignificant
impact on activity and binding on the tested substrates. Finally, S116E and the
S62E/S116E double mutant markedly reduced activity without significantly impacting
RNA binding. The data indicate that Gld2 S116E and the double mutant are able to bind
to the RNA target, but perhaps not in a catalytically competent conformation.
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Table 3.1: Activity and RNA-binding of wildtype (WT) and phosphomimetic Gld2
variants.
miR-122
Specific activity
(µmol/min/mg)

15A RNA
Kd (nM)

Specific activity
(µmol/min/mg)

Kd (nM)

WT

3452 ± 182

15 ± 3

448 ± 10

1.7 ± 0.3

S62E

14186 ± 774

2.7 ± 0.8

2919 ± 239

2.3 ± 0.3

S69E

4670 ± 272

30 ± 9

555 ± 22

5.8 ± 1.1

S95E

2191 ± 78

22 ± 6

698 ± 30

11 ± 2

S110E

7340 ± 433

18 ± 5

171 ± 7

2.9 ± 0.6

S116E

31 ± 5

19 ± 5

28 ± 0.05

3.8 ± 0.8

S62E/S116E

47 ± 2

12 ± 3

89 ± 6

3.4 ± 0.6

150 ± 0.05

35 ± 7

38 ± 16

7.4 ± 1.8

S116A

Standard error is reported; specific activities at 1 µM ATP.

3.3.4

PKA and Akt1 site-specifically phosphorylate Gld2 at S116

As the phosphomimetic mutants displayed significant changes in activity and RNA
substrate binding compared to wildtype Gld2, we next identified kinases that
phosphorylate the Gld2 N-terminus. PhosphoMotif Finder42 and GPS 3.033 were used to
generate a list of potential kinases (Table A2). Using the kinase assay detailed in
Materials and Methods, wildtype Gld2 was incubated with recombinant and active human
kinases (CK2α, CK2 holoenzyme, CDK5, PKA, and Akt1) predicted to have a
recognition motif in Gld2 (Figure 3.5A). The kinase Abl, which was not identified as a
potential Gld2 kinase, was used as a negative control. We used our recently developed
approach31 combining genetic code expansion with in vivo enzymatic phosphorylation to
prepare fully activated and purified recombinant Akt1 with programmed phosphorylation
at both activating sites (ppAkt1T308,S473). This method involves protein production in an E.
coli strain that co-expresses the kinase PDK1 to phosphorylate Akt1 at T308. The strain
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also genetically encodes phosphoserine (pSer) at UAG codons. The serine codon at
position 473 was replaced with a UAG codon to direct pSer incorporation in Akt1.
Following incubation of Gld2 and [γ-32P]-ATP with each kinase in separate reactions,
the radio-labelled phosphorylated Gld2 (pGld2) product was only observed when Gld2
was incubated with PKA or ppAkt1T308,S473 (Figure A3, Figure 3.5A). Quantification of
the Akt1-dependent reaction showed a rapid increase in phosphorylated Gld2 over a 15
min time course (Figure 3.5B). Independent pGld2 preparations resulting from incubation
with PKA or ppAkt1T308,S473 were analyzed by mass spectrometry to determine the site(s)
of phosphorylation. Both unphosphorylated Gld2 and Gld2 incubated with CK2α, which
was inactive in phosphorylating Gld2, were also analyzed by mass spectrometry as
controls (Figure 3.5C). S116 was unambiguously identified as the site of specific
phosphorylation by Akt1 and PKA. Phosphorylation at S116 was not observed in
unphosphorylated Gld2 or in the preparation incubated with CK2α. Next, S116 was
mutated to an alanine residue (Figure A1) to determine if S116 represents the sole Akt1
and PKA phosphorylation site on Gld2. The kinase assay was repeated with Gld2 S116A
incubated with PKA or ppAkt1T308,S473 (Figure 3.5A). For both kinases, no
phosphorylated Gld2 S116A product was observed, confirming that PKA and Akt1
phosphorylate Gld2 specifically and exclusively at S116.
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Figure 3.5: Akt1 and PKA phosphorylate Gld2 at S116.
A) Gld2 or Gld2 S116A were incubated with [γ-32P]-ATP and the indicated kinases.
Formation of phosphorylated Gld2 (75 kDa) was monitored by electrophoretic separation
and subsequent phosphorimaging. R, replicate. B) Quantification of phosphorylated
product formation from a kinase reaction over 15 minutes. C) Mass spectra of
unphosphorylated Gld2 or Gld2 phosphorylated by CK2α, ppAkt1 T308,S473 (ppAkt1), or
PKA. Unphosphorylated peptide is indicated by the light pink peak and the
phosphorylated peptide by the dark pink peak. Position 116 is bolded and underlined. D)
Bar graphs showing the fold change in specific activity at 1 µM ATP between treated WT
(tWT) and Gld2 phosphorylated by PKA with miR-122 (22nt) or oligo(A) tail mimic 15A
RNA (15nt). The inset shows the fold change in activity of Gld2 phosphorylated by PKA
compared to tWT. Error bars show one standard error calculated from triplicate reactions.
Significant changes calculated using a two-tailed t-test are indicted by asterisks. p ≤
0.001 (***).
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3.3.5

Phosphorylation of Gld2 at S116 abolishes nucleotide addition
activity

The phosphomimetic mutant (S116E) was not competent in nucleotide addition, yet
the variant retained RNA binding affinity (Figure 3.4, Table 3.1). As Akt1 and PKA both
phosphorylate S116, we produced pGld2S116 following incubation with PKA as noted
above to investigate the nucleotide addition activity of Gld2 with phosphate on S116. We
performed

nucleotide addition activity assays

with pGld2 S116

and with an

unphosphorylated Gld2 control without PKA addition (treated wildtype, tWT).
PKA-dependent phosphorylation of Gld2 decreased nucleotide addition activity by
two orders of magnitude (Figures 3.5D, A4). Significant reductions in activity were
observed for both 15A RNA (~45-fold) and miR-122 (~400-fold) substrates. Although
both pGld2S116 and the S116E phosphomimetic variant reduced nucleotide addition
activity, as we anticipated, the phosphate at S116 had a significantly stronger inhibitory
effect compared to acidic amino acid substitutions (~3-fold). This observation is even
more striking in light of the fact that our pGld2 S116 preparations are only partially
phosphorylated (Figure 3.5C), suggesting phosphorylation of the Gld2 N-terminal
domain is a potent mechanism for the cell to control nucleotide addition activity.
Nucleotide addition activity assays and binding assays were also performed for the
S116A mutant (Table 3.1, Figure A5). Alanine substitutions are often used as phosphoablated enzyme models. Although the mutant was expected to act similarly to the
wildtype enzyme, the alanine substitution in fact reduced the activity by 23-fold with
miR-122. As described above, the S116E mutation reduced activity by 111-fold with
miR-122, indicating that a serine residue is crucial at this position and cannot be replace
by alanine. Thus, S116A is not an appropriate model for an unphosphorylated Gld2 and
indicates that a serine in position S116 is required for activity. We previously showed
that alanine is not necessarily a good model for a non-phosphorylatable residue31.
Overall, these data indicate that ppAkt1 T308,S473 dependent phosphorylation of Gld2
inactivates Gld2. Our data reveals a novel molecular pathway linking Akt1 activity to
miR-122 stability and activity in vivo.
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3.4
3.4.1

Discussion
Gld2 activity is regulated by phosphorylation

Gld2 is a key regulator in the stabilization and maturation of tumor suppressors miR122 and let-74,7,11. Cellular mechanisms that regulate Gld2 mediated nucleotide addition
were previously unknown. Data from HCC cells18 and proteomic analysis38,40 implicated
post-translational modification as a potential mechanism regulating Gld2 activity. Here,
we presented the first evidence that serine phosphorylation of Gld2 has a profound
impact on catalytic activity and RNA binding.
We identified phosphorylation sites in the N-terminal domain of Gld2 that positively
or negatively regulate nucleotide addition activity. Our findings are reminiscent of
regulation identified in other polymerases. Phosphorylation of specific serine residues in
the C-terminal domain of RNA polymerase II and in the terminal uridylyltransferase
TUT1 regulate their activity and substrate recognition36,37. For RNA polymerase II, serine
phosphorylation in the disordered C-terminal domain is required for promoter
clearance36. Phosphorylation of the uridylyltransferase TUT1 at position S6 plays a role
in its regulation of specific mRNAs and in its nuclear retention, possibly by facilitating
interactions between TUT1 and nuclear proteins 37. Similarly, we found that both
phosphomimetic mutations to acidic residues or true phosphorylation of Gld2 at different
sites in the N-terminal domain substantially altered substrate specificity, enhanced, or
abolished enzyme activity. Although these phosphorylation sites are conserved among
mammalian Gld2 proteins, they are not conserved in the human terminal
uridylyltransferases TUT4 and TUT7, as these enzymes lack the large disordered Nterminal region.
Undoubtedly, human cells possess a robust Gld2 phosphorylation activity (Figure
3.3). We found that lysates from EGF-stimulated HEK 293 cells were active in
phosphorylating Gld2 at S62. In this particular experiment, we were not able to identify
additional phosphorylation sites in Gld2, suggesting that additional Gld2 kinases may not
be activated or sufficiently active in our experimental conditions. While Akt1 and PKA
are expressed in HEK 293 cells, Akt1 activity in these cells even upon EGF stimulation is
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low43 and likely not sufficient to yield quantitative phosphorylation of Gld2 S116
required for mass spectrometry. Alternatively, Gld2 phosphatases may be active at sites
other than Ser62. The data, nevertheless, show that human cells are competent in
phosphorylation of Gld2 in its N-terminal domain.
Our experiments with phosphomimetic mutants indicate that phosphorylation at S62
significantly increases Gld2 activity with miR-122 and the 15A RNA. Although Gld2
S62E showed a significant increase in activity with both RNAs, increased binding
affinity was only observed with miR-122. It is interesting to note that wildtype Gld2 is 9fold more active with miR-122 than with the poly(A) tail mimic. Even the increase in
activity with the poly(A) tail mimic by S62E does not reach the level of wildtype activity
with miR-122. In contrast, experiments with Gld2 S116E and pGld2S116 show that
phosphorylation at this site abolishes nucleotide addition activity. Although enzyme
activity is more than 100-fold reduced with miR-122, Gld2 S116E and pGld2S116 still
retained very low levels of enzymatic activity. In comparison, a mutation in the active
site, D215A, completely abolished enzyme activity on miRNA substrates 4,18. D215A is
part of the conserved catalytic triad responsible for activity3,44,45, while S116 is found in
the predicted disordered N-terminal domain, which was previously shown to be
dispensable for catalytic activity in the related uridylyltransferase Cid1 46–48, but we here
show that its function lies in the regulation of enzyme activity. Using enzymatic assays
and mass spectrometry, we identified and validated Akt1 and PKA as kinases with sitespecific phosphorylation activity at S116 in Gld2. Although acidic amino acids are not
always able to mimic the functional impact of phosphate31, the glutamate variant showed
reduced activity similarly to the pGld2S116 enzyme. Phosphorylation at S116, however,
led to a significantly greater reduction in Gld2 activity, which was two orders of
magnitude below the activity of the unphosphorylated enzyme. Thus, phosphorylation at
S116 effectively controls Gld2 activity.
During HCV infection, the Hepatitis C core protein binds to Gld2 to inhibit its
adenylation activity. Core protein binding is somewhat inefficient, with 13% binding at a
1:1 ratio. Nonetheless, this inhibition leads to a reduction of cellular miR-122 levels by
30%18. Even partial phosphorylation of cellular Gld2 at S116 is expected to have a
80

similar or greater effect on miR-122 levels, making post-translational modification of
Gld2 an efficient means to control cellular miRNA levels.
Although phosphorylation of S116 inhibits Gld2 catalytic activity, RNA binding
affinity was unperturbed, suggesting Gld2 phosphorylated at S116 binds the RNA
substrate in a non-productive conformation. The crystal structures of related
nucleotidyltransferases from yeast49 and C. elegans15,50 as well as the human terminal
uridylyltransferases TUT1 and TUT751,52 revealed a conserved positively charged surface
that may facilitate RNA binding. Despite these efforts, no structural information is
available on the N-terminal domain of Gld2. Our data suggest that Gld2 can assume
different RNA binding modes. The wildtype Gld2 enzyme binds RNA with high affinity
in a catalytically competent mode, which is perhaps stabilized yet further in the activating
mutants S62E and S110E. Conversely, Gld2 variants with phosphomimetic substitution
or phosphorylation at S116 appear to bind the RNA substrate in a non-catalytic mode that
interferes with nucleotide addition. This is not unique to Gld2, as other cases of
catalytically incompetent enzymes have been described in the literature. A small deletion
in RNA polymerase (RNAP) leads to a catalytically incompetent RNAP, that remains
bound to the promoter complex53. It is also well known that phosphorylation of the Cterminal domain of RNAP II is required for promoter clearance but not its activity36,54.
While the structural basis for phosphorylation-dependent modulation of Gld2 activity is
not yet defined, our experiments suggest an allosteric mechanism. We identified Gld2
variants that impact activity independently of RNA binding, indicating that allosteric or
conformational changes in the Gld2 RNA complex may play an important role in Gld2
catalyzed nucleotide addition.
Furthermore, in the cell, phosphorylation of Gld2 may affect interactions with
proteins that are implicated in RNA substrate selectivity12,55–58. In humans, Gld2 was
recently shown to interact with the RNA-binding protein Quaking (QKI-7) to facilitate
polyadenylation of target mRNAs. QKI-7 was shown to bind between residues 1-141 on
Gld258, which correspond to the predicted disordered N-terminal domain, including all of
the phosphorylation sites investigated here. Future efforts will determine the effect of
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phosphorylation on the ability of RNA binding proteins to interact with and regulate Gld2
activity and substrate specificity.

3.4.2

Oncogenic protein kinases signal to miRNA regulation

We identified Gld2 as a previously unknown substrate of two oncogenic kinases.
PKA and Akt1 belong to the evolutionarily conserved AGC family of protein kinases that
are activated upon stimulation with growth factors such as EGF 59. PKA is the key kinase
in the cyclic AMP signaling pathway that is activated upon hormone binding to G-protein
coupled receptors (GPCR). PKA activation has been shown to modulate the expression of
miR-122 through the extracellular signal-regulated kinase (ERK)60 and miRNA let-7b
levels through protein phosphatase 2A (PP2A) activation but the underlying pathway
remained unclear61.
Akt1 is a central hub of the PI3K/Akt signaling pathway, which is the most
commonly activated signal transduction pathway in human cancers 62. Active Akt1 signals
for cell survival and proliferation while also inhibiting apoptosis 59. Akt1 activity is
dependent on phosphorylation at two key regulatory sites (T308, S473). Over-active and
hyper-phosphorylated Akt1 is a hallmark of diverse human malignancies62,63, while the
unmodified Akt1 protein is inactive and rapidly degraded in cells 64. Several reports show
that Akt1 expression is regulated by miRNAs. The miRNAs miR-564 and miR-215
directly negatively regulate Akt1 mRNA stability65,66, while miRNA let-7 inhibits cyclin
D1 expression, leading to reduced Akt1 phosphorylation at S47367. Conversely, miRNA122 overexpression is associated with increased Akt1 phosphorylation in T-cell
lymphoma and renal cell carcinoma cells68, enhancing cancer progression. These reports
correlate PKA or Akt1 activity with miRNA levels yet fail to identify the factor linking
PKA or Akt1 activity to miRNA levels, exposing gaps in our understanding of the signal
transduction network. In addition, neither PKA nor Akt1 were previously shown to
directly phosphorylate any regulator of RNA.
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Although miRNAs are known to regulate Akt1, the ability of Akt1 activity to regulate
an enzyme involved in the regulation of miRNA metabolism has not been documented
previously. The Akt isozyme Akt2 is known to phosphorylate the single-stranded RNA
binding protein KH-type splicing regulatory protein (KSRP), allowing it to switch its
RNA preference from mRNA to primary miRNA (pri-miRNA) and facilitate Drosha
processing to pre-miRNA69. Although KSRP binds RNA, no enzyme that directly
regulates RNA stability has been previously identified as a substrate of Akt1. Using
precise biochemical experiments, we found that both Akt1 and PKA site-specifically
phosphorylate Gld2 at S116, abolishing Gld2 activity with miRNA and mRNA
substrates.

3.4.3

Relevance of Akt1-dependent regulation of miRNAs to disease

Hyperactivity of Akt1 and PKA is common in many cancers70,71. Our data suggest
that phosphorylation of Gld2 by these kinases would further promote carcinogenesis by
destabilizing tumor suppressor miRNAs, thus, further inducing tumorigenesis.
Abolishing Gld2 activity leads to a decrease in levels of tumor suppressor miRNAs
including miR-122 and let-77,16 (Figure 3.6). Decreased miR-122 and let-7 levels and
activity enable over- or un-regulated expression of their target genes, including
oncogenes with roles in cell growth, metastasis, and apoptosis 16,72.
In a related disease context, Gld2 is down-regulated in Hepatitis B and inhibited in
Hepatitis C infections16,18. Both HBV and HCV are contributing factors in the
development of HCC and other liver diseases due to the dysregulation in miR-122 levels
and the resulting expression of miR-122 regulated oncogenes16,19. The extent of Gld2
catalyzed mRNA adenylation, and the effect of specific phosphorylations on the
transcriptome and miRnome remain to be investigated and may reveal additional
contributions of Gld2 regulation to pathogenesis.
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Figure 3.6: Model of Akt1-mediated regulation of Gld2.
Gld2 monoadenylates miRNAs to increase stability and adds a single nucleotide to premiRNAs to enable recognition by Dicer and miRNA maturation. Decreased miRNA
levels (e.g. let-7b61) are associated with increased Akt1 phosphorylation status and
activity. Thus, fully activated Akt1 (ppAkt1T308,S473) phosphorylates Gld2 at S116 and
silences the stabilizing/maturing effect of Gld2 on miRNA. Through phosphorylation of
Gld2, Akt1 activity is expected to reduce miRNA levels. Phosphorylation is indicated by
the orange circles.

3.4.4

Conclusion

While hundreds of Akt1 substrates have been validated and/or predicted in human
cells73, miRNA editing enzymes were not previously known to be part of the Akt1
signaling network. Similarly, it was unclear how Gld2 activity may be regulated to
respond to external stimuli and signaling pathways, in turn controlling miRNAs and an
even larger number of downstream mRNA substrates. We here revealed the first link
between the activity of oncogenic kinases Akt1 and PKA and the regulation of Gld2. We
found that HEK 293 cells contain N-terminal Gld2 kinase activity and that
phosphorylation sites in the N-terminal domain of Gld2 can either positively or
negatively regulate nucleotide addition activity. We identified Gld2 as a bona fide
substrate of PKA and Akt1 and the site-specific phosphorylation catalyzed by either
kinase at Gld2 S116 abolishes nucleotide addition activity. While the overall impact of
Akt1/PKA signaling on miRNA metabolism remains to investigated in a cellular context,
these data significantly enhance our knowledge on miRNA regulation and reveal a

84

previously unrecognized link between oncogenic signal transduction and the regulation of
tumor suppressor miRNAs.
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Chapter 4

4

RNA surveillance by uridylation-dependent RNA decay in
Schizosaccharomyces pombe

4.1

Introduction

RNA synthesis and degradation are regulated through a variety of mechanisms that
amend the transcriptome to match cellular needs throughout the cell cycle and adaptation
to environmental changes1. Messenger RNA (mRNA) degradation can proceed by two
general pathways, in either a 5′-3′ or 3′-5′ direction, catalyzed by exonucleases or the
exosome complex, respectively. These canonical RNA degradation processes usually
commence with an initial deadenylation step, followed by decapping by Dcp1/2 and the
Lsm1–7 complex. Decapped mRNA is subsequently accessible to 5′-3′ decay catalyzed
by the exonuclease Xrn1, while exosome-catalyzed 3′-5′ degradation does not require
decapping2. Recently, a second deadenylation-independent pathway of mRNA decay was
discovered and appears to be conserved in many eukaryotes. Here, uridylation of
polyadenylated mRNAs recruits the Lsm1–7 complex and subsequently leads to mRNA
degradation by designated exonucleases2. This template-independent addition of
nucleotides is catalyzed by terminal RNA nucleotidyltransferases (TENTs), a subfamily
of the polymerase β superfamily of nucleotidyltransferases3. TENTs add ribonucleoside
monophosphates to an RNA substrate through a catalytic process involving two metal ion
cofactors3. Of note, non-templated 3′-end uridylation of a variety of RNA species plays
key roles in eukaryotic RNA processing pathways including mRNA and pre-miRNA
degradation, pre-miRNA maturation, and miRNA silencing4–6. RNA uridylation is
catalyzed by terminal uridylyltransferases (Tutases), and polyuridylated RNAs are
subsequently degraded by the U-specific exonuclease Dis3L26–8. While uridylation and
deadenylation-dependent RNA decay show some redundancy, uridylation is conserved in
many different species indicating that it is important for RNA turnover 9–11.
Fission yeast Cid1 (caffeine-induced death suppressor protein 1) was first discovered
in a genetic screen identifying components of the S-M cell cycle checkpoint
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in Schizosaccharomyces pombe12. Although S. pombe Δcid1 strains are viable, they are
sensitive to a combination of hydroxyurea, a ribonucleotide reductase inhibitor, and
caffeine, which overrides the S-M checkpoint and induces mitosis. Overexpression of
Cid1 confers resistance to this combination of stressors 12. Cid1 was originally thought to
be a poly(A) polymerase due to its significant in vitro poly(A) polymerase activity13, but
recent evidence characterized it as an efficient Tutase in vitro and in vivo14–16. Cid1
encodes a catalytic nucleotidyltransferase motif and a poly(A) polymerase-associated
motif17, but lacks an identifiable RNA recognition motif. Interestingly, nucleotide
specificity appears to have evolved after RNA specificity, with adenylyltransferases and
uridylyltransferases playing opposing roles in promoting RNA stability or degradation in
eukaryotes, respectively18. Nucleotide specificity depends on a critical histidine residue
(H336), which is responsible for UTP over ATP preference19,20 (Figure 4.1A). A H336N
mutation in Cid1 converts the enzyme to an adenylyltransferase 16,20, whereas a histidine
insertion in its human adenylyltransferase counterpart Gld2 confers UTP specificity18.
One of the first Cid1 RNA substrates to be identified was actin1 mRNA, which was
shown to be uridylated upon S-phase arrest in a Cid1-dependent manner15. In S. pombe,
RNA uridylation mediates mRNA turnover: Cid1 uridylates polyadenylated mRNAs to
trigger Lsm1–7-mediated decapping of the RNA 5′-end and subsequent degradation by
the U-specific exonuclease Dis3L27,10. Biochemical and structural investigations revealed
that despite the absence of a specific RNA recognition motif (Figure 4.1B), Cid1 is
capable of binding and uridylating RNAs in a sequence-independent manner14. Due to its
substrate promiscuity, Cid1 is thought to participate in a widespread mechanism of
mRNA decay in S. pombe11,17,19,21,22, and substrate specificity and selectivity may require
accessory proteins, in analogy to the human homologs, Tutases TUT4 and TUT7 and the
adenylyltransferase Gld218,23–26.
Following uridylation, RNAs are quickly degraded by the U-specific 3′-5′
exonuclease

Dis3L26–8,27–29.

Recent

studies

revealed

that

Dis3L2-catalyzed

exonucleolytic RNA degradation constitutes an alternative pathway for RNA decay,
independent of exosome and Xrn1-catalyzed decay pathways7. In S. pombe, Dis3L2
localizes to the cytoplasm and does not associate with the exosome but interacts with
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components of the cytoplasmic mRNA degradation pathway. While a recent study
reported no significant changes in mRNA accumulation in a dis3L2 deletion strain,
uridylated mRNAs were found elevated in a dis3L2 and lsm1 double mutant strain, and
recombinant Dis3L2 degraded uridylated RNA transcripts in vitro7. In humans, Dis3L2 is
involved in the degradation of uridylated mRNA and miRNA transcripts 6,7,30–32.
Mutations in Dis3L2 in humans are associated with the Perlman syndrome of fetal
overgrowth, likely due to its role in the degradation of miRNAs and pre-miRNAs of the
let-7 family33. Dis3L2 displays a typical RNase II-like protein domain organization, and
encodes two cold shock domains (CSDs), an exonucleolytic ribonuclease domain (RNB),
and a nonspecific RNA binding domain (S1) (Figure 4.1B). Structural analysis of Dis3L2
showed that in the absence of RNA, the enzyme displays an open conformation28 and
RNA binding induces a closed conformation, where three RNA binding domains form a
funnel to position the RNA substrate for exonucleolytic degradation 32.
In S. pombe, the Cid1/Dis3L2 RNA degradation pathway constitutes one of three
mRNA surveillance pathways. While the individual proteins, Cid1 and Dis3L2, are now
recognized and biochemically and structurally characterized, it is unclear whether the
three RNA decay pathways (Xrn1, exosome, and Cid1/Dis3L2) are dedicated to specific
substrate RNAs or act as three global albeit independent decay mechanisms. In this study,
we capture the extent of the Cid1/Dis3L2 mediated RNA degradation and find that
depletion of uridylation-dependent RNA decay causes the accumulation of misfolded
proteins and an increase in abundance of mRNAs involved in the stress response. Using
deep sequencing, we find that while Cid1 depletion has little impact on mRNA
homeostasis, Dis3L2 represents a bottleneck in uridylation-dependent RNA decay and its
depletion leads to an increase in mRNAs involved in protein folding and degradation
pathways. We conclude that perturbation of uridylation-dependent RNA decay elicits a
stress response, likely due to the accumulation of misfolded proteins.
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Figure 4.1: Domain structure and amino acid composition of Cid1 and Dis3L2.
A) Amino acid sequence alignment adapted from18. Enzymes known to exercise Tutase
activity encode a histidine residue (His336 in Cid1, highlighted in yellow), that sterically
hinders the larger ATP from entering the active site. Adenylyltransferases (PAPs) do not
encode the respective histidine residue. Nucleotide preference for S. pombe Cid11 and
Cid16 is undetermined, though Cid16 likely prefers UTP. B) Dis3L2 displays a typical
RNase II domain organization, encoding two cold shock domains (CSD), an
exonucleolytic ribonuclease domain (RNB), and a nonspecific RNA binding domain
(S1). Cid1 is composed of a nucleotidyltransferase domain (NTR) and a
poly(A)polymerase domain (PAP).

4.2
4.2.1

Materials and Methods
Yeast strains and growth conditions

S. pombe strains were obtained from Bioneer (Alameda, CA, USA): Wildtype
(BG_0000H6,

ade6-M210

ura4-D18

leu1-32);

Δdis3L2 (BG_H0669;

orfΔ

SPAC2C4.07c: kanMX4/ORF ade6-M210 ura4-D18 leu1-32) and Δcid1 (BG_H0513;
orfΔ SPAC19D5.03: kanMX4/ORF ade6-M210 ura4-D18 leu1-32). Liquid cultures were
grown at 30°C in YPD supplemented with adenine to an optical density of OD 600 = 0.5.
For spotting assays, yeast were grown on Edinburgh minimal media (EMM) (3 g/l
potassium hydrogen phthalate, 2.2 g/l sodium phosphate dibasic, 5 g/l ammonium
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chloride, 20 g/l dextrose, 2.1 g/l mineral salts, 0.02 g/l vitamins, 3 mg/l trace elements)
supplemented with 12 g/l L-leucine (leu), 2 g/l uracil (ura), 2 g/l adenine (ade).

4.2.2

Spotting assays

S. pombe cells were inoculated in 4 mL EMM-URA-LEU-ADE liquid media
overnight in a 30°C incubator shaker. 100 μl of cells were diluted 1:10 in ddH 2O to
measure the OD600 to determine cell density. Cells were standardized to OD 600 = 1 in the
first row of wells on a 96-well plate. A 1:5 serial dilution of cells was performed in the
subsequent five rows of wells. Cells were spotted on YES, and EMM-uracil-leucineadenine media agar plates with or without 100 μM H 2O2, 5 mM caffeine, 2 mM caffeine,
5 mM hydroxyurea, 2 mM hydroxyurea, and 2.5 mM caffeine + 10 mM hydroxyurea.
Plates were incubated in a 30°C incubator. Photographs of plates were taken on different
days to document growth. Spotting assays were photographed, and the image was
modified to black and white with the background blackened out and the yeast colonies
being white. The circular selection tool on ImageJ was used to select an equal area of
colonies and the mean gray value (MGV) was measured for density of cell growth. The
blackened plate background gave a MGV of 0 and complete colony growth gave a value
of 255. Wildtype values were normalized to 1 and the growth of deletion strains were
normalized against wildtype to give a fraction of 1. Unpaired t-test was employed to infer
statistical significance between wildtype and each deletion strain at 95% confidence
interval.

4.2.3

Cid1 cloning, purification, and activity assays

Total RNA was extracted from S. pombe cells using MasterPure Complete DNA and
RNA Purification kit (Epicentre) and reverse transcribed with SuperScript II Reverse
Transcriptase (Invitrogen) and random hexamer primers. The resulting cDNA was
amplified by PCR using gene specific primers (Cid1F 5′-AAGCTTATGAACATTTCTT
CTGCACAATTTATTCCTGGTGT-3′ and Cid1R 5′-CTCGAGCTCAGAATTGTCACC
ATCGGTTTCATTC-3′) and inserted into a pET-20b(+) expression vector with HindIII
and XhoI restriction sites. The construct was confirmed by DNA sequencing (London
Regional Genomics Centre). Escherichia coli BL21 Codon Plus cells were transformed
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with pET-20b(+) encoding His-tagged cid1and grown in LB media with ampicillin (100
μg/ml) and chloramphenicol (34 μg/ml) at 37°C to an OD 600 of 0.6. Protein expression
was induced by the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final
concentration of 1 mM and the culture was grown overnight at 18°C. Cells were
harvested and resuspended in Buffer A (50 mM HEPES, pH 6.8, 100 mM NaCl, 2 mM 2mercaptoethanol) supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF) and
0.25 mg/ml lysozyme and lysed with a French Pressure Cell. Following 1 hour of
centrifugation (41 000 rpm at 4°C), cell free extract was loaded onto a gravity column
containing HisPur Ni-NTA resin (Thermo Scientific) pre-equilibrated in Buffer A. The
resin was washed with Buffer B (50 mM HEPES, pH 6.8, 100 mM NaCl, 2 mM 2mercaptoethanol, 50 mM imidazole) and Cid1 was eluted with Buffer C (50 mM HEPES,
pH 6.8, 100 mM NaCl, 100 mM imidazole). After concentrating the eluted protein,
remaining contaminants were removed by size exclusion chromatography using a
Superdex™ 200 Increase 5/150 GL column and Buffer A. Protein concentration was
determined using a Bradford assay and purified proteins were stored at −80°C with 10%
glycerol. Enzyme activity assays were carried out as described previously18.

4.2.4

Circular rapid amplification of cDNA ends (cRACE) and Northern
blotting

RNA was isolated using the Masterpure RNA purification kit (Epicentre),
dephosphorylated with shrimp alkaline phosphatase (NEB), and phenol chloroform
extracted. For decapping, RNA was incubated with tobacco acid pyrophosphatase (NEB)
and circularized with T4 RNA ligase (NEB). Reverse transcription was carried out using
Superscript Reverse Transcriptase (ThermoFisher) and random hexamer primers. Gene
specific amplification was carried out using primers listed in Appendix B Table B1 and
PCR products cloned into pCR3.1- TopoTA vector (ThermoFisher) and sequenced at the
London Regional Genomics Centre. Northern blots were performed as previously
described34 using 5 or 10 μg of total RNA and 5′-32P-labelled gene specific probes
amplified from genomic DNA using primers listed in Appendix B Table B1.
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4.2.5

RT-qPCR

Reverse transcription and quantitative PCR (RT-qPCR) were performed as
described35. Briefly, total RNA was extracted using the Masterpure RNA purification kit
(Epicentre) and reverse transcribed using the High-Capacity cDNA Reverse
Transcription kit (Applied Biosystems). PowerUp SYBR Green Master Mix (Applied
Biosystems) was used for the qPCR and amplification was performed on the ViiA 7 RealTime PCR System. Six biological replicates of each S. pombe strain (wildtype, Δdis3L2,
and Δcid1) were analyzed in technical triplicates. All primers are listed in Table B1.

4.2.6

Yeast sedimentation assay and Western blot

Wildtype, Δdis3L2, and Δcid1 S. pombe strains were streaked onto YPD agar plates
supplemented with adenine, uracil, and leucine and incubated at 30°C. Three biological
replicates for each strain were grown in 5 mL YPD media supplemented with adenine,
uracil, and leucine overnight at 30°C. The OD600 of all cultures was measured the next
morning before the cells were centrifuged at 4000 × g for 5 min at 4°C. The
sedimentation assay was adapted from36. Briefly, cell pellets were lysed in 200 μl lysis
buffer (100 mM Tris–HCl pH 7.5, 200 mM NaCl, 1 mM ethylenediaminetetraacetic acid
(EDTA), 1 mM dithiothreitol (DTT), 5% glycerol, 0.5% Triton-X, 2 mM
phenylmethylsulfonyl fluoride (PMSF)) supplemented with protease inhibitors (Roche,
04 693 159 001) using glass beads on a Disruptor Genie. Cells were disrupted with six 30
s bursts followed by 30 s on ice between each burst. The lysates were separated from the
glass beads and 50 μl was added to 50 μl SUMEB (1% sodium dodecyl sulfate (SDS), 8
M urea, 10 mM 3-(N-morpholino)propanesulforic acid (MOPS), 10 mM EDTA, 0.01%
bromophenol blue). The remaining lysates were centrifuged at 500 × g for 15 mins at 4°C
and 100 μl of the supernatant was added to 100 μl of SUMEB. The pellets were
resuspended in 100 μl lysis buffer with no PMSF and 100 μl SUMEB. Samples were
analyzed on a 10% SDS gel and total protein in each lane was quantified using the BioRad ChemiDoc MP and Image Lab software. Total lysates were blotted for PGK1
(ThermoFisher Scientific, 459250) as loading control.
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4.2.7

RNA sequencing and data analysis

Three biological and three technical replicates for each S. pombe strain (WT,
Δdis3L2 and Δcid1) were grown in YPD media to an OD 600 of 0.6–0.65. RNA was
isolated using the Masterpure RNA purification kit (Epicentre). Ribosomal RNAs were
depleted using the Ribo zero RNA kit and the RNA library was generated with the
NEBNext® Ultra™ Directional RNA Library Prep Kit for Illumina. Samples were
analyzed on the MiSeq sequencing v2. Sequencing reads were mapped to the S.
pombe mitochondrion (MT) genome (NC_001326.1) using the CLC Genomics
Workbench and changes in gene expression were analyzed with the ANOVA-like
Differential Expression (ALDEx2) tool37 and an effect size cut-off of 1.5. The relative
expression (abundance) of each gene within a sample was calculated as the median
centered log-ratio (clr) from 1000 Monte Carlo Dirichlet instances. Genes were
considered to be differentially expressed if the ALDEx2 effect size was greater than 1.5
(i.e. the difference in abundance between two strains was at least 1.5-fold greater than the
difference between biological replicates). Genes differentially up- or down-regulated by
at least 1.5-fold were analyzed for enrichments in specific pathways using the Search
Tool for the Retrieval of Interacting Genes/proteins (STRING) 38.

4.3
4.3.1

Results
Recombinant Cid1 displays ambiguous substrate specificity in
vitro

Previous studies have shown that S. pombe Cid1 uridylates a variety of RNA
substrates in vivo15, which may subsequently be degraded by the exonuclease Dis3L2 7.
To assess whether Cid1 uridylation is ambiguous or dedicated to specific substrates, we
produced and purified full length Cid1 and assessed its substrate specificity on several
RNA substrates in vitro. We found that Cid1 uridylates a poly(A) tail mimic (15A),
tRNA, total mRNA, pre-miRNA and miRNAs equally (Figure 4.2). It appears that Cid1
uridylates RNA substrates regardless of their secondary structure (pre-miRNA hairpin
structure, tRNA structure), or sequence (miRNAs and poly(A) RNA). Total yeast tRNA
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and total human RNA preparations from cell lines HEK 293T and MDA-MB-231 are
heterogeneous mixtures by nature and the frequency of poly- versus monouridylation
cannot be assessed. In these cases, the observed products are presented in a smear,
consistent with either the uridylation of RNA substrates of varying length or also a
mixture of poly- and monouridylation events. Substrates 15A RNA, miRNAs and premiRNA were either purchased oligoribonucleotides or products of in vitro transcription
(pre-let-7a)18. For these homogenous RNA substrates, the predominant product is
consistent in length with a monouridylated RNA product. In the case of the 15A
nucleotide poly(A) tail mimic 15A RNA, a second band at ∼35 nucleotides is detectable,
indicating the addition of roughly 20 uridines in vitro. For the microRNA substrates miR122 and let-7a, polyuridylation can be observed in the form of a ladder-like pattern, as a
result of multiple nucleotide additions with variable product lengths. Thus, Cid1 displays
no substrate preference in vitro and can act as both a distributive or processive Tutase.

Figure 4.2: Cid1 displays a promiscuous substrate range in vitro.
Cid1 was incubated with different RNA substrates and [α-32P]-UTP as indicated.
Formation of [α-32P]-labelled RNA products was monitored by electrophoretic separation
and subsequent phosphorimaging. Cid1 catalyzed [α-32P]-UTP addition to RNA
substrates pre-let-7a (72 nts), mature human miRNAs let-7a-5p (22 nts) and miR122 (22
nts), an oligo(A) tail mimic 15A (15 nts), total yeast tRNA, and total RNA isolated from
HEK 293T or MDA-MB-321 cells. Radiolabelled RNA Decade marker is used for
reference.
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4.3.2

RNA uridylation is prominent in wildtype S. pombe and a cid1
deletion strain

To further investigate the function and substrate range of Cid1 in vivo, we purified
mRNA from wildtype and Δcid1 S. pombe strains and amplified several mRNA species
to sequence their 3′-end by cRACE. Surprisingly, uridylation of RNAs was found in both
the wildtype and the deletion strain. The small subunit ribosomal RNA, ScpofMR12 is, as
typical for ribosomal RNA, not adenylated, and most samples also did not contain
additional uridyl residues at the 3′-end (Figure 4.3). In S. pombe wildtype cells, one
sequence was retrieved with multiple uridines added to the RNA 3′-end (Figure 4.3A)
and in the cid1 deletion strain, monouridylated RNA was found (Figure 4.3B). Since
uridylations are rare and only few sequences were retrieved, no conclusions as to the
general uridylation pattern can be drawn from this data. SPBC215.11c, a protein coding
RNA, was polyadenylated in both strains, with no 3′-end uridylated RNAs recovered.
Interestingly, a uridylation/adenylation pattern was found in several samples of dak2, a
protein coding RNA, where a poly(A) tail of differing length was interceded by two
uridyl residues, followed by an additional four adenines (5′-NxAUUAAAA-3′). This
pattern was found only in dak2 RNA, in eight out of nine sequenced RNA samples, and is
not derived from the dak2 5′- or 3′-UTRs (Figure 4.3C). For another protein coding
mRNA, SPAC19G12.09, samples encoding poly(A) tails without uridines were most
prevalent. One polyuridylated sample was recovered from the cid1 deletion strain and
two monouridylated RNAs from wildtype S. pombe RNA. Again, due to sample size, no
conclusions can be drawn whether this represents a general uridylation pattern. Though it
appears that uridylation is slightly less prevalent in the cid1 deletion strain, the small
sample size and methodology of cRACE does not allow for a quantification of
uridylation, but rather the qualitative observation that mono- and polyuridylation occurs
in both wildtype and cid1 deletion strains, and that dak2 RNA is prone to an unusual
pattern of RNA uridylation and adenylation.
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Figure 4.3: RNA uridylation of diverse RNA transcripts is found in wildtype and
cid1 deletion strains.
RNA was extracted from wildtype and cid1 deletion strain, and 3′-ends of selected
mRNAs were analyzed by cRACE. In both A) wildtype and B) Δcid1 S. pombe cells
transcripts containing terminal uridyl residues, and residues incorporated into the poly(A)
tail were detected. A slight decrease in uridylated transcripts was detected
upon cid1 deletion. (C) Sequence of the dak2 mRNA 3′-UTR (red) and 5′-UTR (blue).
The protein coding sequence was omitted and is indicated as dak2 coding sequence.

4.3.3

Deletion of the Dis3L2 exonuclease elicits changes in the
transcriptome

To further probe the prevalence of uridylation-dependent RNA decay in S. pombe, we
isolated total RNA from wildtype, Δcid1, and Δdis3L2 strains, depleted ribosomal RNA
and analyzed the RNA content using deep sequencing. Reads were mapped to the S.
pombe genome, and differentially expressed genes (effect size >1.5) with more than a
1.5-fold change in expression between wildtype and Δcid1 or wildtype and Δdis3L2 were
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considered for the data analysis (Figure 4.4A and B, Appendix B Tables B2-B6). Gene
expression changes in Δcid1 and Δdis3L2 deletion strains followed a similar trend, as
outlined in Figure 4.5A, B and Appendix B Figure B1 and Tables B2-B6. Overall, 72
genes were found differentially expressed >1.5-fold between wildtype and Δcid1, and
214 genes were differentially expressed >1.5-fold between wildtype and Δdis3L2 (Table
B2). 24 of the genes were differentially regulated more than 1.5-fold in both deletion
strains (Figure 4.5B). While changes in the transcriptome of >1.5-fold were more
noticeable in Δdis3L2, many of the same genes were similarly up- or down-regulated in
Δcid1 (Figure 4.5A), albeit to a lesser extent. To verify the results obtained by RNA
sequencing, we performed Northern Blotting on several RNAs found to be differentially
expressed in the deletion strains. ecl1 was shown to be 1.4-fold up-regulated in
the cid1 deletion strain, which was confirmed by Northern Blot (Figure 4.6A), and little
to no expression changes were seen in spac19g12.09, spac27e2.11c, thf1 and tdh1, which
confirms our sequencing results (Table 4.1). We further used RT-qPCR to confirm our
sequencing results (Figure 4.6B), and all data confirmed the data observed in our Next
Generation Sequencing data. The qPCR data confirmed no significant change in the
expression of pex22 (Wt/dis3L2: qPCR 0.73-fold change, Sequencing 1.0-fold change).
Four

genes, hsp104 (Wt/dis3L2:

change), hsp78 (Wt/dis3L2:

qPCR

qPCR

2.8-fold

1.8-fold

change,
change,

Sequencing
Sequencing

3.9-fold
2.7-fold

change), ssa2 (Wt/dis3L2: qPCR 1.8-fold change, Sequencing 2.9-fold change)
and tcg1 (Wt/dis3L2: qPCR 1.24-fold change, Sequencing 2.3-fold change) were more
abundant in Δdis3L2, confirming our sequencing results (Table 4.1). As observed in our
next generation sequencing data, the changes in mRNA abundance as measured by RTqPCR are less pronounced in the cid1 deletion strain than in the dis3L2 deletion strain
(Figure 4.6B).
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Figure 4.4: Changes in relative abundance of mRNAs in WT, Δcid1, and Δdis3L2
cells.
Expression plot comparing relative abundance (log2 centered log ratio, clr) of transcripts
from a WT (x-axis) and A) Δcid1 or B) Δdis3L2 strain (y-axis). Differentially expressed
genes (ALDEx2 effect size >1.5) are indicated in red, and dotted lines indicated a 2-fold
change in expression from the line of best fit for the data (Pearson's r = 0.9805).

Figure 4.5: Genes differentially expressed in S. pombe deletion strains compared to
wildtype.
A) Heat map showing fold-change for significantly different genes with hits for both
WT S. pombe and Δcid1 and WT and Δdis3L2 strains. A histogram is included in the
colour key to show the gene fold-change distribution. B) Venn diagram of genes
differentially expressed in Δcid1 and Δdis3L2 deletion strains versus wildtype.
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Figure 4.6: Northern blot and RT-qPCR showing differential expression of genes in
wildtype versus Δcid1 or Δdis3L2 S. pombe.
A) Northern blots of total RNA extracted from WT and Δcid1 S. pombe was run on a 1%
agarose gel in 1 x MOPS and capillary blotted onto a Nylon membrane overnight at 4°C.
RNA was UV-crosslinked to the membrane and probed with gene-specific
oligonucleotides labelled on the 5′-end with 32P. The blot was exposed to a
phosphorimaging screen for two days at −80°C. tdh1 (GAPDH) was used as loading
control. Expected sizes are as following: ecl1 with UTRs, 3597 nts; spac19G12.09 with
UTRs, 1213 nts; spac27E2.11c with UTRs, 2140 nts; thf1 with UTRs, 3449 nts, with
UTRs and introns, 3777 nts; tdh1 with UTRs, 1518 nts. B) RT-qPCR was performed on
WT, Δcid1, or Δdis3L2 S. pombe cells to assess the gene expression changes in the
absence of cid1 or dis3L2. Cultures were grown to exponential phase (OD 600 = 0.6),
harvested, and RNA isolated. Expression of each gene was normalized to the WT strain
grown to early-exponential phase. Internal control used was rpp0. Error bars show the
standard error on the mean (n = 6).
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Table 4.1: Select genes up- or down-regulated in either S. pombe ∆cid1 deletion
strain or S. pombe ∆dis3L2 deletion compared to wildtype S. pombe.
Genes targeted in the Northern blot or RT-qPCR are listed.

SPAC19D5.02c
SPAC27E2.11C
SPBC16D10.08c
SPBC4F6.17c
SPBC839.16
ssa2
tcg1
tdh1

peroxisomal membrane protein
Pex22 (predicted)
Schizosaccharomyces specific
protein
heat shock protein Hsp104
mitochondrial heatshock protein
Hsp78 (predicted)
C1-5,6,7,8-tetrahydrofolate (THF)
synthase, trifunctional enzyme Thf1
heat shock protein Ssa2
single-stranded telomeric binding
protein Tgc1
glyceraldehyde-3-phosphate
dehydrogenase Tdh1

Fold
change
in Δcid1

Effect
change
in Δcid1

Fold
change in
Δdis3L2

Effect
change in
Δdis3L2

2.56

31.96

1.01

1.03

2.00
1.60

3.49
2.85

1.82
3.96

3.57
5.18

1.21

2.01

2.69

10.07

0.80
1.63

0.25
2.13

0.90
2.88

0.48
4.96

1.30

2.34

1.76

3.60

1.57

1.68

2.62

2.88

For genes >1.8-fold up- or down-regulated, we performed STRING analysis for
enrichment of specific pathways38 (Figure 4.7). In the Δdis3L2 strain, we found
significant enrichment in genes up-regulated in protein folding and protein degradation
pathways (false discovery rate <0.001, Table 4.2). Differential expression for genes
involved in stress response, especially heat shock proteins, chaperones, and protein
degradation were most prominent, but enrichment was also observed in sugar and
nucleotide metabolism (false discovery rate <0.01, Table 4.2), specifically in galactose
metabolism (false discovery rate <0.02, Table 4.2). No significant enrichment was found
for genes up- or down-regulated in the cid1 deletion strain (Appendix B Figure B2A and
B). Similarly, few genes were down-regulated in Δdis3L2, and the gene products did not
show enrichment in specific pathways according to our STRING analysis (Appendix B
Figure B2C).
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Figure 4.7: Search tool for the retrieval of interacting genes/proteins (STRING)
diagram of RNAs with altered expression levels in a dis3L2 deletion strain compared
to wildtype.
Respective proteins displayed are up-regulated (>1.5-fold) in the Δdis3L2 strain. The
diagram was generated using the STRING database. Functional associations between
proteins are shown, with confidence of the proposed association denoted by line
thickness.
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Table 4.2: Functional enrichments in genes >1.8-fold up-regulated in S. pombe
Δdis3L2 compared to wildtype.
Gene ontology processes enriched with a false discovery rate <0.01 are listed.
Gene ontology
observed
biological process gene count

false
discovery rate

matching proteins in S. pombe
network

protein folding

12

0.000414

SPBC1711.08.1, bip1, cdc37,
hsp104, hsp78, hsp90, psi1, ssa1,
ssa2, ssc1, sti1, trx1

galactose
catabolic process

4

0.0021

SPBC32F12.10.1, gal1, gal10,
gal7

0.00848

SPAC26F1.07.1,
SPBC32F12.10.1, SPBC3B9.01,
SPCC5E4.05c.1, bip1, cdc48,
gal1, gal10, gal7, glo1, pgi1,
plg7, rpt1, rpt3, trx1

0.00848

SPAC26F1.07.1,
SPBC32F12.10.1, gal1, gal10,
gal7, pgi1

single-organism
catabolic process
monosaccharide
catabolic process

4.3.4

15

6

Deletion of dis3L2 confers resistance to hydroxyurea, whereas
deletion of cid1 increases sensitivity to protein misfolding stress

Since our sequencing analysis revealed major changes to the transcriptome of stress
related genes in the dis3L2 deletion strain, we assessed phenotypic effects on S. pombe in
response to chemical stress (Figure 4.8). Cid1 was first identified as a protein involved in
S-M checkpoint control and cid1 deletion strains were found to be sensitive to caffeine
stress12. For phenotypic analysis, cells were grown on EMM containing 10 mM caffeine,
10 mM hydroxyurea (HU), or a combination of 2.5 mM caffeine and 10 mM HU as
described previously12. Our data shows that the cid1 deletion strain is sensitive to caffeine
and HU (Figure 4.8). Since Cid1 and Dis3L2 function in the same pathway, we next
tested the impact of these chemical stressors on the dis3L2 deletion strain. Surprisingly,
Δdis3L2 cells were more resistant to HU and caffeine, and a combination of caffeine and
HU than wildtype cells (Figure 4.8). In addition, we tested the sensitivity of strains
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bearing a deletion of dis3L2 or cid1 to conditions of protein misfolding stress for growth
in media containing hydrogen peroxide, which causes oxidative damage. Deletion
of dis3L2 did not cause significant changes in sensitivity to hydrogen peroxide compared
to wildtype (Figure 4.8). By contrast, deletion of cid1 resulted in increased sensitivity to
oxidative stress.

Figure 4.8: Growth assay of S. pombe WT, Δdis3L2, and Δcid1.
Cells were grown on EMM with required nutrients and with or without drug treatment at
30C. A) Cells were grown overnight in EMM media with Ura, Leu, and Ade and then
spotted on media plates. B) Quantification of standardized growth differences between
wildtype and deletion strains. WT growth was normalized to 1 and compared against
deletion strains. The p values were calculated using a two-tailed t-test. A p value < 0.05 is
indicated by an asterisk (*) and < 0.01 by (**).
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4.3.5

Deletion of dis3L2 and cid1 causes the accumulation of misfolded
proteins

To test whether the up-regulation of stress response genes in the deletion strains was a
transcriptional response to cellular stress, we tested WT and deletion strains for the
accumulation of misfolded proteins in the cell. Indeed, the overall protein abundance in
the insoluble protein fraction was significantly higher in both deletion strains (Figure
4.9A, C, and D). PGK1 (Phosphoglycerate kinase 1) was blotted for in total cell lysates
as a loading control (Figure 4.9B). To investigate whether dis3L2 or cid1 expression is
up-regulated under stress conditions, we performed a Northern blot on RNAs extracted
from WT cells grown under heat, cold, caffeine and hydroxyurea stress (Figure 4.9E). No
changes in abundance were observed.

Figure 4.9: Sedimentation assay of aggregated proteins in WT, Δcid1, and Δdis3L2
deletion strains.
A) Representative SDS gel of a sedimentation assay showing total, soluble, and insoluble
protein of WT S. pombe cells in triplicate. B) Western Blot showing similar amount of
PGK1 of total cell lysate of WT, Δcid1, and Δdis3L2 deletion strains were used for
sedimentation assays. R, replicate. C) Quantification of total amount of protein in the
supernatant and pellet fractions of three biological replicates from the wildtype, Δcid1,
and Δdis3L2 strains. D) The ratio between the supernatant and pellet for each strain was
calculated and plotted on a bar graph. The p values were calculated using a two-tailed ttest (0.03 between WT and Δcid1, 0.05 between WT and Δdis3L2). A p value <0.05 is
indicated by an asterisk (*). E) Northern blot showing no change in expression
of cid1 or dis3L2 RNA in response to different growth conditions.
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4.4
4.4.1

Discussion
mRNA uridylation does not exclusively depend on Cid1

Uridylation-dependent RNA decay is now well established as an alternative RNA
degradation pathway9. Despite growing knowledge on the biochemical and structural
properties of the responsible enzymes Cid1 and Dis3L2 in S. pombe, little is known about
the prevalence and substrate-specificity of uridylation-dependent mRNA decay. A
truncated Cid1, lacking amino acids 1–31 of the N-terminal domain was previously
shown to be highly processive in vitro15,21, yet only a few U residues are added in vivo
(Figure 4.3 and 15). By contrast, our full-length protein is significantly less processive and
its uridylation activity is restricted to few residues (Figure 4.2). It is therefore possible
that the N-terminal domain of Cid1 serves as an auto-inhibitory domain to prevent
excessive RNA uridylation.
In the cellular context, our data shows that mRNA uridylation in S. pombe is not
exclusive to the founder Tutase Cid1 but is likely also executed by a partially redundant
Tutase. We found evidence of mRNA uridylation in a cid1 deletion strain (Figure 4.3),
indicating the activity of an alternate Tutase in this pathway. In addition, less drastic
changes were observed in the transcriptome upon cid1 deletion (Figures 4.4, 4.5 and
Appendix B Figure B2). It remains to be elucidated which TENTs are responsible for
RNA uridylation in the absence of Cid1. S. pombe encodes several TENT homologs
besides Cid1, namely Cid11, Cid12, Cid13, Cid14, and Cid16. Interestingly,
transcriptional levels of the TENT Cid14 are 2-fold down-regulated in the cid1 deletion
strain. Cid14 is thought to be a poly(A) polymerase and lacks the histidine residue
specifying uridine over adenine specificity (Figure 4.1A). Furthermore, Cid14 has been
shown to act as a poly(A) polymerase in ribosomal RNA processing 39, and is thus
unlikely to also act as a Tutase. Similarly, Cid11, Cid12 and Cid13 are thought to be
adenylyltransferases rather that Tutases 9,40. The most likely candidate for mRNA
uridylation appears to be Cid16, an enzyme previously shown to act as a Tutase on small
RNAs, targeting Argonaute-bound RNAs to promote their degradation41. In a recent
study, spatially separated activities of the nuclear adenylyltransferase Cid14 and the
cytoplasmic Tutase Cid16 were shown to regulate small RNA stability41. While Cid1
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does not compensate for small RNA uridylation in the absence of Cid16 41, it is possible
that Cid16 uridylates mRNAs in the absence of Cid1, or generally functions as a
redundant Tutase acting on mRNA.

4.4.2

Mixed mRNA A/U tails

While adenylyltransferases and Tutases have previously been shown to act on the
same set of RNAs on separate instances41, we show here a previously unreported
combined 3′ A/U modification in S. pombe. The observed combination of A/U addition
suggests that in contrast to the uridylation and adenylation of sRNAs catalyzed by the
spatially separate Cid14/Cid16, the dak2 mRNA 5′-NxAUUAAAA-3′ tail most likely
occurs

in

the

cytoplasm

as

a

cooperative

effort

between

uridylyl-

and

adenylyltransferases. The Tutases Cid1 and Cid16, as well as the adenylyltransferases
Cid11 and Cid13, localize to the cytoplasm42 and could interact to form this unusual 3′end RNA motif. Whether the 5′-N xAUUAAAA-3′ motif serves as a specific signal for
downstream RNA processing, RNA localization, or degradation remains to be
determined. We observed the 5′-NxAUUAAAA-3′ motif on dak2 mRNA, which encodes
a dihydroxyacetone kinase. Whether the 5′-NxAUUAAAA-3′ motif is unique to this
mRNA species is speculative, as we only tested a small sample number of mRNAs.
Excitingly, guanylyl- and adenylyltransferases were shown to generate mixed-tails in
human cells, and mixed tails were shown to shield mRNA from rapid deadenylation43.
Future research will have to explore the biological function and prevalence of combined
A/U tailored transcripts in S. pombe in vivo.

4.4.3

Uridylation-dependent RNA decay is linked to stress response and
telomere maintenance

While Cid1 is not essential for the uridylation-dependent RNA decay pathway under
non-stress conditions, Dis3L2 appears to represent more of a bottleneck in RNA
degradation. Our data shows that the deletion of dis3L2 leads to an accumulation of
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transcripts predominantly in protein folding and degradation pathways, as well as sugar
catabolic processes. While Cid1 does not contain specific RNA recognition motifs, such
as Zinc fingers, its crystal structure revealed a positively charged surface area thought to
facilitate general, sequence-independent RNA binding19,20. It has been suggested that
RNA binding proteins interact with Cid1 to direct the TENT to substrate RNAs, but these
proteins remain to be identified21.
As previously described for chemical stress, the transcriptome of S. pombe undergoes
global changes in response to stress conditions44 (Appendix B Tables B2-B6). We found
most significant changes in the transcriptome in genes related to protein folding, such as
heat shock protein genes hsp90 and hsp70, co-chaperones cdc37 and wos2, protein
remodeling factor hsp104, and chaperone activators aha1 and sti1 with an effect change
between 2- and 10-fold in the dis3L2 deletion strain (Appendix B Tables B2, B5, B6).
Changes to the Δcid1 transcriptome generally followed the same trend, albeit to a lesser
extent, indicating that a partially redundant Tutase reduces the effect of the cid1 deletion
(Appendix B Tables B2, B3, B4). Furthermore, protein catabolic processes and protein
degradation pathways, including AAA-type ATPase cdc48, and 19S proteasome
regulatory subunits rpt1, rpt3 and rpt6, and the ubiquitin C-terminal hydrolase ubp15,
were up-regulated between 2- and 5.4-fold in Δdis3L2, and up to 2.2-fold in Δcid1. Other
accumulated transcripts include RNAs of genes from a variety of metabolic pathways,
transcriptional regulators, cell cycle, and the cytoskeleton (Figure 4.7).
Galactose metabolism genes gal1, gal7, and gal10 are required for using galactose as
a carbon or energy source and are usually repressed in wildtype fission yeast in the
absence of galactose45. We found these genes significantly up-regulated in the
Δdis3L2 strain with effect changes between 3.5 and 8.5 (Appendix B Tables B2, B5, B6).
Expression of gal genes is regulated by telomeric silencing45. We observed an increased
expression of genes involved in telomere organization in the dis3L2 deletion strain,
namely DNA replication factor A subunit Ssb1 (effect change = 6.5), and single-stranded
telomeric binding protein Tgc1 (effect change = 3.6). Overexpression of proteins
involved in telomere organization may be compensatory effects in an effort to counteract
a disruption of telomere organization, which is evident from the de-repression
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of gal genes. Cid1 was initially characterized as a protein involved in S-M checkpoint
control, and it may well be that disruption of uridylation-dependent RNA decay interferes
with telomere maintenance and repair.
Previous studies in frog oocytes show that uridylation-dependent decay is crucial for
clearance of the maternal transcriptome, indicating that this decay pathway plays a role in
the degradation of transcripts that are no longer required46. Similarly, in humans, Dis3L2
depletion is associated with the accumulation of damaged RNA transcripts6. Furthermore,
Dis3L2 depletion inhibits global apoptotic mRNA decay and cell death47. These and
other studies indicate that uridylation-dependent RNA decay is part of a global mRNA
surveillance, aiding in the clearance of unneeded or damaged RNAs. Our data show that
perturbation in uridylation-dependent RNA decay elicits a stress response as evidenced
by increased abundance of transcripts enriched in protein folding and degradation
pathways. It is possible that some of the other transcriptional changes beyond stress
response result in a higher expression rate of those genes. We hypothesize that excess
protein production may overwhelm the cellular protein quality control, leading to the
accumulation of unfolded proteins and consequently elicit the unfolded protein response.
In addition, since the TUT/Dis3L2 pathway in humans functions in damaged transcript
decay6, these transcripts may also be accumulating in S. pombe, but not be detected as a
significant change in abundance rates. Stress response genes are likely up-regulated as a
response to accumulated proteins in the deletion strains (Figure 4.9).

4.4.4

Dis3L2 depletion increases resistance to hydroxyurea-induced
stress

Taking into account that both Cid1 and Dis3L2 are dispensable under normal growth
conditions7,9,12, it is likely that uridylation-dependent RNA decay targets damaged or
incomplete RNA transcripts as part of a stress response, similar to the Cid14/16 small
RNA surveillance pathway41. Cid1 was first described as a protein involved in the S-M
cell cycle checkpoint12. A cid1 deletion strain displays a growth retarded phenotype
under stress conditions when exposed to caffeine, HU, or a combination of caffeine and

112

HU (Figure 4.8) and overexpression of Cid1 increases resistance to this stress-inducing
combination12,48. Our data shows that a dis3L2 deletion on the other hand increases
viability when exposed to HU and caffeine (Figure 4.8). Both HU and caffeine are known
for their interference with the cell cycle49. HU inhibits the enzyme ribonucleotide
reductase, which is essential for DNA synthesis, and its depletion impairs DNA
replication and subsequently arrests cells in S phase50. Interestingly, the RNAs upregulated in the dis3L2 deletion strain included ribonucleotide reductase small
subunit suc22 (1.9-fold) and ribonucleoside reductase large subunit cdc22 (3.4-fold),
which were previously shown to be up-regulated in response to HU51. The increased
expression of ribonucleotide reductase subunits, in combination with an already activated
stress response may give Dis3L2 depleted cells the growth advantage over wildtype cells.
While overexpression or depletion of enzymes in the uridylation-dependent RNA decay
pathway can alter cell viability, we found no evidence that expression of cid1 or dis3L2is
altered at the transcriptional level (Figure 4.9E). Both cid1 and dis3L2 show similar
abundance independent of growth temperature or chemical stress (Figure 4.8). However,
protein production may instead serve as the point of control on the translational level, or
enzyme activity could be modulated by post-translational modification, as described for
other nucleotidyltransferases52,53. It is plausible that enzymes involved in RNA
uridylation and decay are constitutively active and degrade damaged RNA transcripts on
demand.
We also tested the effect of the deletion of dis3L2 or cid1 on protein quality control.
When grown on hydrogen peroxide to induce protein misfolding, the cid1 deletion, but
not the dis3L2 deletion strain showed a significant increase in sensitivity (Figure 4.8). It
is possible that the up-regulation of the cellular stress responses (e.g. the heat shock
response) that we observed in the dis3L2 deletion exerts a protective function compared
to the cid1 deletion strain. We further found that both deletion strains accumulated higher
proportions of misfolded and insoluble proteins compared to wildtype (Figure 4.9). These
results indicate that the defects in RNA processing in these strains leads to an
accumulation of misfolded protein, which in turn appears to induce the expression of
many protein quality control genes possibly by activation of the heat shock response.
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We conclude that uridylation-dependent RNA decay is part of an RNA surveillance
system, and RNA transcripts are not efficiently disposed of in the absence of Dis3L2 or
to a lesser extent Cid1. Translation of these potentially damaged or unwanted RNA
transcripts leads to the accumulation of misfolded proteins, eliciting the cellular stress
response and the increased expression of chaperones and enzymes involved in protein
degradation.
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Chapter 5

5

Summary and Perspectives
RNAs are a fundamental part of cellular homeostasis and are regulated throughout

their life cycle1–11. The addition of non-templated 3’-end nucleotides plays a key role in
RNA regulation12. The enzymes that these reactions are known as terminal RNA
nucleotidyltransferases (TENTs) and are divided into two functional groups,
adenylyltransferases and uridylyltransferases, based on their nucleotide preference.
Adenylation is associated with stabilization while uridylation leads to silencing and
degradation of RNAs, with the exception of a role for uridylation in Group II pre-miRNA
maturation7,12. The first uridylyltransferase discovered was Cid1 in Schizosaccharomyces
pombe. Cid1 was initially assumed to be an adenylyltransferase shown to play a role in
the S-M cell cycle checkpoint13. The unexpected uridylation activity was later identified
through in vitro assays with recombinant Cid1 and in vivo assays in S. pombe14–16. This
uridylation activity is thought to be part of a uridylation-dependent RNA decay pathway
where polyuridylated RNAs are recognized and degraded by the U-specific 3′-5′
exonuclease Dis3L217. The discovery of Cid1 as an uridylyltransferase sparked new
investigations

resulting

in

many

adenylyltransferases

to

be

re-classified

as

uridylyltransferases10–12,18–20. One human homolog of Cid1 is Gld2, which has been
associated with both adenylation and uridylation in different reports7,9,21,22.
Both Cid1 and Gld2 encode two domains necessary for catalytic activity but lack
recognizable RNA binding domains23. Therefore, their catalytic activity and RNA
specificity are thought to be regulated by interacting proteins. In humans, some of those
interacting proteins were identified and characterized, but remain uncharacterized in S.
pombe22,24,25. The fact that Cid1 and Gld2 likely require accessory proteins to determine
their substrate specificity makes it challenging to identify what RNAs are targeted by
these enzymes. In addition, their similar domain structure and high amino acid
conservation,

but

seemingly

different

nucleotide

preferences,

suggest

that

uridylyltransferases and adenylyltransferases are closely related despite having opposing
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roles. The work in this thesis provides insights into the regulation and cellular impact of
TENT-catalyzed nucleotide additions to RNAs.

5.1

The evolution of adenylyl- and uridylyltransferase nucleotide
specificities

In previous studies, Gld2 has been reported to both adenylate and uridylate the 3’-end
of RNAs7,9,21,22,25,26. As adenylation (stabilizing) and uridylation (silencing and/or
degradation) have opposing effects on RNA stability12, the cellular roles of Gld2 were not
clear. Through extensive enzyme kinetic analysis, I showed that Gld2 is a true
adenylyltransferase with an 83-fold preference for ATP over UTP. As the cellular
concentrations of ATP vastly exceeds that of UTP 27, it is most likely that Gld2 acts as an
adenylyltransferase in vivo to stabilize RNAs.
The

high

amino

acid

conservation

and

structural

similarity

between

adenylyltransferases and uridylyltransferases suggests these enzymes are homologous
and evolved from a common ancestor. A detailed phylogenetic analysis showed that
uridylyl- and adenylyltransferases do not separate into two distinct groups according to
nucleotide specificity. Rather the phylogeny (see Figure 2.6 in Chapter 2) showed that
nucleotide specificity evolved multiple times, suggesting a simple mechanism governing
ATP versus UTP selectivity in the TENT family. My experiments revealed that UTP
specificity is accomplished through insertion of a crucial histidine residue in the active
site. This histidine is absent in adenylyltransferases and present in uridylyltransferases,
where it sterically blocks the larger ATP from the active site. Insertion of the histidine
into the coding sequence of Gld2 did indeed switch the nucleotide preference from ATP
to UTP. This simple insertion/deletion of a histidine residue could explain how uridylyland adenylyltransferases appeared multiple times throughout evolution of the TENT
family.
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5.2 Regulation of Gld2 activity by post-translational
phosphorylation
The activity and RNA specificity of Gld2 is regulated through interactions with other
proteins such as the Hepatitis C (HepC) core protein28 and the RNA binding proteins
QKI-724 and CPEB25,29,30. No other modes of regulation, such as regulation of protein
stability, have been described in the literature. Large scale proteomic studies using mass
spectrometry revealed five phosphorylated serine residues in the predicted disordered Nterminal domain of Gld231–33, suggesting the possibility of Gld2 regulation through
phosphorylation. I showed that phosphomimetic substitutions at each of the five serine
positions lead to changes in Gld2 activity and RNA binding that were dependent on the
position as well as the RNA substrate. Two sites of interest were identified where one site
(S62) increased enzymatic activity by ~5-fold while another site (S116) severely
inhibited Gld2’s adenylation activity up to 111-fold. When both sites were combined, the
inhibiting ability of S116E overwhelmed the activating function of S62E. This was the
first evidence that phosphorylation at these sites may regulate Gld2 activity.
Using kinase activity assays and mass spectrometry, I identified the first known
kinases of Gld2: protein kinase A (PKA) and protein kinase B (Akt1). Both kinases were
found to specifically and exclusively phosphorylate Gld2 at S116 and reduced Gld2
activity to an even greater extent than the phosphomimetic. The data suggest that these
kinases may play a role in inactivating Gld2. Gld2 promotes the stability and maturation
of the miRNAs miR-122 and let-7a, respectively7,9,21. Both miRNAs function as tumor
suppressors and reduced levels of these miRNAs lead to dysregulation of their target
genes, some of which are involved in cell growth, metastasis, and apoptosis 34,35. As Akt1
and PKA are commonly over-activated in many cancers36,37, their ability to inhibit Gld2
may promote tumorigenesis by decreasing the levels of miRNA tumor suppressors. Thus,
the data reveal a possible novel link between oncogenic kinases signaling and miRNA
regulation.
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5.3

The role of the Cid1/Dis3L2 pathway in global RNA decay

The Cid1/Dis3L2 RNA decay pathway in S. pombe plays a major role in mRNA
homeostasis17,19,38–42. However, the contribution of the Cid1/Dis3L2 pathway to total
RNA decay is unknown. Deletion of cid1 did not display any major changes in the
uridylation status compared to wildtype S. pombe. However, an interesting
uridylation/adenylation pattern (5′-NxAUUAAAA-3′) was found on the 3′-ends of dak2, a
protein coding RNA. Such mixed RNA ends were previously shown to alter RNA
stability in human cells43. The role of the mixed RNA tail in S. pombe remains to be
investigated. Deep sequencing revealed that deleting cid1 or dis3L2 elicited similar
changes to the transcriptome. However, the changes in gene expression were much
greater in the dis3L2 deletion strain. Genes involved in protein folding and degradation
were up-regulated with the greatest change, indicating an up-regulated stress response.
The transcriptome of both deletion strains showed similar accumulation of transcripts
related to stress response, yet larger and more significant changes were observed in the
dis3L2 deletion strain. The greater transcriptional response as well as the presence of
somewhat redundant uridylyltransferase activity in the cid1 deletion strain indicates that
Dis3L2 represents a bottleneck in the RNA decay pathway.
The data suggests that the increase of mRNA transcripts of stress response genes
could be due to the accumulation of misfolded proteins. As the Cid1/Dis3L2 RNA decay
pathway was compromised in the deletion strains, we expect accumulation of RNA
transcripts that would usually be decayed in the Cid1/Dis3L2 pathway. These transcripts
could be translated into proteins, resulting in a dysregulated proteome, which may then
overwhelm the protein control machinery. The accumulation of misfolded proteins,
which we observed experimentally, may trigger the cellular stress response. Our data
suggests that the uridylation-dependent RNA decay pathway mediated by Cid1 and
Dis3L2 plays an important role in maintaining mRNA and proteome homeostasis.
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5.4
5.4.1

Future Directions and Perspectives
The role of post-translational modifications in regulating Gld2

Post-translational modifications (PTMs) are an efficient means for the cell to regulate
proteins44. In Chapter 3, phosphomimetic substitutions at specific serine residues in the
predicted disordered N-terminal domain of Gld2 demonstrated that the activity and RNA
binding of Gld2 is affected and that two different oncogenic kinases were able to
phosphorylate and inhibit Gld2 activity through one site (S116). Confirming these results
in human cell lines and animal models would be the next steps in connecting the kinases
to miRNA regulation. As PKA and Akt1 are hyperactive is many cancers36,37, mass
spectrometry of tumor samples that show hyperactivity of either kinase would be a
valuable tool to determine if Gld2 pS116 is present in those samples. In addition,
determining additional upstream kinases for Gld2 would reveal different pathways that
regulate Gld2 activity.
The majority of PTMs were shown to be in the predicted disordered N-terminal
domain of Gld245. Disordered regions are known as protein docking areas due to their
ability to adopt different conformations46. In fact, the RNA binding protein QKI-7 was
shown to bind to the predicted disordered N-terminal domain of Gld224. As Gld2 lacks
known RNA binding motifs, it seems the enzyme depends on RNA binding proteins to
promote recognition with specific RNA substrates and regulate Gld2 activity12,22–25. It is
possible that these interacting proteins bind the N-terminal domain of Gld2 and PTMs in
this region may regulate Gld2 binding to specific proteins at specific times.
Although PTMs may affect the binding of interacting proteins, phosphorylation of
five serine sites were shown to directly affect Gld2 activity and RNA binding in Chapter
3. It would be interesting to extend the study to include different RNAs such as a wider
range of miRNA forms, poly(A) tail mimics of different lengths, and poly(A) tail mimics
that include different sequence motifs. In addition, testing the effect that serine
phosphorylation may have on nucleotide specificity may be worthwhile as Gld2 can
accept and use ATP and UTP7,9,21,47. As Gld2 is currently viewed as an enzyme involved
in promoting RNA stability through adenylation, this would significantly change the
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biological function of Gld2 as a RNA regulating enzyme. The ability to switch between
either nucleotide based on the phosphorylation status would allow Gld2 to take part in
stabilizing (adenylation) and silencing/degrading (uridylation) RNAs, two opposing roles
thought to be carried out by different enzymes.
The Gld2 N-terminal domain constitutes approximately one third of the protein and it
is possible that the domain can act as a regulatory element for the two catalytic domains.
This was observed for Cid1, where the full-length enzyme was less processive than an
enzyme lacking the first 31 amino acids15,48. I have unpublished data revealing that Gld2
lacking the N-terminal domain is approximately 20-fold more active than wildtype Gld2.
Besides the five serine positions that were studied, other phosphorylation sites throughout
Gld2 and modifications such as methylation and ubiquitination were also reported in
mass proteomic studies of various samples31,32,49–53. Future studies will probe the function
of these other modifications.
In a disease context, determining if there are different PTMs on Gld2 in diseases such
as cancer or cardiovascular diseases would be of great interest as a diagnostic tool. The
HepC core protein has been shown to inhibit Gld2 activity without affecting protein
expression levels28, leading to decreased miR-122 levels. The reported PTMs of
Gld231,32,45,49–53 were identified in a variety of tumors, tissues, and immortalized human
cells, making it difficult to determine what modifications are a result of healthy
conditions or cellular dysregulation. As miR-122 is a known substrate of Gld29,21 and
miR-122 is highly expressed in the liver54, immunoprecipitation and mass spectrometry
of Gld2 from healthy livers of animal models such as mice would reveal PTMs on Gld2
in healthy tissue. These can be compared to PTMs reported in the literature 31,32,45,49–53 or
disease mouse models. Immunoprecipitation and mass spectrometry of Gld2 from a
variety of liver cells lines, such as the HepG2 liver hepatocellular carcinoma cell line and
the PLC/PRF/5 hepatoma cell line, would also give an overview of PTMs that are
associated with specific conditions.
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5.4.2

Regulating miR-122 through Gld2 in health and disease

The miRNA miR-122 is the most abundant miRNA in the liver, comprising 70% of
the total miRNA population in human livers54. It is a naturally unstable miRNA that
requires the post-transcriptional addition of a 3′-end adenine residue to enhance its
stability9,21. Gld2 was identified as the nucleotidyltransferase responsible for stabilizing
miR-1229,21. Not only does miR-122 play important roles in liver development and
homeostasis, but also in viral infections and liver diseases34. The levels of miR-122 in
viral infections vary. HepC infected livers have moderate levels of miR-122 as the virus
requires miR-122 for replication. On the other hand, Hepatitis B (HepB) infected livers
have non-detectable miR-122 levels. HepB actively reduces miR-122 as miR-122 was
shown to exert an inhibitory effect on the replicative ability of the virus 28,34,55. Both HepC
and HepB regulate miR-122 stability. The HepC core protein binds to Gld2 and inhibits
its activity28 while the HepB virus X protein (HBx) impairs Gld2 gene expression55.
Although miR-122 has been a target for HepC therapeutic intervention, patients require
constant dosages to reduce miR-122 levels due to the instability of the therapeutic
RNAs56–58. Thus, inhibiting Gld2 with a small molecule is a potentially more desirable
route to deplete miR-122 levels.
Investigating how Gld2 is regulated during viral infection or in cancers may reveal
specific post-translational modifications that are not present in healthy cells. The
resulting data would enable downstream development of drugs, such as antibodies,
against those different modifications or protein conformations. However, inhibiting Gld2
to reduce miR-122 levels would be counterproductive in treating diseases such as HepB
that require therapies to increase miR-122 levels. Therefore, drugs that could lock Gld2
in a catalytically-active conformation or inhibitors of kinases that inactivate Gld2, such as
Akt1 and PKA, would be preferred in this situation.

5.4.3

Identifying new cellular roles of Gld2

In studies, C. elegans Gld2 has been shown to play an important role in
development26,59,60. Here, Gld2 is involved in extending the poly(A) tails of genes
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associated with meiosis to increase protein expression and promote entry into
meiosis26,59,60. In humans, Gld2 plays a role in controlling mRNA stability, in addition to
miRNA maturation and stability7,9,12,21,61. However, whether Gld2 has the same function
in different tissues and if Gld2 regulation is tissue-specific remains to be answered.
As Gld2 lacks recognizable RNA binding domains, studies have shown that it
interacts with RNA binding proteins to recognize specific substrates 22,24,25. In addition,
these RNA binding proteins may also modulate Gld2 processivity by allowing Gld2 to
stay in contact with the RNA longer22,24,25. Thus, Gld2 could be regulated through RNA
binding proteins that are differentially expressed in different cell types or tissues. As cell
lines are commonly used to study proteins in a cellular context, co-immunoprecipitation
assays can be used to identify interacting proteins that can then be verified through
biochemical approaches and further in vivo experiments such as protein expression
knockdowns with siRNAs and co-localization studies.
Although the studies in Chapter 3 showed that phosphomimetics at specific serine
residues on Gld2 changed the activity and RNA binding, the experiments were performed
in vitro and further studies in cells and ultimately animal models should be pursued. As
Gld2 has been shown to stabilize the liver-specific miRNA miR-1229,21, liver cell lines
are the standard used by the field to study miR-122. The phosphomimetic variants and a
non-phosphorylatable variant as a control could be expressed through transient
transfections and their activity can be measured through miR-122 levels either indirectly
using a GFP reporter construct developed in the Heinemann lab 62 or directly using
miRNA RT-qPCR. Since we found glutamate substitutions provided an accurate mimic
of phosphorylation at Ser116, a systems level analysis of the impact of phosphomimetic
variants on mRNA levels can also be studied through deep sequencing.

5.4.4

Impact of Cid1 and Dis3L2 on Schizosaccharomyces pombe RNA
metabolism

Deep sequencing of S. pombe cid1 and dis3L2 deletion strains revealed changes
across the transcriptome. Although both deletion strains showed similar changes in RNA
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expression, the dis3L2 deletion strain showed gene expression changes of far greater
magnitude. This is potentially due to a partially redundant uridylyltransferase such as
Cid16 in S. pombe that can take on Cid1’s role. Deep sequencing of a cid1/dis3L2 double
deletion strain would provide additional information on what genes are specifically
affected through the Cid1/Dis3L2 decay pathway. Other deletion strains to study would
be a cid16 single deletion strain and double deletion strains of cid1/cid16 and
cid16/dis3L2.
Select genes from different pathways that were differentially expressed were further
verified in Chapter 4 but many others involved in pathways such as telomere and
mitochondria organization were identified in the analysis. Genes that were affected in
both deletion strains, such as ubiquitin-protein ligase E3 Dbl5 and acetyl-CoA Cacetyltransferase Erg10, would be a good starting point for further studies. Chapter 4
discussed how the dis3L2 deletion disrupted telomere organization which led to an upregulation in galactose metabolism genes and telomere organization genes. As many
genes were up- or down-regulated, it is possible that not all of them are a direct result
from the cid1 or dis3L2 deletion and are a downstream effect of other dysregulated genes.
A possible experiment to determine what RNAs Cid1 uridylate would be to crosslink
Cid1

with

interacting

RNA

in

S.

pombe

cells,

pull-down

Cid1

through

immunoprecipitation, and identify the RNAs through RNA sequencing.
Terminal nucleotidyltransferases that exhibit different nucleotide preferences have
been reported to act on the same RNA substrates at different times63. In S. pombe, a
unique pattern was found at the end of the dak2 mRNA tail where 2 uridine residues were
added before the terminal four adenine residues. Such U/A mixed 3’-terminal RNA tails
were also observed in human cells where uridine residues were found on short poly(A)
tails (<25 nucleotides) and guanine residues on long tails (>40 nucleotides) 64.
Polyuridylation at the 3′-end of mRNAs is commonly associated with degradation10,18 but
the addition of single guanine residues within the poly(A) tail was shown to prevent rapid
deadenylation43. As the U/A pattern was observed on short and long poly(A) tails and
consists of only 2 uridine residues, the poly(A) tail interspaced with two uridine residues
potentially have the same protective function in S. pombe as the single guanine residues
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do in human cells43. This can be studied by determining the half-lives of RNAs with and
without the mixed tails transfected into human cells. As the guanylation was found on
multiple mRNA tails64, determining if the uridine/adenine pattern also exists on other S.
pombe mRNA tails would indicate that mixed tails is an evolutionarily conserved
mechanism to prevent rapid deadenylation of RNAs.

5.5

Conclusion

RNAs play an essential role in many cellular processes and RNA homeostasis is thus
highly regulated. The discovery of RNA regulation through non-templated 3′-end
nucleotide additions by terminal nucleotidyltransferases added an additional layer of
complexity to the network regulating RNA metabolism. The work presented in this thesis
aimed to elucidate the impact of these nucleotide additions on RNA homeostasis and the
regulatory mechanisms controlling terminal nucleotidyltransferases. The included data
broadens our understanding of the enzymes and pathways regulating cellular RNAs.
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Appendices
Appendix A
Table A1: Primers for cloning of Gld2 into pGEX-6P-2 and mutagenesis of Gld2.
Primer Name

Primer Sequence

Gld2BamHIfor
Gld2XhoIrev
Gld2Glu62for
Gld2Glu62rev
Gld2Glu69for
Gld2Glu69rev
Gld2Glu95for
Gld2Glu95rev
Gld2Glu110for
Gld2Glu110rev
Gld2Glu116for
Gld2Glu116rev
Gld2Ala116for
Gld2Ala116rev

5′-ATGCGGATCCGAAAATCTGTACTTC-3′
5′-TAATCTCGAGTTAACGTTTTAACACGG-3′
5′-CATACGGTAACGTGGAACCGATCCAGACCAGCGC-3′
5′-GCGCTGGTCTGGATCGGTTCCACGTTACCGTATG-3′
5′-GATCCAGACCAGCGCCGAACCTCTGTTCCGTGG-3′
5′-CCACGGAACAGAGGTTCGGCGCTGGTCTGGATC-3′
5′-CGCCAGCGTTTTCATGAACCGCACCAAGAACCG-3′
5′-CGGTTCTTGGTGCGGTTCATGAAAACGCTGGCG-3′
5′-GAACCAGATTGTGCCGTTAGAAGGTGAACGTCGCTATAGC-3′
5′-GCTATAGCGACGTTCACCTTCTAACGGCACAATCTGGTTC-3′
5′-CGGTGAACGTCGCTATGAAATGCCTCCGCTGTTTC-3′
5′-GAAACAGCGGAGGCATTTCATAGCGACGTTCACCG-3′
5′-CGGTGAACGTCGCTATGCCATGCCTCCGCTGTTTC-3′
5′-GAAACAGCGGAGGCATGGCATAGCGACGTTCACCG-3′

Table A2: Kinases predicted to phosphorylate Gld2 at residues S62, S69, S95, S110
and S116.
Position in Gld2 Gld2 Sequence*

Predicted Kinases

62
62
62
69
69
95
95
95
95
110
116

GSK-3, ERK1, ERK2, CDK5
MAPKAPK2
PKA, PIKK, CDK, MAPK, ERK1, ERK2
GSK-3, ERK1, ERK2, CDK5
PKA, PKC
Akt2, MAPKAPK
PKA, PKC
GSK-3, ERK1, ERK2, CDK5
Akt, Akt2, AGC, CDK5
CK2
PKA, PKC, Akt, AGC, CAMK

NVSP
SPIQT
QLTYGNVSPIQTSAS
SASP
SPIQTSASPLFRGRK
RQRFHS
RFHS
FHSP
GKRQRFHSPHQEPTV
SGE
LSGERRYSMPPLFHT

*Serine residue predicted to be phosphorylated is bolded and underlined
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Figure A1: Purified Gld2 constructs.
Purified GST-Gld2 constructs were visualized on a 10% polyacrylamide SDS gel stained
with Coomassie Brilliant Blue G-250 and Western blotted using an anti-Gld2 antibody.
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Figure A2: Catalytic activity and RNA binding of Gld2 phosphomimetic variants.
The activity plots show the amount of product formed at 1 µM ATP plotted over time
with A) miR-122 (22 nts) or B) oligo(A) tail mimic 15A RNA (15 nts). Insets of Gld2
S116E and the no enzyme control are for better visualization of the data. Wildtype Gld2
(WT) and no enzyme reactions are plotted on all graphs for comparison and the insets
show the low activity Gld2 variants. Error bars represent the standard error. The binding
assay plots show the binding of wildtype Gld2 and Gld2 mutants to C) miR-122 or D)
oligo(A) tail mimic 15A RNA. WT reaction is plotted on all graphs for comparison. Gld2
mutants are graphed separately for better visualization of the data. Each Gld2 variant was
incubated with 1 µM unlabelled and [α-32P]-labelled ATP and 2 µM RNA substrate.
Samples were taken every 2 minutes and stopped with the addition of 2 x RNA loading
dye. Reactions were analyzed via electrophoretic separation and subsequent
phosphorimaging. Specific activity was calculated from the linear slope of the curve.
Fluorescence anisotropy was used to determine the Kd. Each Gld2 enzyme was incubated
with a RNA substrate fluorescently labelled on the 5′-end with 6-FAM and incubated at
room temperature for 20 minutes. Fluorescence polarization was measured at Ex. 492nm
and Em. 535/20 nm and the Kd was calculated using SigmaPlot. Error bars represent the
standard error from triplicate reactions. ΔmP, change in fluorescence polarization in
millipolarization units.
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Figure A3: PKA and Akt1 produce phosphorylated Gld2.
The activity plot shows the amount of phosphorylated Gld2 (nM) produced over time
when incubated with PKA or Akt1. A no kinase control is also plotted. Gld2 WT and a
kinase were incubated with [γ-32P]-ATP and samples were taken every 5 minutes and
stopped with the addition of 2 x SDS loading dye. Reactions were analyzed on a 10%
polyacrylamide SDS gel and subsequent phosphorimaging and product quantification.
Error bars are one standard error calculated from triplicate reactions.

Figure A4: PKA-mediated phosphorylation down-regulates Gld2 catalytic activity.
The activity plots show the amount of product formed at 1 µM ATP plotted against time
with miR-122 (22 nts) or oligo(A) tail mimic 15A RNA (15 nts). Gld2 was incubated
with PKA and purified before activity assay. Phosphorylated Gld2 was incubated with 1
µM unlabelled and [α-32P]-labelled ATP and 2 µM RNA substrate. Samples were taken
every 2 minutes and stopped with the addition of 2 x RNA loading dye. Reactions were
analyzed via electrophoretic separation and subsequent phosphorimaging. Wildtype Gld2
treated in the same way without kinase (treated wildtype, tWT) and no enzyme reactions
are plotted on all graphs for comparison. Insets of Gld2 phosphorylated by PKA and the
no enzyme control are for better visualization of the data. Error bars are one standard
error calculated from triplicate reactions.
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Figure A5: Gld2 S116A does not mimic wildtype activity and binding.
A) The activity plots show the amount of product formed at 1 µM ATP plotted over time
with miR-122 (22 nts) or oligo(A) tail mimic 15A RNA (15 nts). Insets of Gld2 S116E,
Gld2 S116A, and the no enzyme control are for better visualization of the data. Wildtype
Gld2 (WT) and no enzyme reactions are plotted on all graphs for comparison. Each Gld2
variant was incubated with 1 µM unlabelled and [α-32P]-labelled ATP and 2 µM RNA
substrate. Samples were taken every 2 minutes and stopped with the addition of 2 x RNA
loading dye. Reactions were analyzed via electrophoretic separation and subsequent
phosphorimaging. Specific activity was calculated from the linear slope of the curve.
Error bars represent the standard error. B) The binding assay plots generated through
fluorescence anisotropy show the binding of wildtype Gld2 and Gld2 S116E and S116A
mutants to miR-122 or oligo(A) tail mimic 15A RNA. WT reaction is plotted on all
graphs for comparison. Each Gld2 enzyme was incubated with a RNA substrate
fluorescently labelled on the 5′-end with 6-FAM and incubated at room temperature for
20 minutes. Fluorescence polarization was measured at Ex. 492nm and Em. 535/20 nm
and the binding affinity (Kd) was calculated using SigmaPlot. Error bars represent the
standard error from triplicate reactions. C) Bar graphs showing the fold change in
specific activity at 1 µM ATP and Kd between wildtype Gld2, S116E, and S116A with
miR-122 or oligo(A) tail mimic 15A RNA calculated from A) and B). ΔmP, change in
fluorescence polarization in millipolarization units.
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Appendix B
Table B1: Oligonucleotide primers.
Target

Method Forward Primer 5′-3′

Thf1
ECl1
SPAC19G12.09
Tdh1

Northern
Blot

Reverse Primer 5′-3′

CGAAGGTCAACCCTTGTTTAC
CG
GGAGACATACATTTACAAAG
CG
GGTACAGCTTTGTTTAAGAA
AG
GGTGCTGACTACGTTATCGA
G
GCCATGATTGCTGTCGCTTGC
TCTGTC

CCAACATCAATAGCGACAAC
G
GAGCAGTCATGATTTCTTCCT
GTC
GGAATAGGACTATGCAAAAG
G
CTTGGAGGGACCGTCAACG

Cid1

TCACGTTATCAAGCCTCCCG

Dis3L2

AGGAGTCATCGGGAGCAACT

CGACACCACACAGAATAATA
TAGTTGAATGG
AAGCGGCCATAAATTCCCCT
C
AGACTGGCACCATTACGCTC

ScpofMr12

GAAGGAGGAATTGCGAG

GATTACGATTTGAGCTTG

CAGTCCGGTTATGCTACC

GCAAGCCTCTTTGTC

GGCATATCATGTAACCTG

GTTTAGTAGAGGGAGAAGC

GCGTTATACCTATCACTAC
GTCTTTTCCTCAGGTTCGGAC
T
CTTCGTCCTTCTCACGCTCT

CAACATGCTTATCGCTGC

GCTCCTTCCAGGTCACTCAG

ATCCTGCGTTAGTTGGTCCG

GGTGACGCTGCTAAGAACCA

CGGGGGTAAAGGTCTTGGTC
CCGTTTCAAACAATGAACGG
ATT
GATTCGTCGTGCTATGCGTG

SPAC27E2.11c

SPBC215.11c

cRACE

dak2
SPAC19G12.09
Pex22
Hsp104
Hsp78
Ssa2

RT-qPCR

Tcg1

CCGCTGAGGAAACTGTAACC

Rpp0

GTTACCGGCAGGGACAAAGA

TCCGACTCAGAAAGTGCTGT
TGGTTACTGCTGCCCATCTC

Table B2: Genes up- or down-regulated in either S. pombe ∆cid1 deletion strain or S.
pombe ∆dis3L2 deletion compared to wildtype S. pombe.

Actin cytoskeleton organization
adf1
actin depolymerizing factor, cofilin
ARP2/3 actin-organizing complex
arp2
subunit Arp2
Arp2/3 protein complex, actin-like
arp3
protein subunit Arp3
myo1
myosin type I
cytoskeletal signaling protein Slm1
SPAC637.13c
(predicted)
Antisense RNA
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Fold
change
in Δcid1
1.21

Effect
change
in Δcid1
2.05

Fold
change in
Δdis3L2
1.34

Effect
change in
Δdis3L2
3.80

0.98

0.89

1.27

5.65

1.49
0.98

2.40
0.89

1.83
1.33

3.76
6.11

0.98
Fold

0.95
Effect

1.54
Fold

3.46
Effect

SPNCRNA.1036
SPNCRNA.1132
SPNCRNA.1138
SPNCRNA.1170
SPNCRNA.1204
SPNCRNA.1212
SPNCRNA.1235
SPNCRNA.1447
SPNCRNA.1451
SPNCRNA.1467
SPNCRNA.1548
SPNCRNA.1563
SPNCRNA.1626
SPNCRNA.1665
SPNCRNA.579
SPNCRNA.606
SPNCRNA.636
SPNCRNA.706
SPNCRNA.857
SPNCRNA.886
SPNCRNA.949
SPNCRNA.967

antisense RNA (predicted)
antisense RNA (predicted)
antisense RNA (predicted)
antisense RNA (predicted)
antisense RNA (predicted)
antisense RNA (predicted)
antisense RNA (predicted)
antisense RNA (predicted)
antisense RNA (predicted)
antisense RNA (predicted), possible
alternative UTR
antisense RNA (predicted)
antisense RNA (predicted)
antisense RNA (predicted)
antisense RNA (predicted)
antisense RNA (predicted)
antisense RNA (predicted)
antisense RNA (predicted)
antisense RNA (predicted)
antisense RNA (predicted)
antisense RNA (predicted)
antisense RNA (predicted)
antisense RNA (predicted)

Carbohydrate metabolic process
adh4
alcohol dehydrogenase Adh4
dak1
dihydroxyacetone kinase Dak1
gal1
galactokinase Gal1
UDP-glucose 4-epimerase/aldose 1gal10
epimerase Gal10
galactose-1-phosphate
gal7
uridylyltransferase Gal7
glycerol-3-phosphate
gpd2
dehydrogenase Gpd2
mal1
maltase alpha-glucosidase Mal1
glucose-6-phosphate isomerase
pgi1
(predicted)
glucose 1-dehydrogenase (NADP+)
SPAC26F1.07
(predicted)
alpha,alpha-trehalose-phosphate
SPACUNK4.16c synthase (predicted)
glycosyl hydrolase family 3
SPBC1683.04
(predicted)
SPBC2G2.17c
beta-glucosidase Psu2 (predicted)
SPBC32F12.10
phosphoglucomutase (predicted)
SPCC306.06c
ER membrane protein, BIG1 family
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change
in Δcid1
1.37
3.02
0.86
2.49
0.88
0.39
1.10
1.14
0.87

change
in Δcid1
2.59
2.91
0.86
3.06
0.87
0.26
1.34
1.58
0.68

change in
Δdis3L2
2.29
1.65
0.19
1.24
0.38
1.00
1.82
1.72
0.61

change in
Δdis3L2
14.8
1.56
0.16
1.24
0.22
1.00
2.89
8.58
0.13

0.94
0.39
2.01
0.88
1.27
0.79
0.68
1.50
1.26
1.00
0.78
1.20
0.59
Fold
change
in Δcid1
0.90
1.02
1.35

0.78
0.25
1.61
0.76
2.07
0.74
0.55
4.30
1.15
1.00
0.64
1.46
0.34
Effect
change
in Δcid1
0.73
1.05
1.65

0.58
0.27
2.85
2.66
1.42
0.51
0.33
1.73
4.98
1.79
0.48
0.67
0.69
Fold
change in
Δdis3L2
0.46
1.81
3.78

0.14
0.16
2.89
7.15
2.83
0.23
0.25
2.95
3.15
3.07
0.34
0.30
0.38
Effect
change in
Δdis3L2
0.16
3.41
8.51

0.83

0.82

2.63

6.07

0.84

0.78

1.67

3.52

0.93
0.74

0.69
0.34

0.63
0.88

0.12
0.73

1.16

2.49

1.87

4.75

0.87

0.78

2.36

4.63

0.99

0.99

2.45

5.29

0.77
0.53
1.11
0.80

0.26
0.54
1.44
0.32

1.17
0.33
1.93
0.81

1.59
0.28
3.75
0.23

tdh1
tps1

(predicted)
glyceraldehyde-3-phosphate
dehydrogenase Tdh1
alpha,alpha-trehalose-phosphate
synthase [UDP-forming]

Carbohydrate derived metabolic process
UTP-glucose-1-phosphate
SPCC1322.04
uridylyltransferase Fyu1

Cell adhesion
SPBPJ4664.02

cell surface glycoprotein, flocculin,
related to Gsf2

Cell wall organization or biogenesis
alpha-1,2-mannosyltransferase
omh5
Omh5 (predicted)

Cellular amino acid metabolic process
arg1
acetylornithine aminotransferase
N-acetyl-gamma-glutamylphosphate reductase/acetylglutamate
arg11
kinase
NADP-specific glutamate
gdh1
dehydrogenase Gdh1 (predicted)
leu2
3-isopropylmalate dehydratase Leu2
SPBC19F5.04
aspartate kinase (predicted)
homoserine dehydrogenase
SPBC776.03
(predicted)
SPBPB2B2.05
peptidase family C26 protein
proline dehydrogenase Put1
SPCC70.03c
(predicted)
trx1
cytosolic thioredoxin Trx1

Chromatin organization
cell cycle regulated GATA-type
ams2
transcription factor Ams2
asa1
Astra associated protein 1 Asa1
SPBC582.04c
RNAi protein, Dsh1
swc3
Swr1 complex subunit Swc3
swd3
WD repeat protein Swd3
Tel2/Rad-5/Clk-2 family protein
tel2
Tel2

Cofactor metabolic process
hexaprenyldihydroxybenzoate
coq3
methyltransferase Coq3
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1.57

1.68

2.62

2.88

1.18
Fold
change
in Δcid1

1.28
Effect
change
in Δcid1

2.75
Fold
change in
Δdis3L2

4.08
Effect
change in
Δdis3L2

1.19
Fold
change
in Δcid1

1.38
Effect
change
in Δcid1

2.25
Fold
change in
Δdis3L2

4.67
Effect
change in
Δdis3L2

0.63
Fold
change
in Δcid1

0.34
Effect
change
in Δcid1

1.07
Fold
change in
Δdis3L2

1.24
Effect
change in
Δdis3L2

1.36
Fold
change
in Δcid1
0.86

3.14
Effect
change
in Δcid1
0.29

1.04
Fold
change in
Δdis3L2
0.82

1.15
Effect
change in
Δdis3L2
0.20

0.86

0.32

0.86

0.29

1.28
0.94
0.89

3.27
0.61
0.35

1.35
0.61
0.77

7.05
0.10
0.10

1.09
1.57

1.46
1.54

1.28
3.80

3.01
5.73

0.84
1.02
Fold
change
in Δcid1

0.24
1.10
Effect
change
in Δcid1

0.90
1.51
Fold
change in
Δdis3L2

0.36
6.99
Effect
change in
Δdis3L2

1.20
0.78
0.72
1.12
0.81

1.62
0.50
0.29
1.28
0.42

1.54
0.64
0.72
1.52
0.73

4.09
0.29
0.28
2.93
0.26

0.72
Fold
change
in Δcid1

0.32
Effect
change
in Δcid1

0.86
Fold
change in
Δdis3L2

0.58
Effect
change in
Δdis3L2

1.44

1.73

2.15

3.15

pdx1

SPAC806.06c
SPBC1709.19c
SPBC4B4.01c

SPBC947.15c

pyruvate dehydrogenase protein x
component, Pdx1 (predicted)
nicotinamide mononucleotide
(NMN) adenylyltransferase
(predicted)
mitochondrial iron-sulfur cluster
assembly protein Nfu1 (predicted)
fumble family pantothenate kinase
(predicted)
mitochondrial NADH
dehydrogenase (ubiquinone) Nde1
(predicted)

Cytoplasmic translation
diphthamide biosynthesis protein
dph2
(predicted)
hri2
eIF2 alpha kinase Hri1
psi1
DNAJ domain protein Psi1
Hsp70 nucleotide exchange factor
SPBC3B9.01
Fes1 (predicted)
translation initiation factor eIF2 beta
tif212
subunit (predicted)

Detoxification
glo1
SPAC869.02c

glyoxalase I
nitric oxide dioxygenase Yhb1

DNA-templated transcription
nut2
mediator complex subunit Med10
rad24
14-3-3 protein Rad24
DNA-directed RNA polymerase III
rpc53
complex subunit Rpc53 (predicted)
ribosomal DNA (rDNA)
rrn3
transcription factor Rrn3
CK2 family regulatory subunit
SPBC2G5.02c
Ckb2 (predicted)
transcriptional coactivator,
multiprotein bridging factor Mbf1
SPBC83.17
(predicted)
SPCC548.05c
ubiquitin-protein ligase E3 Dbl5

DNA recombination
meiosis specific coiled-coil protein
mcp7
Mcp7
meiotic recombination protein
rec10
Rec10
Tf2-1
(NC_003424
1465326.14702
retrotransposable
52)
element/transposon Tf2-type
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0.95

0.81

0.69

0.29

2.21

4.15

2.02

6.54

0.82

0.48

0.70

0.23

1.39

2.38

1.44

2.85

1.14
Fold
change
in Δcid1

1.56
Effect
change
in Δcid1

1.71
Fold
change in
Δdis3L2

10.56
Effect
change in
Δdis3L2

0.91
0.96
1.07

0.78
0.87
1.24

0.69
1.42
2.60

0.28
4.06
7.32

1.33

2.59

2.74

4.35

1.31
Fold
change
in Δcid1
1.27
0.55
Fold
change
in Δcid1
0.84
1.19

3.53
Effect
change
in Δcid1
2.44
0.11
Effect
change
in Δcid1
0.58
1.68

0.99
Fold
change in
Δdis3L2
1.83
1.12
Fold
change in
Δdis3L2
0.69
1.49

0.94
Effect
change in
Δdis3L2
4.86
1.37
Effect
change in
Δdis3L2
0.33
3.55

0.74

0.50

0.70

0.33

0.90

0.66

0.66

0.17

0.91

0.60

0.76

0.22

1.28
0.36
Fold
change
in Δcid1

2.34
0.27
Effect
change
in Δcid1

1.51
0.37
Fold
change in
Δdis3L2

3.78
0.26
Effect
change in
Δdis3L2

0.83

0.60

0.64

0.19

0.54

0.32

0.87

0.75

2.58

2.90

1.70

1.60

DNA repair
lub1
msh6
nse4
nth1
pnk1
pso2
rik1

SPBC23E6.02
tdp1
tra2

WD repeat protein Lub1
MutS protein homolog
Smc5-6 complex non-SMC deltakleisin subunit Nse4
DNA endonuclease III
DNA kinase/phosphatase Pnk1
DNA 5' exonuclease (predicted)
silencing protein Rik1
ATP-dependent DNA helicase,
ubiquitin-protein ligase E3
(predicted)
tyrosyl-DNA phosphodiesterase
Tdp1
NuA4 complex phosphatidylinositol
pseudokinase complex subunit Tra2

DNA replication
cdc23
MCM-associated protein Mcm10
cdt2
WD repeat protein Cdt2
DNA replication endonucleasedna2
helicase Dna2

Establishment or maintenance of cell polarity
protein phosphatase regulatory
paa1
subunit Paa1
tea3
cell end marker Tea3

Generation of precursor metabolites and energy
cob
cytochrome b, Cob1 (predicted)
cox1
cytochrome c oxidase 1 (predicted)
isocitrate dehydrogenase Idp1
idp1
(predicted)
phosphogluconate dehydrogenase,
SPBC660.16
decarboxylating
succinate-CoA ligase beta subunit
SPCC1620.08
Lsc2 (predicted)

Intergenic RNA
SPNCRNA.1115
SPNCRNA.1164
SPNCRNA.1297
SPNCRNA.1325

intergenic RNA (predicted),
possible alternative UTR
intergenic RNA (predicted)
intergenic RNA (predicted),
possible alternative UTR
intergenic RNA (predicted),
possible alternative UTR
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Fold
change
in Δcid1

Effect
change
in Δcid1

Fold
change in
Δdis3L2

Effect
change in
Δdis3L2

0.98
1.18

0.91
1.61

1.47
1.49

2.97
5.18

0.90
0.89
0.95
0.70
5.07

0.70
0.71
0.85
0.39
3.52

0.71
0.70
0.76
0.67
3.65

0.35
0.34
0.34
0.26
2.61

2.45

4.46

1.39

1.69

0.74

0.34

0.93

0.83

0.80
Fold
change
in Δcid1
0.52
1.38

0.34
Effect
change
in Δcid1
0.33
1.97

0.88
Fold
change in
Δdis3L2
0.50
1.78

0.64
Effect
change in
Δdis3L2
0.26
4.01

0.81
Fold
change
in Δcid1

0.39
Effect
change
in Δcid1

0.80
Fold
change in
Δdis3L2

0.25
Effect
change in
Δdis3L2

1.19
0.84
Fold
change
in Δcid1
0.89
0.97

2.41
0.38
Effect
change
in Δcid1
0.61
0.92

1.38
0.77
Fold
change in
Δdis3L2
0.65
0.66

4.45
0.19
Effect
change in
Δdis3L2
0.25
0.35

0.81

0.64

1.35

4.33

1.15

1.98

1.80

4.88

0.82
Fold
change
in Δcid1

0.32
Effect
change
in Δcid1

1.15
Fold
change in
Δdis3L2

1.81
Effect
change in
Δdis3L2

1.12
1.76

1.40
3.34

1.37
1.13

3.04
1.24

0.80

0.67

0.31

0.16

2.28

2.05

3.05

2.93

SPNCRNA.1474
SPNCRNA.1657
SPNCRNA.1673
SPNCRNA.671
SPNCRNA.672
SPNCRNA.737
SPNCRNA.781
SPNCRNA.877
SPNCRNA.935
SPNCRNA.968

intergenic RNA (predicted)
intergenic RNA (predicted),
possible alternative UTR
intergenic RNA (predicted)
intergenic RNA (predicted)
intergenic RNA (predicted)
intergenic RNA (predicted)
intergenic RNA (predicted)
intergenic RNA (predicted)
intergenic RNA (predicted),
possible alternative UTR
intergenic RNA (predicted),
possible alternative UTR

Lipid metabolic process
aim22
erg10
plg7
SPAC4A8.10
SPAC977.09c

SPBC36.10
SPCC5E4.05c

lipoate-protein ligase A (predicted)
acetyl-CoA C-acetyltransferase
Erg10 (predicted)
phospholipase A2, PAF family
homolog
acylglycerol lipase (predicted)
phospholipase (predicted)
mitochondrial intermembrane space
protein; involved in phospholipid
metabolism Ups2 (predicted)
mitochondrial acylglycerol lipase
Mgl1 (predicted)

Microtubule cytoskeleton organization
spindle pole body SUN domain
sad1
protein Sad1

Mitochondrion organization
mitochondrial single stranded DNA
specific 5'-3' exodeoxyribonuclease
exo5
Exo5 (predicted)
mitochondrial DNAJ domain
mdj1
protein Mdj1 (predicted)
phb1
prohibitin Phb1 (predicted)
MICOS complex subunit Mic26/27
SPCC1442.05c
(predicted)
CBS domain protein implicated in
SPCC4B3.03c
magnesium homeostasis (predicted)

Mitotic cytokinesis
fim1
mid2
rng2

fimbrin
medial ring protein Mid2
IQGAP
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0.50

0.60

0.40

0.35

2.14
2.05
1.00
2.24
1.14
1.63
2.05

2.96
3.19
1.00
3.23
1.08
2.69
1.94

0.62
0.84
0.53
1.26
0.49
0.48
2.98

0.54
0.83
0.29
1.52
0.34
0.30
3.26

1.06

1.16

0.70

0.19

1.13
Fold
change
in Δcid1

1.28
Effect
change
in Δcid1

0.62
Fold
change in
Δdis3L2

0.35
Effect
change in
Δdis3L2

0.74

0.34

0.72

0.31

1.39

3.93

1.47

4.34

1.02
0.77
1.14

1.10
0.43
1.33

1.36
0.64
2.92

3.89
0.31
10.71

0.97

0.93

0.68

0.35

1.28
Fold
change
in Δcid1

2.36
Effect
change
in Δcid1

1.48
Fold
change in
Δdis3L2

3.69
Effect
change in
Δdis3L2

1.07
Fold
change
in Δcid1

1.26
Effect
change
in Δcid1

1.32
Fold
change in
Δdis3L2

3.30
Effect
change in
Δdis3L2

0.54

0.33

0.71

0.50

1.11
0.97

1.32
0.89

1.62
1.23

3.01
2.94

1.25

1.81

1.40

3.72

0.85
Fold
change
in Δcid1

0.46
Effect
change
in Δcid1

0.77
Fold
change in
Δdis3L2

0.33
Effect
change in
Δdis3L2

1.03
1.95
0.75

1.15
2.96
0.49

1.62
2.05
0.80

4.60
4.30
0.33

Mitotic sister chromatid segregation
kinetochore protein, CENP-C
cnp3
ortholog Cnp3
19S proteasome regulatory subunit
rpn2
Rpn2 (predicted)
19S proteasome regulatory subunit
rpn7
Rpn7
mitotic centromere-SPB clustering
SPBC2G2.14
protein Csi1
ssl3
cohesin loading factor Ssl3

mRNA metabolic process
ATP-dependent RNA helicase
cdc28
Cdc28
cleavage factor two
Cft2/polyadenylation factor CPSFcft2
73 (predicted)
complexed with Cdc5 protein
cwf21
Cwf21
edc3
enhancer of mRNA decapping Edc3
FRG1 family protein, involved in
frg1
mRNA splicing (predicted)
CwfJ family protein, splicing factor
mug161
(predicted)
U2 snRNP-associated protein
prp10
Sap155
SPAC2C4.07c
Dis3L2
pumilio family RNA-binding
SPBC56F2.08c
protein Puf1 (predicted)
Nucleobase-containing small molecule metabolic
process
phosphoribosylformylglycinamidine
ade3
synthase Ade3
adk1
adenylate kinase activity
ribonucleoside reductase large
cdc22
subunit Cdc22
2',3'-cyclic-nucleotide 3'SPACUNK4.15
phosphodiesterase (predicted)
C1-5,6,7,8-tetrahydrofolate (THF)
SPBC839.16
synthase, trifunctional enzyme Thf1
ribonucleotide reductase small
suc22
subunit Suc22

Nucleocytoplasmic transport
ribosome biogenesis protein Rei1
SPCC550.15c
(predicted)

Other
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Fold
change
in Δcid1

Effect
change
in Δcid1

Fold
change in
Δdis3L2

Effect
change in
Δdis3L2

0.89

0.71

0.57

0.28

1.04

1.34

1.31

5.02

1.01

1.06

1.25

3.78

0.88
0.93
Fold
change
in Δcid1

0.72
0.71
Effect
change
in Δcid1

0.79
0.79
Fold
change in
Δdis3L2

0.26
0.34
Effect
change in
Δdis3L2

1.67

1.91

1.83

2.85

1.32

2.54

1.75

5.59

0.88
0.74

0.64
0.25

0.72
0.98

0.35
0.93

0.89

0.68

0.51

0.08

1.05

1.13

1.80

4.33

0.82
0.87

0.35
0.75

0.92
0.09

0.61
0.04

0.92
Fold
change
in Δcid1

0.76
Effect
change
in Δcid1

0.61
Fold
change in
Δdis3L2

0.13
Effect
change in
Δdis3L2

0.90
2.53

0.47
3.19

0.87
2.73

0.32
2.73

1.19

1.89

1.68

3.29

1.13

1.53

1.47

3.65

0.80

0.25

0.90

0.48

1.10
Fold
change
in Δcid1

3.72
Effect
change
in Δcid1

1.12
Fold
change in
Δdis3L2

1.87
Effect
change in
Δdis3L2

0.93
Fold
change
in Δcid1

0.71
Effect
change
in Δcid1

0.80
Fold
change in
Δdis3L2

0.12
Effect
change in
Δdis3L2

abp2

cnt6
meu31
mug74
ppr3
ppr5
slt1
SPAC11E3.12
SPAC17G6.15c
SPAC22A12.06c
SPAC22A12.14c
SPAC22A12.17c
SPAC27D7.09c
SPAC27E2.11c
SPAC2E1P3.05
c
SPAC30C2.03
SPAC513.02
SPAC513.07
SPAC750.05c
SPAC750.06c
SPAC7D4.05
SPAC977.15
SPAPB18E9.05
c
SPAPB2B4.07

SPBC216.01c

SPBC21B10.08c
SPBC21C3.19
SPBC29A10.17
SPBC30D10.14

ARS binding protein Abp2
centaurin ADOP ribosylation factor
GTPase activating protein family
(predicted)
Schizosaccharomyces specific
protein Meu31
Schizosaccharomyces specific
protein Mug74
mitochondrial PPR repeat protein
Ppr3
mitochondrial PPR repeat protein
Ppr5
Schizosaccharomyces specific
protein Slt1
mitochondrial thioredoxin family
protein
MTC tricarboxylate transmembrane
transporter Fsf1 (predicted)
serine hydrolase-like
BSD domain protein, unknown
biological role
short chain dehydrogenase
(predicted)
But2 family protein
Schizosaccharomyces specific
protein
fungal cellulose binding domain
protein
Schizosaccharomyces specific
protein
phosphoglycerate mutase family
flavonol reductase/cinnamoyl-CoA
reductase family
S. pombe specific 5Tm protein
family
S. pombe specific DUF999 protein
family 4
hydrolase (predicted)
dienelactone hydrolase family
Schizosaccharomyces pombe
specific protein
ubiquitin family protein, human
UBTD1 homolog
protein phosphatase PP4 complex
regulatory subunit 3 Psy2
(predicted)
antibiotic biosynthesis
monooxygenase-like domain
(predicted)
SBDS family protein Rtc3
(predicted)
Schizosaccharomyces specific
protein
dienelactone hydrolase family
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0.97

0.95

0.54

0.30

0.76

0.31

0.76

0.25

1.08

1.12

0.39

0.31

4.02

3.53

1.91

2.14

0.82

0.49

0.74

0.34

0.76

0.46

0.70

0.32

1.05

1.15

2.47

4.87

1.27

1.87

1.42

4.05

0.99
0.69

0.96
0.61

0.77
0.36

0.35
0.16

1.39

2.02

1.63

3.71

1.25
1.24

3.23
1.18

1.75
5.12

12.70
3.15

2.00

3.49

1.82

3.57

0.90

0.68

1.85

8.22

1.25
0.58

1.18
0.69

2.80
5.34

4.45
3.46

1.00

1.00

1.66

3.13

1.25

1.23

4.26

3.91

1.56
0.88
0.78

1.59
0.76
0.68

2.44
0.68
1.83

3.77
0.27
3.03

0.61

0.34

1.11

1.33

0.73

0.43

0.60

0.31

0.85

0.35

0.81

0.34

1.11

1.59

1.86

4.38

1.02

1.04

1.87

3.13

0.77
1.09

0.27
1.20

0.82
2.71

0.37
4.76

(predicted)
SPBC3B8.06
SPBC651.04

SPBC8E4.05c
SPBP8B7.32
SPBPB21E7.08
SPBPB2B2.08
SPCC1235.01
SPCC1322.09
SPCC1682.08c
SPCC569.03
SPCC663.09c
SPNCRNA.1436
vps901

conserved fungal protein
Schizosaccharomyces specific
protein
fumarate lyase superfamily,
bacterial 3-carboxy-cis,cismuconate cycloisomerase related
dubious
Unassigned
conserved fungal protein
Schizosaccharomyces specific
protein
conserved fungal protein
pumilio family RNA-binding
protein Mcp2
mug2/mug135/meu2 family
short chain dehydrogenase
(predicted)
box H/ACA small nucleolar RNA
snR95
guanyl-nucleotide exchange factor
Vps902

Protein catabolic process
bip1
ER heat shock protein BiP
AAA family ATPase involved in
ubiquitin-mediated protein
cdc48
degradation Cdc48
PI31 proteasome regulator Fub2
fub2
(predicted)
protein N-terminal amidase Nta1
nta1
(predicted)
19S proteasome regulatory subunit
rpt1
Rpt1 (predicted)
19S proteasome regulatory subunit
rpt3
Rpt3 (predicted)
19S proteasome regulatory subunit
rpt6
Rpt6 (predicted)
ubiquitin C-terminal hydrolase
ubp15
Ubp15

Protein complex assembly
proteasome assembly chaperone
SPCC18.17c
(predicted)

Protein folding
cct5
cdc37
cnx1

chaperonin-containing T-complex
epsilon subunit Cct5
Hsp90 co-chaperone Cdc37
calnexin Cnx1
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1.17

1.78

1.33

2.91

0.99

0.97

1.50

4.80

1.02
1.22
1.07
1.42

1.02
1.45
1.08
1.10

1.86
0.54
2.95
7.42

3.98
0.20
4.70
3.20

0.94
1.06

0.82
1.30

1.94
1.36

3.70
3.77

0.83
0.95

0.54
0.86

0.64
1.87

0.33
5.54

1.06

1.26

1.67

4.04

1.16

2.92

1.02

1.10

0.99
Fold
change
in Δcid1
1.10

0.93
Effect
change
in Δcid1
2.21

0.85
Fold
change in
Δdis3L2
1.40

0.28
Effect
change in
Δdis3L2
5.70

1.10

2.11

1.81

5.03

0.86

0.47

0.78

0.24

0.34

0.25

0.83

0.75

1.15

1.99

1.34

3.78

1.14

1.61

1.42

3.89

1.00

0.97

1.23

3.37

1.08
Fold
change
in Δcid1

1.19
Effect
change
in Δcid1

1.62
Fold
change in
Δdis3L2

3.24
Effect
change in
Δdis3L2

0.77
Fold
change
in Δcid1

0.36
Effect
change
in Δcid1

0.66
Fold
change in
Δdis3L2

0.24
Effect
change in
Δdis3L2

1.50
0.95
1.18

1.76
0.95
1.85

2.13
2.04
1.58

3.20
3.73
3.28

hsp90
mcp60
SPBC16D10.08
c
SPBC1711.08
SPBC4F6.17c
ssa1
ssa2
ssc1
sti1
wos2

Hsp90 chaperone
mitochondrial heat shock protein
Hsp60/Mcp60

1.64

2.58

2.29

6.48

1.40

2.02

1.67

3.17

heat shock protein Hsp104
chaperone activator Aha1
mitochondrial heatshock protein
Hsp78 (predicted)
heat shock protein Ssa1 (predicted)
heat shock protein Ssa2
mitochondrial heat shock protein
Hsp70
chaperone activator Sti1 (predicted)
p23 homolog, predicted cochaperone Wos2

1.60
1.63

2.85
3.50

3.96
2.20

5.18
7.46

1.21
1.36
1.63

2.01
1.84
2.13

2.69
3.08
2.88

10.07
5.16
4.96

1.38
1.46

2.34
2.51

1.88
2.78

5.15
5.34

1.22
Fold
change
in Δcid1

1.62
Effect
change
in Δcid1

1.74
Fold
change in
Δdis3L2

3.15
Effect
change in
Δdis3L2

1.05
Fold
change
in Δcid1

1.16
Effect
change
in Δcid1

0.78
Fold
change in
Δdis3L2

0.30
Effect
change in
Δdis3L2

0.85

0.57

0.73

0.32

0.80
Fold
change
in Δcid1

0.68
Effect
change
in Δcid1

0.64
Fold
change in
Δdis3L2

0.35
Effect
change in
Δdis3L2

1.44

2.98

1.14

1.39

0.80
Fold
change
in Δcid1

0.34
Effect
change
in Δcid1

0.74
Fold
change in
Δdis3L2

0.23
Effect
change in
Δdis3L2

0.98

0.94

1.30

3.38

0.85

0.25

1.08

1.39

2.56

31.96

1.01

1.03

1.19
1.18
Fold
change
in Δcid1

1.96
1.16
Effect
change
in Δcid1

1.39
0.21
Fold
change in
Δdis3L2

6.63
0.29
Effect
change in
Δdis3L2

0.60
Fold
change
in Δcid1

0.35
Effect
change
in Δcid1

0.74
Fold
change in
Δdis3L2

0.47
Effect
change in
Δdis3L2

Protein glycosylation
alpha-1,2-galactosyltransferase
gma12
Gma12

Protein maturation
grx5
SPAC2G11.05c

monothiol glutaredoxin Grx5
BRO1 domain protein Rim20
(predicted)

Protein modification by small protein conjugation or
removal
ubiquitin conjugating enzyme E2
ubc4
Ubc4/UbcP1
SUMO deconjugating cysteine
ulp2
peptidase Ulp2 (predicted)

Protein targeting
kap109

qcr1
SPAC19D5.02c
tim21
tlh2

karyopherin Kap109
mitochondrial processing peptidase
(MPP) complex beta subunit Mas1
(predicted)
peroxisomal membrane protein
Pex22 (predicted)
TIM23 translocase complex subunit
Tim21 (predicted)
RecQ type DNA helicase Tlh1

Regulation of mitotic cell cycle phase transition
M phase inhibitor protein kinase
wee1
Wee1

Ribosome biogenesis
145

fib1
mrm2
SPAPB8E5.07c
SPBC13G1.09
SPBP8B7.10c
SPCC830.09c
SPCP1E11.08
utp20

fibrillarin, rRNA methyltransferase
mitochondrial 2' O-ribose
methyltransferase Mrm2 (predicted)
rRNA processing protein Rrp12
(predicted)
bystin family U3 and U14 snoRNA
associated protein Enp1 (predicted)
U3 snoRNP-associated protein
Utp16 (predicted)
RNase P and RNase MRP subunit
(predicted)
ribosome biogenesis protein Nsa2
(predicted)
U3 snoRNP protein Utp20
(predicted)

Signaling
efc25
gap1
ncs1
ptc2
ric1

Ras1 guanyl-nucleotide exchange
factor Efc25
GTPase activating protein Gap1
neuronal calcium sensor related
protein Ncs1
protein phosphatase 2C Ptc2
Ypt/Rab-specific guanyl-nucleotide
exchange factor (GEF) subunit Ric1

snoRNA metabolic process
TRAMP complex poly(A)
cid14
polymerase subunit Cid14

Telomere organization
DNA replication factor A subunit
ssb1
Ssb1
single-stranded telomeric binding
tcg1
protein Tgc1

Transmembrane transport
ammonium transmembrane
amt2
transporter Amt2
atp2
F1-ATPase beta subunit Atp2
cch1
calcium ion channel Cch1
magnesium ion transmembrane
mrs2
transporter Mrs2 (predicted)
plasma membrane amino acid
per1
permease Per1
SPAC12G12.07
c
conserved fungal protein
mitochondrial hydrogen/potassium
SPAC23H3.12c
transport system protein (predicted)
SPAC24H6.11c
sulfate transmembrane transporter
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2.70

2.59

2.40

3.06

2.48

3.22

1.30

1.29

0.92

0.56

0.66

0.08

0.88

0.41

0.65

0.05

0.86

0.71

0.61

0.33

1.00

0.99

0.75

0.27

1.06

1.32

0.73

0.33

0.89
Fold
change
in Δcid1

0.40
Effect
change
in Δcid1

0.78
Fold
change in
Δdis3L2

0.11
Effect
change in
Δdis3L2

0.81
0.90

0.83
0.75

0.64
0.61

0.34
0.12

0.59
0.97

0.20
0.85

0.67
0.77

0.35
0.24

0.53
Fold
change
in Δcid1

0.23
Effect
change
in Δcid1

1.26
Fold
change in
Δdis3L2

1.28
Effect
change in
Δdis3L2

0.89
Fold
change
in Δcid1

0.58
Effect
change
in Δcid1

0.74
Fold
change in
Δdis3L2

0.26
Effect
change in
Δdis3L2

1.09

1.64

1.48

6.48

1.30
Fold
change
in Δcid1

2.34
Effect
change
in Δcid1

1.76
Fold
change in
Δdis3L2

3.60
Effect
change in
Δdis3L2

0.98
0.97
0.86

0.94
0.55
0.53

0.78
1.29
0.83

0.25
4.29
0.30

0.82

0.53

0.66

0.29

0.73

0.50

0.63

0.31

1.20

3.03

1.42

4.71

0.75
0.86

0.58
0.64

0.58
0.68

0.25
0.30

SPAC30D11.06
c
SPAC323.07c

SPAC328.09
SPBPB2B2.01

SPCC1235.11
SPCC320.08
SPCC4B3.13
SPCC965.11c
str1
vma6

(predicted)
Lazarus1 family transmembrane
transporter
MatE family transmembrane
transporter (predicted)
mitochondrial 2-oxoadipate and 2oxoglutarate transmembrane
transporter (predicted)
amino acid transmembrane
transporter (predicted)
mitochondrial pyruvate
transmembrane transporter subunit
Mpc1 (predicted)
transmembrane transporter
(predicted)
MatE family transmembrane
transporter (predicted)
amino acid transmembrane
transporter (predicted)
siderophore-iron transmembrane
transporter Str1
V-type ATPase V0 subunit d
(predicted)

tRNA metabolic process
mitochondrial metallopeptidase,
tRNA N6-threonyl-carbamoyladenosine (t6A), a modification
pgp1
protein Pgp1
tRNA specific adenosine-37
SPBC16A3.06
deaminase Tad1 (predicted)
tRNA guanylyltransferase Thg1
SPCC63.07
(predicted)
mitochondrial valine-tRNA ligase
vrs2
Vrs2/Vas2

Vesicle-mediated transport
clathrin heavy chain Chc1
chc1
(predicted)
Golgi transport complex subunit
cog1
Cog1 (predicted)
Huntingtin-interacting protein
end4
homolog
sec26
coatomer beta subunit (predicted)
SPBC18H10.20 arrestin-related endocytic adaptor
c
Any1
COPII-coated vesicle component
SPBC4.03c
Sfb3 (predicted)
coatomer alpha subunit Cop1
SPBPJ4664.04
(predicted)
WD repeat protein, involved in
diphthamide biosynthesis Dph7
SPCC18.15
(predicted)
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0.76

0.56

0.64

0.34

0.74

0.58

0.58

0.24

0.79

0.44

0.68

0.26

0.78

0.73

2.44

2.92

0.73

0.50

0.54

0.21

1.03

1.13

0.73

0.31

1.12

1.44

1.51

3.52

0.81

0.70

0.69

0.29

1.09

1.16

2.41

4.77

0.84
Fold
change
in Δcid1

0.30
Effect
change
in Δcid1

0.94
Fold
change in
Δdis3L2

0.66
Effect
change in
Δdis3L2

0.65

0.34

0.66

0.38

1.57

2.35

1.74

3.30

1.53

2.94

1.28

2.11

0.77
Fold
change
in Δcid1

0.33
Effect
change
in Δcid1

0.84
Fold
change in
Δdis3L2

0.47
Effect
change in
Δdis3L2

0.91

0.61

1.24

5.08

0.77

0.29

0.91

0.48

0.92
1.08

0.57
1.43

1.15
1.29

3.07
3.39

1.00

1.02

0.74

0.15

1.19

1.73

1.32

2.83

1.03

1.34

1.22

7.41

1.87

1.74

2.60

6.65

SPCC970.06

COP II adaptor Erv29 (predicted)

Vitamin metabolic process
CMP deaminase family/
methyltransferase bifunctional
enzyme involved in riboflavin
biosynthesis and tRNA
pseudouridine biosynthesis Rib2
SPCC4G3.16
(predicted)

1.18
Fold
change
in Δcid1

2.36
Effect
change
in Δcid1

1.23
Fold
change in
Δdis3L2

3.33
Effect
change in
Δdis3L2

0.63

0.30

0.66

0.30

Table B3: Genes up-regulated at least 1.8-fold in the S. pombe ∆cid1 deletion strain
compared to wildtype S. pombe.
Fold up in Δcid1

Gene

Protein name

SPAC19D5.02c
rps1101
SPBC23E6.02
SPNCRNA.636

5.00
2.57
2.16
2.10

SPAC806.06c
erg10
suc22
tif212
mug74

peroxisomal membrane protein Pex22
40S ribosomal protein S11
ATP-dependent DNA helicase
antisense RNA (predicted)
nicotinamide mononucleotide (NMN)
adenylyltransferase
acetylCoA Cacetyltransferase Erg10
ribonucleotide reductase small subunit Suc22
translation initiation factor eIF2 beta subunit
sequence orphan; with a role in meiosis

rik1
SPBC1711.08

Silencing protein Rik1, component of the
rik1-associated E3 ubiquitin ligase complex
chaperone activator Aha1

1.82

SPAC27E2.11c

sequence orphan

2.05
1.97
1.90
1.82
1.82

1.81
1.80

Table B4: Genes down-regulated at least 1.8-fold in the S. pombe ∆cid1 deletion
strain compared to wildtype S. pombe.
Gene

Protein name

SPAC869.02c
ncs1

nitric oxide dioxygenase Yhb1
neuronal calcium sensor related protein Ncs1
Ypt/Rabspecific guanylnucleotide exchange
factor (GEF) subunit Ric1

ric1
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Fold Down in
Δcid1
3.15
2.30
2.13

SPCC70.03c
SPNCRNA.1548
nta1
qcr1
SPBC839.16
edc3
SPNCRNA.1212
SPBC1683.04
SPCC548.05c
SPBC29A10.17

proline dehydrogenase
SPBC336.13c-antisense-1
protein Nterminal amidase Nta1
mitochondrial processing peptidase (MPP)
complex beta subunit Mas1
C15,6,7,8tetrahydrofolate (THF) synthase,
trifunctional enzyme Thf1
enhancer of mRNA decapping Edc3
antisense RNA (predicted)
glycosyl hydrolase family 3
ubiquitinprotein ligase E3 Dbl5
Schizosaccharomyces specific protein

2.04
2.03
2.02
2.02
2.01
2.00
1.97
1.93
1.88
1.86

Table B5: Genes down-regulated at least 1.8-fold in the S. pombe ∆dis3L2 deletion
strain compared to wildtype S. pombe.
Gene
SPBC13G1.09
frg1
SPAPB8E5.07c
leu2
SPBC19F5.04
utp20
gpd2
gap1
SPCC550.15c
SPNCRNA.1451
SPBC56F2.08c
SPNCRNA.1467
SPBC18H10.20c
adh4
SPNCRNA.1138
SPNCRNA.1297
SPNCRNA.1548
SPAC22A12.06c

Fold Down in
Δdis3L2

Protein name
bystin family U3 and U14 snoRNA
associated protein Enp1
FRG1 family protein, involved in mRNA
splicing
rRNA processing protein Rrp12
3-isopropylmalate dehydratase Leu2
aspartate kinase
U3 snoRNP protein Utp20
glycerol-3-phosphate dehydrogenase Gpd2
GTPase activating protein Gap1
ribosome biogenesis protein Rei1
cdc28-antisense-1 RNA
pumilio family RNA-binding protein Puf1
mdl1-antisense-1 RNA
arrestin-related endocytic adaptor Any1
alcohol dehydrogenase Adh4
antisense RNA (predicted)
intergenic RNA (predicted), possible
alternative UTR
SPBC336.13c-antisense-1 RNA
serine hydrolase-like
149

4.29
3.63
3.63
3.31
3.30
3.16
3.10
3.08
3.02
2.93
2.91
2.86
2.78
2.68
2.64
2.64
2.62
2.61

rrn3
SPNCRNA.935
tea3
mcp7
arg1
SPBP8B7.32
SPCC1235.11
SPNCRNA.1204
SPBC2G5.02c
SPNCRNA.579
ulp2
SPCC306.06c
SPBC1709.19c
fub2
SPAC323.07c
ptc2
SPCC18.17c
SPNCRNA.606
amt2
cob
cnt6
dna2
SPAC23H3.12c
cid14
SPAC328.09
SPBC2G2.14
SPCC548.05c
swd3
pso2

ribosomal DNA (rDNA) transcription factor
Rrn3
intergenic RNA (predicted), possible
alternative UTR
cell end marker Tea3
meiosis specific coiled-coil protein Mcp7
acetylornithine aminotransferase
Unassigned
mitochondrial pyruvate transmembrane
transporter subunit Mpc1
rsm1-antisense-1 RNA
CK2 family regulatory subunit Ckb2
ggc1-antisense-1 RNA
SUMO deconjugating cysteine peptidase
Ulp2
ER membrane protein, BIG1 family
mitochondrial iron-sulfur cluster assembly
protein Nfu1
PI31 proteasome regulator Fub2
MatE family transmembrane transporter
protein phosphatase 2C Ptc2
proteasome assembly chaperone
isp3-antisense-1 RNA
ammonium transmembrane transporter Amt2
cytochrome b
centaurin ADOP ribosylation factor GTPase
activating protein family
DNA replication endonuclease-helicase
Dna2
mitochondrial hydrogen/potassium transport
system protein
TRAMP complex poly(A) polymerase
subunit Cid14
mitochondrial 2-oxoadipate and 2oxoglutarate transmembrane transporter
mitotic centromere-SPB clustering protein
Csi1
ubiquitin-protein ligase E3 Dbl5
WD repeat protein Swd3
DNA 5' exonuclease
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2.60
2.41
2.40
2.40
2.34
2.34
2.24
2.21
2.17
2.13
2.12
2.11
2.10
2.09
2.07
2.05
2.04
2.01
2.00
2.00
2.00
1.98
1.98
1.97
1.96
1.95
1.95
1.93
1.92

cdc23
SPCC830.09c
SPAC7D4.05
vps901
SPBC2G2.17c
cnp3
SPBC582.04c

MCM-associated protein Mcm10
RNase P and RNase MRP subunit
hydrolase
guanyl-nucleotide exchange factor Vps902
beta-glucosidase Psu2
kinetochore protein, CENP-C ortholog Cnp3
RNAi protein, Dsh1

1.92
1.90
1.88
1.86
1.85
1.84
1.83

dph2

diphthamide biosynthesis protein

1.82

Table B6: Genes up-regulated at least 1.8-fold in the S. pombe ∆dis3L2 deletion
strain compared to wildtype S. pombe.

Heat shock proteins/chaperones
SPBC4F6.17c
mitochondrial heatshock protein Hsp78
SPBC1711.08
chaperone activator Aha1
psi1
DNAJ domain protein Psi1
tim21
TIM23 translocase complex subunit Tim21
hsp90
Hsp90 chaperone
bip1
ER heat shock protein BiP
SPCC569.03
mug2/mug135/meu2 family
sti1
chaperone activator Sti1
SPBC16D10.08c heat shock protein Hsp104
ssa1
heat shock protein Ssa1
ssc1
mitochondrial heat shock protein Hsp70
ssa2
heat shock protein Ssa2
cdc37
Hsp90 co-chaperone Cdc37
SPBC3B9.01
Hsp70 nucleotide exchange factor Fes1
Metabolism
SPAC22A12.17c
SPAC977.09c
SPBC947.15c
gal1
SPAC2E1P3.05c

short chain dehydrogenase
phospholipase
mitochondrial NADH dehydrogenase
(ubiquinone) Nde1
galactokinase Gal1
fungal cellulose binding domain protein
151

Fold up in
Δdis3L2
3.33
2.90
2.87
2.73
2.70
2.51
2.47
2.42
2.37
2.37
2.36
2.31
1.90
2.12
Fold change
3.67
3.42
3.40
3.09
3.04

gdh1
SPCC18.15
SPAC806.06c
gal10
SPACUNK4.16c
SPBC660.16
glo1
SPBC30D10.14
pgi1
SPCC1322.04
SPAC26F1.07
SPBC21B10.08c
erg10
idp1
atp2
tps1
SPCC663.09c

SPBC8E4.05c
plg7
SPBC32F12.10
SPCC5E4.05c
SPACUNK4.15
gal7

NADP-specific glutamate dehydrogenase Gdh1
WD repeat protein, involved in diphthamide
biosynthesis Dph7
nicotinamide mononucleotide (NMN)
adenylyltransferase
UDP-glucose 4-epimerase/aldose 1-epimerase
Gal10
alpha,alpha-trehalose-phosphate synthase
phosphogluconate dehydrogenase,
decarboxylating
glyoxalase I
dienelactone hydrolase family
glucose-6-phosphate isomerase
UTP-glucose-1-phosphate uridylyltransferase
glucose 1-dehydrogenase (NADP+)
antibiotic biosynthesis monooxygenase-like
domain
acetyl-CoA C-acetyltransferase Erg10
isocitrate dehydrogenase Idp1
F1-ATPase beta subunit Atp2
alpha,alpha-trehalose-phosphate synthase
[UDP-forming]
short chain dehydrogenase (predicted)
fumarate lyase superfamily, bacterial 3carboxy-cis,cis-muconate cycloisomerase
related
phospholipase A2, PAF family homolog
phosphoglucomutase
mitochondrial acylglycerol lipase Mgl1
2',3'-cyclic-nucleotide 3'-phosphodiesterase
galactose-1-phosphate uridylyltransferase Gal7

Oxidative Stress
trx1
SPAC11E3.12

2.73
2.71
2.60
2.40
2.29
2.28
2.25
2.25
2.22
2.21
2.13
2.12
2.11
2.10
2.03
2.02

1.99
1.96
1.91
1.88
1.87
1.81
Fold change

cytosolic thioredoxin Trx1
mitochondrial thioredoxin family protein

Protein degradation
cdc48
rpn2

2.82

2.81
2.02
Fold change

AAA family ATPase involved in ubiquitinmediated protein degradation Cdc48
19S proteasome regulatory subunit Rpn2
152

2.33
2.33

rpt3
rpt1
rpn7
Vesicles
SPBPJ4664.04
chc1
Antisense RNA
SPNCRNA.1036
SPNCRNA.1447
SPNCRNA.1626
Cell cycle
ssb1
cft2
msh6
SPBC651.04
paa1
mid2
ams2
cdt2
tcg1
rad24
Cytoskeleton
myo1
arp2
fim1
adf1
arp3

19S proteasome regulatory subunit Rpt3
19S proteasome regulatory subunit Rpt1
19S proteasome regulatory subunit Rpn7

1.96
1.92
1.92

coatomer alpha subunit Cop1 (predicted)
clathrin heavy chain Chc1

Fold change
2.89
2.35

wis2-antisense-1 RNA
uds1- antisense RNA
antisense RNA

Fold change
3.89
3.10
2.84

DNA replication factor A subunit Ssb1
cleavage factor two Cft2/polyadenylation factor
CPSF-73
MutS protein homolog
Schizosaccharomyces specific protein
protein phosphatase regulatory subunit Paa1
medial ring protein Mid2
cell cycle regulated GATA-type transcription
factor Ams2
WD repeat protein Cdt2
single-stranded telomeric binding protein Tgc1
14-3-3 protein Rad24

myosin type I
ARP2/3 actin-organizing complex subunit Arp2
fimbrin
actin depolymerizing factor, cofilin
Arp2/3 protein complex, actin-like protein
subunit Arp3

Other
SPBPB2B2.05
slt1

Fold change
2.69
2.48
2.37
2.26
2.15
2.11
2.03
2.00
1.85
1.83
Fold change
2.61
2.50
2.20
1.92
1.91
Fold change

peptidase family C26 protein
Schizosaccharomyces specific protein Slt1
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2.52
2.28

str1
SPAC12G12.07c
SPBPB21E7.08
SPAC30C2.03
mug161
hri2
SPAC750.05c

siderophore-iron transmembrane transporter
Str1
conserved fungal protein
Unassigned
Schizosaccharomyces specific protein
CwfJ family protein, splicing factor
eIF2 alpha kinase Hri2
S. pombe specific 5Tm protein family

2.25
2.24
2.23
2.15
2.11
2.02
1.97

SPBC83.17
SPAC750.06c
SPCC1322.09
SPCC1442.05c
SPAC22A12.14c
SPCC1235.01
SPAC27E2.11c
SPCC4B3.13

transcriptional coactivator, multiprotein
bridging factor Mbf1
S. pombe specific DUF999 protein family 4
conserved fungal protein
MICOS complex subunit Mic26/27
BSD domain protein, unknown biological role
Unassigned
Schizosaccharomyces specific protein
MatE family transmembrane transporter

1.92
1.92
1.91
1.90
1.89
1.89
1.84
1.81
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cid1 dis3L2

cid1

cid1 dis3L2

cid1 dis3L2

disL32

cid1

disL32

cid1

cid1 dis3L2

disL32

cid1

SPRRNA.42

cft2

SPCC1620.08

SPNCRNA.967

SPRRNA.45

SPBC16A3.06

ubc4

nut2

SPRRNA.43

wos2

SPNCRNA.1164

SPCC965.11c

SPRRNA.46

SPNCRNA.636

suc22

dph2

SPRRNA.44

SPNCRNA.1447

SPAC869.02c

SPAC328.09

SPBPB2B2.08

SPBC947.15c

SPAPB18E9.05c

SPBC36.10

SPAC513.02

Tf2-1

rps1101

SPAC24H6.11c

SPAC27D7.09c

cdc22

qcr1

SPAC7D4.05

SPNCRNA.706

rps2

SPBPJ4664.02

SPNCRNA.949

SPAC750.05c

mcp60

omh5

pso2

SPBC16D10.08c

gal7

SPNCRNA.1436

ncs1

SPBPB2B2.05

SPCC663.09c

SPAC19D5.02c

cox1

gal1

SPAC513.07

SPNCRNA.1212

rrn3

rik1

SPNCRNA.1132

tif212

mrs2

ssa1

SPAC22A12.14c

edc3

SPCC4G3.16

SPNCRNA.1325

ubp15

vma6

pgp1

SPNCRNA.877

fim1

tdp1

SPCC18.17c

SPBPB21E7.08

mdj1

prp10

SPAPB8E5.07c

SPAC977.09c

cnx1

cog1

cob

ssa2

ams2

SPBC839.16

SPBC13G1.09

SPNCRNA.1563

SPAC637.13c

SPCC70.03c

SPAC2G11.05c

SPAC30C2.03

swc3

tra2

SPCC1682.08c

sti1

SPBC83.17

mal1

efc25

tps1
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Figure B1: Colour map of gene expression changes between wildtype S. pombe and
Δcid1 or Δdis3L2 strains.
Rank-ordered false colour map showing the fold-change in gene expression (relative to
the WT strain) for all genes identified as differentially expressed in either Δcid1 or
Δdis3L2 strains. An effect size cut off of 1.5 was applied to identify differentially
expressed genes in each mutant strain.

155

Figure B2: Search tool for the retrieval of interacting genes/proteins (STRING)
diagram of RNAs with altered expression levels in cid1 and dis3L2 deletion strains
compared to wildtype.
Expression of genes encoding respective proteins displayed are down-regulated more
than 1.5-fold. The diagram was generated using the STRING database. Functional
associations between proteins are shown, with confidence of the proposed association
denoted by line thickness. A) RNAs up-regulated in a Δcid1 strain compared to wildtype
S. pombe cells. B) RNAs down-regulated in a Δcid1 strain compared to wildtype S.
pombe cells. C) RNAs down-regulated in a Δdis3L2 strain compared to wildtype S.
pombe cells. No significant functional enrichments were detected.
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